Systems approaches to identify molecular signatures from high-throughput expression data: towards next generation patient diagnostics by Sung, Jaeyun
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 2012 Jaeyun Sung	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  	  	  	  	  	  
SYSTEMS APPROACHES TO IDENTIFY MOLECULAR SIGNATURES FROM  
HIGH-THROUGHPUT EXPRESSION DATA: TOWARDS NEXT  
GENERATION PATIENT DIAGNOSTICS 
 
 
 
 
 
 
BY 
 
JAEYUN SUNG 
 
 
 
 
 
 
 
 
DISSERTATION 
 
Submitted in partial fulfillment of the requirements 
for the degree of Doctor of Philosophy in Chemical Engineering 
in the Graduate College of the 
University of Illinois at Urbana-Champaign, 2012 
 
 
 
 
 
Urbana, Illinois 
 
 
Doctoral Committee: 
 
Associate Professor Nathan D. Price, Chair 
Associate Professor Sheng Zhong 
Professor Daniel W. Pack 
Professor Debra E. Leckband 
 
 ii 
Abstract 
The advent of high-throughput (so called “omics”) technologies for the comprehensive 
and rapid measurement of virtually all molecular components within human cells, tissues, 
organs, and serum has led to the generation of a tremendous amount of raw information.  
However, converting large-scale data to essential knowledge on human health and 
disease mechanisms has been a significant challenge thus far to the scientific and medical 
community.  To this end, we call for the systems biology approach to medicine (Systems 
Medicine), in which disease is viewed as a result of one or more disease-perturbed 
biomolecular networks caused by DNA mutations, pathogenic microorganisms, or 
environmental toxins.  These perturbations lead to alterations in the abundance of 
intra/extracellular biomolecules, which offer diagnostic clues to the presence, as well as 
progression of disease. 
 
 In this dissertation, I describe my investigations of developing computational 
systems approaches that aim to identify robust molecular diagnostic signatures from 
omics data, and to thereby advance personalized medicine and blood diagnostics.  
Specifically, this work makes three novel contributions based on the analysis of publicly 
archived high-throughput expression data: (1) Development of two classification 
algorithms based on relative expression reversals of biological features, which 
demonstrate robust phenotype distinction in binary and multi-category scenarios; (2) 
Discovery of organ-level diagnostic signatures and addressing of batch effects through 
multi-study integration of brain cancer transcriptomes; and (3) Identification of conserved 
expression patterns in mRNA and protein profiles from human cancers for prediction of 
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relative feature abundances across heterogeneous data types for in vivo monitoring of 
disease-perturbed networks.  We hope the work presented in this dissertation will play a 
significant role in bringing omics-based technologies into clinical practice, and lead to 
innovative medical applications that enhance our understanding of human health and 
disease. 
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Chapter 1. Motivation and outline 
 
1.1 Background and motivation for this work 
We are confronted by many staggering challenges in healthcare and biomedicine today.  
Rising costs associated with an aging population, diminishing access to quality healthcare 
despite the ever-increasing costs (Clancy, 2006), and the lack of sophisticated 
technologies to detect diseases at earlier, more treatable stages, are just a few of the 
obstacles we face.  Furthermore, the development of blockbuster approaches to 
effectively prevent and treat chronic diseases (e.g. cancer, neuro-degenerative diseases, 
diabetes) has been disappointing, despite major investments by both public and private 
organizations (O'donnell, et al., 2007; Thorpe, 2006; Weinstein and Skinner, 2010).  
There has thus never been a greater need in clinical research to enhance our 
understanding of human health and disease mechanisms, break barriers across disciplines, 
and translate research results into clinical practice.  
  Personalized medicine is an emerging field that can bring radical changes to the 
current practice of healthcare.  The vision of personalized medicine is to use a patient’s 
own molecular profile to first diagnose the pathological condition specific to that patient, 
and to then deliver the right therapeutic regimen(s) at the right time.  In addition, his/her 
predisposition for a particular disease is determined a priori, and necessary treatment is 
provided for timely prevention (Demeure, 2009; Gonzalez-Angulo, et al., 2010; Schilsky, 
2010).   
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 To fully realize the promise of personalized medicine, one of the first necessary 
steps is to determine more objective, standardized definitions of “health” and “disease” 
by identifying molecular markers that indicate the transition between the two states, and 
those that distinguish various pathological conditions.  For this to be achieved, all units of 
biological information (i.e. DNA, mRNA, proteins, metabolites and so forth) need to be 
analyzed comprehensively and simultaneously using high-throughput (so called “omics”) 
approaches.  Indeed, the widespread use of omics technologies has generated a wealth of 
previously inconceivable, genomic, transcriptomic, proteomic, and metabolomic data 
from clinical specimens, and thereby driving advances in personalized medicine 
(Gurwitz, et al., 2006; Sadee and Dai, 2005).  Consequently, traditional medicine is in the 
midst of a digital revolution that is transforming the discipline into a more quantitative, 
information-based, and personalized field of study (Arsenault, 2009; Hood, et al., 2004; 
Topol, 2012).  
 High-throughput measurements provide information only in the form of raw 
expression values.  The challenge now is to be able to harness and correctly analyze 
large-scale datasets to produce clinically useful knowledge.  This will be facilitated by 
the development of computational and mathematical tools that allow investigators to 
discover “molecular signatures” that serve various clinical applications (Chapter 2, 
Chapter 3, and Fig. 1.1).  These applications include the detection of disease, 
classification of disease sub-types and progression stages, prediction of clinical outcomes 
and treatment efficacy, and identification of at-risk groups (Bovelstad, et al., 2007; 
Cohen, et al., 2011; Friedman, et al., 2009; Hines, et al., 2010; Hur, et al., 2011; Pericak-
Vance, et al., 1997; Pittman, et al., 2004; Price, et al., 2007; van 't Veer, et al., 2002).  
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Figure 1.1 The identification of molecular signatures from omics data to guide 
clinical practice.  Promising applications include omics-based tests for disease-specific 
diagnostics and clinical phenotype classification. 
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   To fully exploit omics technologies for the rational discovery of molecular 
signatures and development of personalized disease models, the genetic, molecular, and 
cellular mechanisms underlying human pathologies must be better understood.  There is 
thus a clear need to determine how the components inside a biological system interact 
with one another over space and time to carry out biological functions, and how 
disruptions to these interactions can lead to the manifestation of disease.  Such global, 
integrative, and dynamic analyses and principles lie at the heart of the systems biology 
approach to medicine, or “systems medicine”. 
 Systems medicine promises to transform the practice of medicine from a reactive 
discipline (responding after the patient is sick), to a predictive, preventive, and 
personalized discipline (Hood and Friend, 2011; Hood, et al., 2004; Tian, et al., 2012).  In 
systems medicine, disease is viewed as a result of one or more disease-perturbed 
biomolecular networks caused by DNA mutations, pathogenic microorganisms, or 
environmental toxins.  These perturbations lead to alterations in the abundance of 
intra/extracellular biomolecules, which offer diagnostic clues to the presence, as well as 
progression of disease.  Interestingly, some of these biomolecules (especially proteins) 
are expressed only in the diseased organ (organ-specific), and a small fraction of these 
are secreted into the cell microenvironment and eventually into the blood.   
 Blood circulates throughout the body and contains proteins secreted from all 
organs and tissues.  Since disease-perturbed networks result in altered levels of these 
proteins, the changes in abundance within the blood can be utilized as a basis for 
reporting the health status of a particular organ (Hood and Flores, 2012).  The 
development of such non-invasive diagnostic approaches would be highly ideal for 
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studying the brain, as the brain is the most difficult human organ to biopsy, and tissue-
based diagnoses are impractical.   
 Since blood is a very heterogeneous mixture of various biomolecules from a range 
of sources, blood-based molecular diagnostic signatures must be highly specific for a 
particular disease and tissue of origin.  For this, the successful implementation of a 
simultaneous, global approach for molecular signature discovery is critical to address 
(Chapter 4).  As we learn to precisely read these molecular fingerprints (Lausted, et al., 
2008; Shi, et al., 2012), and understand how to: (1) correlate different levels of 
biomolecules with distinct diseases in a unique organ system (Chapter 5); (2) address 
“batch effects” issues, which compromise the performance and consistency of molecular 
signatures (Chapter 6); and (3) monitor perturbations within intracellular biomolecular 
networks using secreted protein patterns (Chapter 7), blood will become a highly 
informative window into human health and disease (Fig. 1.2).  This will not only provide 
a novel approach to early disease diagnostics, personalized treatment, and disease 
prevention, but also fundamentally change the practice of medicine. 
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Figure 1.2 The successful implementation of systems approaches towards identifying 
blood-based, organ-specific molecular diagnostic signatures can make blood truly a 
“window into human health and disease”.  
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1.2 General aim and organization of this dissertation  
This dissertation is primarily focused on developing computational systems approaches 
that aim to identify robust molecular signatures from omics data, and to thereby advance 
personalized medicine and blood diagnostics.  Although the work presented in this 
dissertation are my own and has been produced as the result of my own original research, 
I will use ‘we’ throughout this document, since for most parts other people were 
involved, as stated in the acknowledgements. 
 This dissertation is structured as follows:  
• Chapter 2 provides background information on the current process of molecular 
signature discovery on the basis of omics data.  Potential pitfalls in the discovery 
process are highlighted, and strategies are proposed that can be used to increase 
the odds of successful discovery. 
• Chapter 3 summarizes relevant literature on Relative Expression Analysis (RXA), 
a collection of computational methods that form the foundation of all machine-
learning methods presented in this dissertation.  A new methodology called TSPL 
(Top Scoring Pair Lists) is introduced that addresses some of the limitations of 
current RXA-based methods. 
• Chapter 4 describes a novel algorithm called ISSAC (Identification of Structured 
Signatures And Classifiers), which creates a multi-class decision hierarchy to find 
phenotype-specific molecular diagnostic signatures based on feature sets of 
relative expression reversals.  Classification performances on various datasets are 
presented.	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• Chapter 5 presents detailed methods, results, and discussion of the first 
application of ISSAC on a single organ system, i.e. the identification of 
comprehensive molecular signatures of major cancers of the human brain from a 
multi-study, integrated transcriptomic dataset. 
• Chapter 6 details the methods used to examine batch effects on the classification 
performance of our brain cancer marker-panel (using ISSAC).  Our approach of 
sufficient dataset integration to address this issue is presented, as well as results 
and discussion. 
• Chapter 7 describes a novel algorithm called SOMEIRA (Signatures Of Matching 
Expression to Infer Relative Abundances), which detects conserved expression 
patterns hidden in both gene and protein data to infer relative abundances of each 
data type, for the overall purpose of identifying intracellular network 
perturbations from a given secreted protein profile.  Results and discussion are 
included.   
• Chapter 8 presents final concluding remarks by summarizing the contributions of 
this dissertation and discussing directions for future work. 
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Chapter 2. Molecular signatures from omics data: 
From chaos to consensus 
 
2.1 Introduction 
In recent years, new high-throughput measurement technologies for biomolecules such as 
DNA, RNA, and proteins have enabled unprecedented views of biological systems at the 
molecular level. The fields of research associated with obtaining and understanding such 
measurements – for instance, genomics, transcriptomics, and proteomics – are sometimes 
referred to in aggregate as omics. Given molecular measurements taken from a biological 
system, a natural goal is to develop a statistical model that uses these measurements to 
predict a clinical outcome of interest, such as disease status, survival time, or response to 
therapy. In this chapter, we will discuss the process of using omics data to discover a 
molecular signature. Here we define a molecular signature as “a set of biomolecular 
features (e.g. DNA sequence, DNA copy number, RNA, protein, and metabolite 
expression), together with a predefined computational procedure that applies those 
features to predict a phenotype of clinical interest on a previously unseen patient 
sample”. A signature can be based on a single data type (Golub, et al., 1999; Gomez 
Ravetti and Moscato, 2008; Price, et al., 2007; Ramaswamy, et al., 2003) or on multiple 
data types (Hood, et al., 2004; Schadt, 2009; Varambally, et al., 2005; Zender, et al., 
2006). The overall process of identifying molecular signatures from various omics data 
types for a number of clinical applications is summarized below in Figure 2.1. 
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Figure 2.1 Overview of the discovery and application of molecular signatures from 
omics data. Molecular signatures can be derived from a broad range of omics data types 
(e.g. DNA sequence, mRNA, and protein expression) and can be used to predict various 
clinical phenotypes (e.g. response to therapy, prognosis) for previously unseen patient 
specimens. 
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 Many possible clinical phenotypes might be predicted by a molecular signature; a 
few examples include prediction of disease risk and progression (Hur, et al., 2011; 
Mehrabian, et al., 2005; Pericak-Vance, et al., 1997), response to therapeutic drugs 
(Cohen, et al., 2011; Friedman, et al., 2009; Xie, et al., 2012) and their physiological 
toxicity (Guerreiro, et al., 2003; Hines, et al., 2010), and time to disease recurrence or 
death (Bovelstad, et al., 2007; Pittman, et al., 2004). (Note that in this thesis, the 
molecular signatures that we consider may be effect modifiers or may only be of 
prognostic value; in either case, we refer to the molecular signature as “predicting” a 
clinical phenotype of interest.) A successful case of the clinical utility of omics-derived 
molecular signatures is MammaPrint (van 't Veer, et al., 2002), a diagnostic test approved 
by the Food and Drug Administration for clinical use. MammaPrint is a 70-gene 
expression signature used to predict breast cancer prognosis and to determine the 
appropriate therapeutic regimen for lymph node negative breast cancer patients with 
either ER positive or negative. The list of 70 genes was selected based on correlation with 
clinical outcome (distant metastasis vs. no metastasis), and underwent successful 
validations on independent patient cohorts (Buyse, et al., 2006; van de Vijver, et al., 
2002). 
 Despite a few notable exceptions such as MammaPrint, the successful discovery 
of molecular signatures has largely been hampered by limited reproducibility and 
variable performance on independent test sets (Brenner and Normolle, 2007; Feng, et al., 
2004; Hughes, 2009; McIntosh, et al., 2008; Ntzani and Ioannidis, 2003; Ransohoff, 
2005; Simon, 2005), as well as difficulty in identifying signatures that outperform 
standard clinical measurements like the cardiovascular disease risk C-reactive protein 
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(CRP) (McDonnell, et al., 2009). These difficulties can be attributed in large part to the 
low signal-to-noise ratio inherent to omics datasets, the prevalence of batch effects in 
omics data, and molecular heterogeneity between samples and within populations 
(Ideker, et al., 2011). These issues are exacerbated by the fact that the datasets used to 
develop molecular signatures tend to have small sample sizes relative to the number of 
molecular measurements (Dougherty, 2001). Moreover, improper study design, 
inconsistent experimental techniques, and flawed data analysis can lead to further 
challenges in the process of molecular signature discovery. Though there has been 
marked progress in the field of molecular signature discovery in recent years, there 
remains a clear need for further improvements in the discovery process in order for 
omics-based technologies to begin to achieve their full clinical potential. 
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2.2 The four stages of molecular signature discovery 
Roughly speaking, the process of molecular signature discovery on the basis of omics 
data consists of four major stages: 
1. Defining the scientific and clinical context for the molecular signature.  
2. Procuring the data.  
3. Performing feature selection and model building.  
4. Evaluating the molecular signature on independent data sets.  
In the sections that follow, we will discuss each of these stages in turn. 
2.2.1 Stage 1: Defining the scientific and clinical context 
Before embarking on the process of molecular signature discovery, one must first identify 
a specific scientific and clinical context for the molecular signature. A molecular 
signature uses omics measurements to predict a clinical phenotype of interest; therefore, 
it is natural that before constructing such a signature, one must first determine what type 
of omics measurements will be used, and what clinical phenotype will be predicted.  
 We first consider the problem of selecting a suitable omics data type for a 
molecular signature. A signature intended to distinguish between cancer and normal 
tissue could be based upon a number of omics data types; for instance, one might base the 
signature upon gene expression measurements, if it is believed that this type of cancer 
shows altered expression of some genes relative to normal tissue, or upon DNA sequence 
data, if samples from this cancer are characterized by particular mutations or copy 
number changes. However, given a clinical phenotype of interest, certain types of omics 
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data might not form the basis for a sensible molecular signature. For instance, it would 
not be reasonable to attempt to create a molecular signature to screen for adult onset (type 
II) diabetes on the basis of DNA sequence data alone because an individual’s DNA 
sequence remains essentially static throughout his or her lifetime, but risk of developing 
the disease may change.  
 We now consider the clinical context of the molecular signature. A gene 
expression-based signature that can distinguish between cancer and normal tissues would 
be of little practical use if a physician can easily make the same distinction using standard 
(and less expensive) clinical approaches. Similarly, a signature that can distinguish 
between two subtypes of cancer is useful only if those two subtypes differ in some 
clinically relevant way, such as in survival time or response to therapy, since otherwise 
the information about cancer subtype provided by the molecular signature may not serve 
a practical purpose. As an example, gastrointestinal stromal tumors (GISTs) and 
leiomyosarcomas (LMSs) are remarkably similar morphologically and were originally 
classified as being the same cancer. However, it was found that they respond very 
differently to distinct therapies, and thus a signature that can distinguish between these 
two diseases based on gene expression in tissue samples can be useful (Price, et al., 2007). 
An example outside of cancer involves the use of metabolomic information from human 
serum to noninvasively diagnose and monitor Alzheimer’s Disease (AD) progression 
(Barba, et al., 2008; Greenberg, et al., 2009; Orešič, 2011).  
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2.2.2 Stage 2: Data procurement 
The development of a molecular signature requires the availability of adequate omics 
data for which the clinical phenotype of interest is available. In general, there are two 
ways in which such data can be procured: new data can be collected experimentally for 
the specific purpose of molecular signature discovery, or else existing data (collected 
previously for other purposes, and generally publicly available) can be used. There are 
pros and cons of either approach. Collecting new data has a major advantage, in that all 
aspects of the experiment can be carefully controlled. On the other hand, data collection 
is expensive, and given the large sample sizes necessary for successful molecular 
signature discovery, using existing data sets may be a more feasible approach. There are a 
number of public data repositories from which omics data and associated clinical 
phenotypes can be obtained. For instance, a useful source of gene expression data is 
NCBI Gene Expression Omnibus (GEO), a repository of over twenty six thousand studies 
that continues to grow at a rapid pace. Other public data repositories include 
ArrayExpress (Parkinson, et al., 2011) and Sequence Read Archive (Kodama, et al., 
2011). Regardless of how the data are procured, it is crucial that the samples correspond 
to the scientific and clinical context of interest, as described in the previous section.  
 In order for a data set to be suitable for molecular signature discovery, the 
samples must be collected under appropriate experimental and analytical conditions. As 
an example, any biological factors (such as gender, age, or ethnicity) that may be 
associated with the clinical phenotype of interest or with the omics measurements should 
be taken into consideration in the process of data procurement. In addition, to reduce the 
prevalence of batch effects, factors such as sample collection and processing procedures, 
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laboratory personnel, study run-dates, reagent sources, measurement instruments, and 
data processing methods should be carefully controlled (Akey, et al., 2007; Allison, et al., 
2006; Scherer, 2009). Deviations in these protocols can have a surprisingly large effect 
on the omics measurements obtained, often larger than the effect of the clinical 
phenotype of interest (Leek, et al., 2010). Ideally, there should be no association between 
the clinical phenotype of interest and these factors. For instance, in the case of a 
molecular signature that classifies tissue samples into tumor versus normal, there should 
be no difference between the tumor and normal samples in terms of the laboratory 
personnel who performed the sample preparation, or the sample run-dates. If 
experimental and analytical procedures are not carefully controlled, they can result in 
confounding with the clinical phenotype of interest, leading to the development of a 
classifier that performs very well on the data used in its development, but that will 
perform poorly on independent test samples. 
 To the extent that analytical and experimental factors do vary among the samples, 
these factors should be explicitly included in the model used to develop the classifier. 
Normalization procedures have been proposed that are intended to reduce the effect of 
measured and unmeasured external factors on omics data (Leek and Storey, 2007); 
however, good experimental design remains the best strategy (Reimers, 2010). 
Exploratory data analysis techniques, such as hierarchical clustering (Fig. 2.2a) and 
principal components analysis (Fig. 2.2b) can be useful tools to assess the extent to 
which covariates that are not of primary interest may have affected the data. 
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Figure 2.2 Two hypothetical scenarios in which (a) hierarchical clustering and (b) 
principal components analysis reveal that covariates other than the clinical outcome of 
interest have resulted in considerable discrepancies between patient populations. Here, 
batch characteristics and not group labels (cancer versus normal clinical specimens) are 
responsible for most of the observed variation among the samples. Such batch effects can 
arise due to changes in experimental protocols, data-processing techniques, or laboratory 
personnel at any point in the experimental process. 
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 When existing data is used for omics-based molecular signature discovery, it is 
particularly important that sufficient information about the experiment is available to 
ensure that good experimental design was followed (this will be discussed further in 
Section 2.4). For instance, if the run date for each sample is not given, then one cannot be 
certain that the clinical phenotype of interest is not highly confounded with run date. 
 Unfortunately, many omics studies have sample sizes substantially smaller than 
would be required for the successful identification of molecular signatures. A molecular 
signature that is developed on the basis of a small number of samples is more likely to be 
sensitive to technical and biological sources of noise and variation, and less likely to 
capture the aspects of the data that are truly associated with the phenotype of interest. 
This exacerbates the risk of over-fitting, wherein the signature performs well on the 
samples used for signature development but fails to correctly predict the clinical 
phenotype of interest in previously unseen samples. In contrast, global molecular 
characteristics of a particular phenotype may become more apparent as sample size 
increases. Therefore, having a large sample size, while by no means a cure-all, will 
greatly improve the odds that a given attempt at molecular signature discovery will prove 
fruitful.   Integrating across multiple datasets of the same phenotypes from different labs 
can also help to amplify the primary biological signal of interest relative to noise.  Of 
course, whether a given sample size is “large” or “small” depends the type of omics data 
being used for signature discovery, the clinical phenotype of interest, and many other 
factors.  
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2.2.3 Stage 3: Feature selection and model building 
Once a scientific and clinical context has been established and one or more data sets have 
been identified, we can develop a molecular signature through (1) feature selection; and 
(2) model building. These two tasks can be performed together or separately. 
 We first consider the task of feature selection. A typical omics experiment 
simultaneously measures thousands or even millions of biological features (e.g. single 
nucleotide polymorphisms, RNA transcripts, protein levels) on each patient sample. 
However, just because thousands of molecular measurements are obtained does not mean 
that thousands of molecular measurements should be used in the molecular signature. 
Since financial cost, technical practicality, and measurement robustness are important 
criteria to select signatures, then if all else is equal, a signature that could be ultimately 
measured via PCR or Western blot is favored over a signature that requires a technique 
involving many more protocol steps, such as in omics measurements. In order to reduce 
the number of features used in molecular signature development, feature selection is 
performed. Feature selection can be performed in a supervised manner (e.g. the 20% of 
features that are most associated with the clinical phenotype of interest are selected), or in 
an unsupervised manner (e.g. the 20% of features with the highest variance are selected). 
Once a set of features has been selected, only those features are used in the model 
building process, which is described next. 
 We now consider the task of model building – that is, the process of developing a 
specific computational procedure that can be applied to the omics measurements from a 
future patient sample in order to predict the unknown clinical phenotype of interest for 
that sample. There are many possible approaches to building such a model, and in 
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particular, the type of model used will depend on the clinical phenotype of interest. For 
instance, if we wish to develop a molecular signature to predict time to cancer recurrence, 
then a Cox proportional hazards model might be appropriate. On the other hand, to 
develop a molecular signature that can distinguish between cancer and normal tissue, one 
could use a classification approach, such as logistic regression, support vector machines, 
neural networks, or linear discriminant analysis. Some approaches for model-building 
involve first performing an unsupervised technique, such as clustering or principal 
components analysis, followed by a supervised procedure, such as logistic regression.  
 It is worth noting that it is not always obvious what type of model should be used 
in a given setting. For instance, suppose that we wish to develop an expression-based 
signature in order to distinguish between tumor and normal samples. It sounds easy 
enough. An obvious approach is to develop a binary classifier, using e.g. logistic 
regression, which assumes that there is a linear boundary separating the two classes 
(tumor and normal). However, in some settings, this assumption might not be appropriate. 
For instance, maybe the normal samples do not belong to a single homogeneous group: 
there may be differences among the normal patients that are at least as great as the 
differences between tumor and normal patients. Alternatively, perhaps the tumor samples 
are heterogeneous because there are in fact several distinct subtypes of the tumor. In such 
a setting, a binary treatment of the problem that assumes a linear decision boundary may 
be inappropriate. Therefore, it is important to choose a model that is well-suited for the 
scientific and clinical contexts. 
 Once we have developed a model, how can we determine whether it is any good? 
Despite certain drawbacks (Ambroise and McLachlan, 2002; Braga-Neto and Dougherty, 
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2004), the most popular approach for evaluating model performance in this context is 
cross-validation. (Cross-validation is also often used for tuning parameter selection, 
though that application is outside of the scope of this article.) Cross-validation involves 
repeatedly splitting the samples in the data set into training and test sets, performing all 
aspects of feature selection and model building on the training set, and evaluating the 
model’s performance on the test set. Cross-validation can also be used to select from 
among a small number of possible models: the model with the smallest cross-validation 
error rate should be chosen. 
 Cross-validation is a simple and intuitive approach to estimating the error rate 
associated with a model, but it must be performed with care. Most importantly, within 
each cross-validation fold, no information about the test set can be used in building the 
model on the training set. For instance, suppose that one performs feature selection by 
selecting the 10% of features whose t-statistics between cases and controls are largest. 
One then performs logistic regression, using only these features, to develop a classifier to 
distinguish between cases and controls. How should the cross-validation error rate be 
calculated? Consider the following two approaches: 
Approach 1 (incorrect) 
Identify the 10% of features that differ most between cases and controls, and use 
only those features henceforth. Perform cross-validation by repeatedly splitting 
the samples into training and test sets, fitting a logistic regression model on the 
training set (using just the 10% of features previously identified), and then 
evaluating the model’s performance on the test set. 
	   25 
 
Approach 2 (correct) 
Perform cross-validation by repeatedly splitting the samples into a training set and 
a test set. Within each training set, identify the 10% of features that differ most 
between cases and controls, and use those features to fit a logistic regression 
model. Then evaluate the performance of this model on the test set. 
The difference may seem subtle, but it is in fact crucial. Approach 1 will yield a woeful 
underestimate of the true error rate, because the 10% of features that differ most between 
cases and controls were identified using all of the samples, including those in the test set, 
rather than simply the training samples. In effect, if Approach 1 for cross-validation is 
taken, then perfect error rates can potentially be obtained even on data sets in which the 
“case” and “control” labels were assigned randomly! On the other hand, in Approach 2, 
feature selection is performed using the training set within each cross validation fold, and 
so the resulting cross-validation error rate is valid. Unfortunately, the difference between 
Approaches 1 and 2 is often overlooked, and the literature is rife with papers in which 
extraordinarily low, but grossly inaccurate, cross-validation error rates are reported 
because some variant of Approach 1 has been performed. The key principle is that in 
computing cross-validation error rates, within each cross-validation fold only training 
observations can be used in any aspect of feature selection or model development. 
Deviations from this principle, even if seemingly innocuous, may result in dramatic 
underestimates of error.  
 At the end of the feature selection and model building process, the molecular 
signature must be locked down – that is, the precise computational procedure used to 
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convert a new omics sample into a prediction of the clinical phenotype must be 
completely specified. Only then can the molecular signature be fairly evaluated on 
independent data sets, as described next. 
2.2.4 Stage 4: Evaluation on independent data sets 
Once a promising molecular signature has been identified, its performance needs to be 
evaluated on completely independent patient samples. Unlike cross-validation, wherein 
the test set is drawn from the same population as that of the training set, an independent 
sample is one that is completely separate from the set of samples used for feature 
selection and model building. In particular, this means that the test set is not simply a 
random split from a large dataset (even if sequestered and not used in any training sets). 
If a molecular signature performs well on a truly independent set of samples, then this 
provides evidence that it will likely generalize to future patient samples. However, the 
amount of evidence for a molecular signature’s performance based on independent data 
depends critically upon specific characteristics of the independent data set.  
Lower level of evidence: Good performance on an independent data set collected at the 
same institution using carefully controlled protocols. This provides evidence that the 
molecular signature works well in this particular setting, with these protocols, with the 
patient profile at this institution, etc. However, it may not hold up elsewhere. At the very 
least, its ability to work in other settings has not been demonstrated. 
Higher level of evidence: Good performance on multiple independent data sets collected 
at multiple institutions. Success in this setting is the best evidence that a molecular 
signature will perform well on future patient samples. This indicates that the signature is 
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robust to the kinds of things that might change between locations: namely, aspects of the 
biology of the populations that tend to go to particular hospital, sample preparation and 
measurement techniques used, and so forth.  
 Evaluation of a molecular signature on fully independent patient samples is the 
gold standard for assessing its performance. Unfortunately, it often is the case that 
molecular signatures that seem promising in the feature selection and model building 
stage (i.e. that have very low cross-validation error rates) exhibit poor performance on 
independent data.  
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2.3 Disclosing all experimental protocols, data sets, and source code 
A key principle of science is that other researchers must be able to reproduce the results. 
In order for a molecular signature to be reproduced, three essential pieces of information 
are required: 1. The experimental and analytical protocols; 2. The raw data; and 3. The 
source code used to develop the signature. We discuss each of these points in turn. 
 In order for a molecular signature to be fully understood by other researchers, 
detailed information on the experimental protocol, including the patient selection criteria 
and experimental and analytic procedures, must be made available. Without this 
information, one cannot determine the scientific or clinical contexts in which the 
molecular signature is intended, appropriate, or useful. 
 Second, in order for a molecular signature to be reproduced, the omics data used 
in its development, as well as the associated metadata and clinical data, must be made 
available. If the data are not released, then it simply is not possible for other research 
groups to determine whether the molecular signature is valid. Since large sample sizes are 
generally required in order to develop satisfactory molecular signatures, it is infeasible 
due to both time and cost constraints for another group to collect their own data set in 
order to validate the molecular signature. In addition to allowing for independent 
confirmation of the molecular signature (and thereby increasing confidence in its 
scientific merit), releasing data also serves to further science, since then other 
investigators can use the data for their own molecular signature development. This is 
particularly important because in many applications, no single research group will be able 
to collect a sufficiently large data set, making meta-analyses of large numbers of 
published datasets highly valuable as an alterative approach. Given the large public 
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investment in biomedical science, there is a strong argument for omics data to be made 
publicly available whenever possible, so that it can be leveraged maximally for the public 
good (Baggerly, 2010; John P. A. Ioannidis, 2011). 
 Finally, even if the data are made available, other research groups will not be able 
re-derive the molecular signature based on the same data used for its discovery, and 
confirm that the signature does truly work well on independent data, unless all data 
processing techniques and all analytical and computational methods are made available. 
Unfortunately, in practice this information often is not provided in sufficient detail. For 
instance, there is a tendency for authors to publish a list of the features (e.g. genes) 
involved in the signature, without the detailed mathematical formulas required to 
understand precisely how the omics measurements are used in order to predict the clinical 
phenotype of interest. This is a major obstacle to progress in the field, as other research 
groups cannot reproduce or validate – much less build upon – research that is not 
sufficiently reported. Unfortunately, due to the complexity of omics data sets and the 
analyses required to develop molecular signatures, it is almost impossible to describe an 
analysis in sufficient detail that another researcher could exactly reproduce those steps. In 
order to address this problem, the source code used to develop the molecular signature 
should be released. Ideally, this code should encompass all aspects of signature 
development, from processing and normalization of the raw omics data, to feature 
selection to model building to evaluation on an independent data set. 
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2.4 Using multiple data sets for molecular signature discovery 
Thus far, we have described the development of a molecular signature on the basis of a 
single data set, followed by evaluation of the signature on one or more independent data 
sets. However, in principle, multiple data sets can be used for molecular signature 
discovery. In fact, this can often lead to more accurate and more broadly applicable 
molecular signatures. 
 When a molecular signature is developed on the basis of a single data set and then 
tested on an independent data set, its performance tends to degrade severely in the 
independent data set relative to its cross-validation error rate in the data set used for 
development. This drop in performance can stem from heterogeneity between studies due 
to underlying variance in the biology of the patients studied, as well as from technical 
variations in measurement, normalization, and analysis. That is, a signature developed 
using a single data set may overfit certain aspects of the data set that are not of primary 
scientific interest, leading to poor performance on independent data. This problem can be 
partially overcome by developing the signature on the basis of multiple data sets, 
collected at different institutions and at different time points (Dudley, et al., 2009; Miller, 
et al., 2010; Xu, et al., 2008). (However, the primary clinical phenotype of interest, such 
as tumor versus normal, must be balanced between the data sets in order to avoid 
confounding between the data sets and the clinical phenotype.) 
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2.5 Using multiple data types for molecular signature discovery 
Given the complexity of biological systems in general and pathological processes in 
particular, there is an upper limit to how well a molecular signature developed on the 
basis of a single data type (e.g. genome-wide expression on DNA microarrays) can 
predict disease phenotypes and clinical outcomes. Integrating multiple types of omics 
data may allow for the development of increasingly accurate and robust molecular 
signatures. For example, gene expression data can be combined with copy number 
variation data or DNA sequence data. Successful multi-scale integration of different types 
of biological information is one of the current challenges in systems biology (Hwang, et 
al., 2005; Hwang, et al., 2005). In Figure 2.3 below, we provide brief summaries of a few 
recently published studies (Chandrasekaran and Price, 2010; Chuang, et al., 2007; 
English and Butte, 2007; Hwang, et al., 2009; Hwang, et al., 2005; Hwang, et al., 2005; 
Lu, et al., 2011; Network, 2008) in which multiple data types were used for molecular 
signature discovery. 
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Figure 2.3 Combining different types of data across different measurement platforms can 
lead to more accurate molecular signatures for characterizing or predicting clinical 
phenotypes. Rows and columns of the checkered box correspond to data types and 
published studies, respectively. The collection of green boxes in each column represents 
the combination of data types used in a particular study. The arrows designate the brief 
objective of each study.  
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 A number of methods to combine diverse types of omics data across different 
measurement platforms and laboratories have been proposed (Hwang, et al., 2005; 
Hwang, et al., 2005; Slater, et al., 2008), in order to more accurately select clinically 
relevant features or to develop better molecular signatures. For example, English and 
Butte evaluated data from 49 obesity-related studies that used different experiment types, 
including DNA microarrays, genome-wide association, proteomics, and RNAi 
knockdowns (English and Butte, 2007). The investigators found that the biomolecules 
reported to be associated with obesity in individual studies had little overlap with 
previously known obesity-related genes. The investigators then determined a gene to be 
obesity-related if 5 or more studies reported the gene to be obesity-related. Using this 
approach of feature selection, they were able to identify a higher proportion of known 
obesity related genes than from any of the 49 individual studies, and also discovered new 
genes for which there was compelling support of association with obesity (English and 
Butte, 2007). This demonstrated that even straightforward integration of multiple omics 
data types can substantially improve the feature selection process. In a study by Lu et al., 
the investigators integrated data types in order to perform more effective feature selection: 
they identified 475 genes that were differentially expressed between lung 
adenocarcinoma and normal tissue, and that were also located in copy number varying 
regions (Lu, et al., 2011). This gene set was used to create a predictive model for patient 
survival, which was then shown to be accurate on three independent patient cohorts. 
Advances in integrating diverse omics data types may lead to a reduction in spurious 
signal caused by technical limitations of individual platforms, and an increased ability to 
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identify molecular signatures associated with the underlying mechanistic roles in disease 
pathogenesis.  
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2.6 A network-based approach to molecular signature discovery 
The use of network-based approaches is a promising avenue for molecular signature 
discovery. These networks represent a complex web of interactions among diverse 
components in a cell, and can be used to develop more reproducible and accurate 
molecular signatures by exploiting the underlying biology of the system. Network-based 
approaches extend beyond simple integration of different omics data types, and can 
involve evaluating complex interactions that can vary due to disease or other 
perturbations. 
 Most statistical methods for feature selection and model building do not take a 
network-based approach: they implicitly assume that the features are independent, or that 
they are only weakly dependent, though this has begun to change in recent years (Caiyan 
Li, 2010; Li and Li, 2008; Witten and Tibshirani, 2009). However, in most biological 
contexts, the assumption of independent features is certainly violated. For instance, genes 
regulated by the same set of transcription factors, or genes encoding enzymes for the 
same metabolic pathway, will tend to show correlated expression. Therefore, rather than 
treating each feature in an omics data set individually, it may be preferable to map from 
the high-dimensional molecular space to a much smaller number of (possibly curated) 
functional biological networks. Mapping features into functional sets reduces 
dimensionality, increases the statistical power to detect small but coordinated disease 
perturbations, and improves the interpretability of the resulting molecular signatures.  
 In order to identify features that are associated with a clinical phenotype of 
interest, features can be mapped onto a priori defined and manually curated modules or 
“pathways”. Gene Set Enrichment Analysis (GSEA) (Subramanian, et al., 2005) is a very 
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widely used approach to investigate pathway-level changes in gene expression data, and 
more recent proposals have also been made. One recently developed approach to 
identifying pathway-based molecular signatures for phenotype classification is the 
Differential Rank Conservation (DIRAC) method (Eddy, et al., 2010). Unlike GSEA or 
other enrichment methods that usually return p-values for gene set enrichment, DIRAC 
builds a network-based molecular signature that identifies robust differences in pathway 
activity between two disease states.  
 However, one major caveat to such pathway-based approaches is that a priori 
defined pathways do not fully represent the complexity of the underlying biology, and 
may not be accurate within the particular physiological context. To overcome this 
limitation, molecular features can be mapped into more comprehensive interaction 
networks, such as protein-protein or protein-DNA interaction networks, which can be 
much more comprehensive and unbiased, as well as disease and context specific. 
Specifically, biological networks can be used as a structured framework to integrate 
omics data for the purpose of molecular signature development. For example, Chuang et 
al. integrated microarray gene expression data with protein-protein interaction networks 
to identify network-based prognostic biomarkers for breast cancer metastasis, and 
generated novel hypotheses regarding cancer progression (Chuang, et al., 2007). The 
average sub-network activity, defined in this study as a function of expression levels of 
genes that compose the sub-network, was used to predict clinical outcome of breast 
cancer specimens. The network-based markers displayed better predictive accuracy on an 
independent dataset than markers selected without network information. In another study, 
Nibbe et al. used proteins that were differentially expressed between normal and cancer 
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colon tissue from proteomics experiments as seeds to identify sub-networks enriched in 
these differentially expressed proteins from the human protein interaction network 
(Nibbe, et al., 2010). Then, the mRNA expression profiles of the components of these 
sub-networks were used as input features to a support vector machine in order to classify 
colorectal cancer and normal samples.  The prevalence of these networks being perturbed 
in colon cancer demonstrated by these features alone was sufficient to achieve 90% 
classification accuracy in independent validations.   
 In the particular case of prion disease, a set of neurodegenerative disorders caused 
by the misfolding of prion proteins in the brain, Hwang et al. analyzed the dynamic 
network perturbations during the onset and progression of disease (Hwang, et al., 2009). 
In this study, infectious prion proteins were delivered into the brains of living mice, and 
were harbored within the tissue for different time-spans of disease progression. At the 
end of each time-point, gene expression measurements were taken from harvested 
diseased brain tissue, and subsequently mapped onto physical protein interaction 
networks for comparative analysis. Intriguingly, this study showed reproducible 
perturbations that occurred in core networks that could be monitored prior to the 
manifestation of disease symptoms.  
 In the work summarized above, thousands of feature measurements for static 
biological states were used to characterize molecular networks. However, a more 
complete understanding of molecular networks requires perturbing the biological system 
under study in order to understand how the network components, as well as the clinical 
phenotype of interest, are affected by those perturbations. For example, stimulating one 
or more signaling pathways using in vitro cytokine assays can lead to different 
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immunologic and metabolic responses in different diagnostic phenotypes (Irish, et al., 
2004), such as different disease progression levels. In a study by Hale et al. (Hale, et al., 
2009), the investigators used a cocktail of cytokines and mitogens to stimulate whole 
blood cells from patients with different stages of systemic lupus erythematosus, an 
autoimmune disease. They then used flow cytometry to measure multiple signaling 
responses at the single-cell level, generating a highly multiplexed view of intracellular 
signaling network activity during disease progression. They found that robust changes in 
signaling protein interactions in response to stimuli were good indicators of disease stage. 
Therefore, evaluating cell response after an activating stimulus may serve as a 
compelling approach for incorporating perturbations into patient classification going 
forward.  
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2.7 Are my features truly correct? 
Given that two molecular signatures seem to perform well on independent data sets, how 
can we decide which is better? If all else is equal, we should prefer the molecular 
signature for which there is a plausible biological mechanism, as such a signature is much 
more likely to hold up in future patient samples as opposed to having overfit the data 
used in its development. Ideally, if sufficient numbers of samples were available, then a 
molecular signature’s performance on one or many independent data sets would be the 
preferred way of assessing its suitability, regardless of whether or not a mechanism for its 
performance is known. But in reality, sample sizes are limited, and thus a molecular 
signature for which there is a plausible biological mechanism tends to be more 
convincing than one for which no such mechanism is known.  Such biologically 
motivated signatures can also hold great promise to be developed as companion 
diagnostics for therapies, which may be motivated by the underlying mechanism.  Thus, 
while lack of a known biological mechanism underlying a molecular signature certainly 
does not preclude its use provided that it works well in practice on independent samples, 
mechanistic information can increase our confidence that the signature will hold up to 
further scrutiny.  
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2.8 Pervasive bias in reported results 
Another major challenge in omics-based molecular signature discovery is the prevalence 
of overly optimistic accuracies in reported results. This problem is not unique to omics 
research but is problematic in many data-driven research settings (Ioannidis, 2005). Such 
bias can occur for a number of reasons: 1) research groups tend to report only the best 
results among many attempted approaches; and 2) only positive results are published. 
Consequently, across the literature there is an overly optimistic view of how well 
molecular signatures perform. This pervasive bias is not necessarily the result of faulty 
science in any particular lab, but rather is a consequence of the way in which science is 
conducted and reported. This is responsible, in part, for the fact that many reported 
molecular signatures have not held up in follow-up studies.  
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2.9 The future of molecular signature discovery 
In the future, we envision the development of molecular signatures using large publicly-
available repositories of data, coupled with unbiased assessment of the successes and 
failures of these signatures. An automated system will integrate all available data for a 
clinical phenotype of interest, identify the most accurate molecular signature using a 
standard set of computational algorithms, and continuously update the signature as new 
data become available. The candidate molecular signature and all relevant performance 
results (e.g. overall accuracy, sensitivity, and specificity) will be reported and tracked 
over time. Once the molecular signature stabilizes, the system will eventually report a 
final molecular signature for the phenotype of interest. The results obtained from such an 
automated system will be unbiased, in the sense that both positive and negative outcomes 
(e.g. correct and incorrect predictions in the case of a categorical phenotype) will be 
recorded and reported. By integrating huge amounts of publicly available data, such a 
system will avoid some of the issues associated with batch effects and confounding that 
arise when smaller sample sizes are used for molecular signature discovery. Such a 
system will allow us to develop the most accurate possible molecular signatures and 
assess their performances as objectively and comprehensively as possible.  
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2.10 Chapter summary 
In this chapter, we have discussed some of the key considerations and challenges facing 
the discovery of omics-based molecular signatures of clinical phenotypes, such as good 
experimental design, careful data procurement, avoidance of over-fitting, validation on 
independent data sets, and integration of multiple data sets and data types. For guidance 
to the reader, Figure 2.4 summarizes the key steps in molecular signature discovery that 
were discussed throughout this chapter. We hope that this methodological checklist will 
aid investigators interested in identifying omics-based molecular signatures.  
 Since the emergence of the field of omics-based molecular signature discovery, 
researchers have developed an improved understanding of how to discover (and how not 
to discover!) such signatures. The field is still young, and as time passes, best practices in 
this area will continue to evolve. Currently, the number of validated and useful molecular 
signatures is disappointingly (but not surprisingly) small relative to the number of 
signatures that have been reported in the literature. However, we remain optimistic that as 
experimental and analytical practices improve, as sample sizes increase, and as 
techniques for data type integration continue to develop, omics-based molecular 
signatures will indeed transform the practice of medicine. 
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Figure 2.4 Steps for the development of molecular signatures on the basis of omics data.  
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Chapter 3. Molecular diagnostics using relative 
expression analysis  
 
3.1 Introduction to Relative Expression Analysis (RXA) 
General computational approaches towards the analysis and classification of large-scale 
expression data were described in Chapter 1, and will not be further mentioned in this thesis.  In 
this section, we review the recent advances in Relative Expression Analysis (RXA) methods, 
which use the rank orderings among the expression values of a small number of genes to develop 
molecular diagnostic signatures.  Additionally, we survey studies wherein these methods have 
been used towards classification of clinical phenotypes based on genome-wide expression 
(transcriptomic) microarray data.   
3.1.1 Relative expression analysis and its advantages for transcriptomics-based 
classification studies 
As discussed in Chapter 1, perhaps the most evident challenge for developing useful molecular 
signatures is to identify those that are accurate and robust across a wide range of clinical settings 
and platforms.  Previous studies have aimed to identify sets of individual genes whose differential 
expression is highly correlated with phenotypic changes (e.g., genes that may be over- or under-
expressed in cancer relative to normal) (Alizadeh, et al., 2000; Hippo, et al., 2001; LaTulippe, et 
al., 2002; Singh, et al., 2002).  In these cases, increased or decreased absolute mRNA 
concentration levels above some threshold (i.e., more than would be statistically expected by 
chance for a gene on the microarray) are put forth as candidates for disease-induced (or causing) 
perturbations.  Unfortunately, the significant genetic changes often depend largely on the context 
of the microarray experiment.  Even when thresholds are tuned to produce statistically significant 
results, findings can still depend heavily on a number of factors, such as the experimental design 
	   52 
 
and the type of data normalization.  Consequently, there may be little to no overlap in the 
molecular signatures identified from one platform to another, or by extension, from one clinical 
setting to another.   
 A less evident, but equally important, challenge for phenotype classification using gene 
expression data is to develop techniques that not only yield accurate and robust decision rules, but 
also provide rules that are easy to interpret and might contribute to biological understanding.  
Advanced statistical learning and pattern recognition methods are routinely applied to 
transcriptomics and other high-throughput data types.  These include neural networks (Bicciato, 
et al., 2003; Bloom, et al., 2004; Khan, et al., 2001), decision trees (Boulesteix, et al., 2003; 
Dettling and Buhlmann, 2003; Zhang, et al., 2003), boosting (Dettling and Buhlmann, 2003; Qu, 
et al., 2002) and support vector machines (Peng, et al., 2003; Yeang, et al., 2001).  In many cases, 
these methods achieve good classification performance, with sensitivities and specificities above 
ninety percent.  However, they generally result in extremely complex decision rules based on 
nonlinear functions of many gene expression values.  Therefore, whereas advanced methods may 
be more accurate than those based on the patterns of individual genes, they usually produce 
decision rules which are virtually impossible to interpret.  Furthermore, as the number of 
variables (transcripts) far exceeds the number of observations in most microarray studies, 
building more complex classifiers entails a greater risk of over-fitting onto the training data and 
poor generalization. 
 An important potential benefit of simple and interpretable decision rules is to provide 
insight into the underlying biological differences between phenotypes.  Notably, malignant 
phenotypes in cancer arise from the net effect of interactions among multiple genes and other 
molecular agents within biological networks.  Genes in networks operate in a combinatorial 
manner—the actions of one gene greatly influence the actions of other genes.  This often limits 
the information that can be revealed by the expression patterns of individual genes.  As an 
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alternative approach, studying gene expression in the context of networks may yield greater 
insight into mechanisms and functional changes associated with disease.  Recently, methods for 
analyzing microarray data have focused not on individual genes, but instead on biologically 
meaningful pathways or networks (Chuang, et al., 2007; Lee, et al., 2008; Subramanian, et al., 
2007; Subramanian, et al., 2005).  These frameworks have been applied to diverse cancer systems 
and serve as a robust source of biological discovery (Auffray, 2007; Chuang, et al., 2007). 
 At scales smaller than biological networks or even pathways, assessing the relationships 
among a small number of genes—for example, the patterns of interactions among just two or 
three genes—can provide useful information about biomolecular processes.  One way to probe 
the interactions among several genes is to study their relative expression, i.e., the ordering among 
the expression values, rather than their absolute expression values.  One then searches for 
characteristic perturbations in this ordering from one phenotype to another.  The simplest form of 
such an interaction is the ordering of expression among two genes, in which case one seeks to 
identify typical “reversals”—pairs of genes for which one of the two possible orderings is usually 
present in one phenotype and rarely present in the other.  We refer to the family of such rank-
based methods as Relative Expression Analysis (RXA).  This methodology is characterized by 
replacing each expression level across all genes by its corresponding rank within a single 
microarray profile.   
 Previous RXA methods involve a small number of gene pairs, each exhibiting a 
characteristic “relative expression reversal” between the phenotypes or classes of interest. Basing 
decisions on one pair is called the top-scoring pair (TSP) classifier (Geman, et al., 2004) and on k 
pairs is called  the k-TSP classifier (Tan, et al., 2005).  Thus, in TSP, a sample is classified based 
on a decision rule that only involves comparing the ranks, and hence the relative expression 
levels, of two genes within a profile.  For the k-TSP classifier, the decision rule combines a 
disjoint set of TSPs by simple majority voting.  As will be discussed in later sections, aggregating 
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the decisions from a few such pairs, even just one, is surprisingly powerful.  Other RXA methods 
include those based on the six possible orderings among three genes (the top-scoring triplet 
classifier (Lin, et al., 2009)) and comparing the average ranks in two groups of genes (Xu, et al., 
2007).  Details on the algorithms of TSP, k-TSP, and other RXA methods can be found in their 
respective references. 
 The TSP and k-TSP classifiers are parameter-free methods that are invariant to all 
normalization techniques that are monotonic transformations of the original expression values 
within each chip or microarray.  That is, if the data are processed in such a way that if gene gi is 
expressed more than gene gj before normalization (original raw data) then it is still expressed 
more after normalization (processed data), then the TSP and k-TSP classifiers derived from the 
original and processed data are the same.  It is in this sense that these classifiers are “invariant” to 
normalization.  Moreover, the TSP and k-TSP classifiers are especially favorable in terms of the 
simplicity of the decision rule and the small number of genes involved in classification.  They are 
easy to implement in practice since the classifier only requires measurement of the expression of 
small number (at most 2k) of genes using techniques such as RT-PCR.  They also remain context-
independent by not requiring any parameter-tuning or data pre-processing based on genes outside 
of the pairs involved.  Furthermore, since data normalization is not required, RXA classifiers 
have been shown to be useful in the integration of data across different studies and platforms for 
the purpose of increasing sample size and facilitating meta-analysis of microarray data (Xu, et al., 
2005).  
3.1.2 Cancer studies using relative expression prior to the development of TSP and 
k-TSP 
Gene-pair relative expression markers, specifically in the form of a two-gene expression-level 
ratio, have been previously used for disease classification and prognosis.  Gordon et al. 
successfully distinguished between malignant pleural mesothelioma (MPM) and adenocarcinoma 
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(ADCA) of the lung based on ratios of expression (Gordon, et al., 2002).  Although genetically 
disparate, the tissues of MPM and ADCA can be difficult to distinguish based on established 
histopathological methods.  Gorden et al. tested the fidelity of ratio-based diagnosis in 
differentiating between the two tissue types in 181 samples (31 MPM and 150 ADCA).  First, the 
investigators used a training set of 32 samples (16 MPM and 16 ADCA) to identify differentially 
expressed genes based on various methods (fold changes, standard t-tests, expression cutoffs, 
etc.).  They then formed 15 ratios using individual or combinations of those genes that showed 
the highest significance in inversely correlated expression levels.  Any single ratio of the 15 
examined was at least 90% accurate in predicting diagnosis for the remaining 149 samples (e.g., 
test set).  They then examined (in the test set) the accuracy of multiple ratios combined to form a 
simple diagnostic tool.  Using two and three expression ratios, the investigators found that the 
differential diagnoses of MPM and lung ADCA were 95% and 99% accurate, respectively.  
Whereas, in this study, these gene-pairs are not combined in the same way as TSP, they are 
sensitive to normalization and parameter choices.  Still, their work illustrates the utility and 
discriminatory power of gene pairs in important clinical diagnoses. 
 Ma et al. found that a two-gene expression ratio derived from a genome-wide, 
oligonucleotide microarray analysis of estrogen receptor (ER)-positive, invasive breast cancers 
predicts tumor relapse and survival in patients treated with tamoxifen (Ma, et al., 2004).  
Tamoxifen is one of the most commonly used medications in the treatment of early-stage and 
metastatic ER-positive breast cancer (Clarke, et al., 2003; Jordan, 2002).  When administered to 
women with surgically treated ER-positive breast cancer, tamoxifen therapy reduces the annual 
risk of recurrence by 40-50%, leading to a 5.6-10.9% improvement in 10-year survival (Clarke, 
2008).  However, 25-66% of women diagnosed with ER-positive breast tumors fail to show a 
prolonged response or develop early resistance to adjuvant therapy (Clarke, et al., 2003; 
Nicholson, et al., 2003).  Currently, there are no markers that reliably predict clinical outcome of 
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cancer patients treated with tamoxifen.  Therefore, a reliable means to accurately predict 
tamoxifen treatment outcome is crucial for early-stage breast cancer management. 
 In the tamoxifen study conducted by Ma et al., a set of 60 patients with receptor-positive 
primary breast cancers were treated with tamoxifen alone.  The results from gene expression 
profiling of the extracted tumor tissues before therapy indicated that the homeobox gene 
(HOXB13) was over-expressed in patients who experienced disease recurrence, whereas the 
interleukin-17B receptor gene (IL-17BR) and EST gene were over-expressed in those with no 
evidence of recurrence after a 5-year treatment period.  The investigators evaluated the prognostic 
utility of each of these three genes by itself and in combination with genes that have opposing 
patterns of expression between the two classes.  Results from a t-test and ROC analyses revealed 
that a two-gene ratio of HOXB13 over IL-17BR had a stronger correlation with treatment outcome 
than any of the genes alone with AUC values reaching 0.84, and was able to accurately predict 
tumor recurrence in adjuvant tamoxifen-treated patients. 
 This observation was also confirmed in real-time quantitative PCR analysis, where the 
predictive accuracy of the two-gene ratio was 81%.  Furthermore, the expression ratio of 
HOXB13 over IL-17BR outperformed existing biomarkers for prognosis of breast cancer, such as 
patient age, tumor size, grade, and lymph node status.  In this study pre-dating any formal RXA 
classification approaches, Ma et al. demonstrated the utility of a two-gene expression biomarker 
in identifying a subset of patients with early-stage ER-positive breast cancer who are at a risk for 
tumor recurrence even with tamoxifen therapy.  Such a biomarker provides a potential means to 
identify patients appropriate for alternative therapeutic regimens in early-stage breast cancer. 
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3.1.3 TSP and k-TSP performance in cancer classification 
Geman et al. introduced the TSP method and demonstrated its efficacy on several gene 
expression data sets involving breast, prostate and leukemia cancers (Geman, et al., 2004).  The 
phenotype classification problems considered were: (i) predicting the status of lymph nodes 
(affected vs. non-affected) in patients with breast tumors using data from (Dudoit, et al., 2002); 
(ii) classifying the subtypes of leukemia (AML vs. ALL) using data from (Golub, et al., 1999); 
and (iii) distinguishing prostate tumors from normal profiles using data from (Singh, et al., 2002).  
The reported accuracies for TSP results were based on leave-one-out cross-validation (LOOCV), 
and comparison to randomly permuted data was made to estimate the statistical significance for 
each classifier. 
 In predicting the status of lymph nodes in the breast cancer data set, a cross-validation 
classification rate of 79% was achieved from 49 patient samples.  The authors also mention a 
separate study where estimated error rates for these data—based on LOOCV and using a wide 
variety of common machine learning techniques—are summarized for varying numbers of pre-
filtered genes (Dudoit, et al., 2002).  Other methods, more complex than TSP and using many 
more genes, did not result in better classification rates, and the low accuracy observed in all 
methods applied to date is probably a function of the complexity and similarity of the phenotypes 
being separated.  In the case of separating AML from ALL, the TSP classifier correctly classified 
68 samples out of 72 samples in cross-validation.  In comparison, the study in Golub et al. used a 
fifty-gene classifier to predict 65 samples correctly out of 72. 
 In addition to demonstrating improved performance in classifying breast cancer and 
leukemia samples, Geman et al. also investigated the ability of TSP to detect the presence of 
prostate cancer.  In a previous study, Singh et al. found a strong correlation between patterns of 
gene expression of prostate cancer and various clinical and pathological aspects of the disease 
(Singh, et al., 2002).  The top-scoring gene pair using the TSP algorithm on their data could 
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discriminate non-tumor versus prostate tumor samples at a prediction rate of 95%.  Hence, the 
classification rates using TSP were comparable to the best results reported previously in the 
literature, often incorporating hundreds of genes or more in complex decision rules.   
 The performance of TSP and k-TSP classifiers were compared with those of other 
machine learning methods on 19 gene expression datasets involving human cancers in a study by 
Tan et al. (Tan, et al., 2005).  The study investigated a number of publicly available datasets, with 
sample sizes ranging from 33 to 327 for each disease phenotype within a particular dataset.  The 
collection of datasets comprised various studies of human cancer, including colorectal, leukemia, 
lung, prostate, breast, central nervous system, lymphoma, bladder, melanoma, renal, uterus, 
pancreas, ovary, and mesothelioma.  The classification performances of TSP and k-TSP was 
compared to those of decision trees (DT), Naïve Bayes (NB), k-nearest neighbor (k-NN), support 
vector machines (SVM), and prediction analysis of microarrays (PAM), which is essentially 
linear discriminant analysis.  The TSP and k-TSP techniques were also extended beyond binary 
classification to the multi-class setting, where several well-known aggregation strategies, such as 
“one-vs-all” and “one-vs-other,” were applied to combine the results of binary sub-problems into 
one final decision rule.  
 LOOCV was used to estimate the classification rate.  The best classifier based on the 
average accuracy for the binary classification problems used in this study was k-TSP (92.01%), 
followed by SVM (91.18%), PAM (88.91%) and TSP (88.26%).  The differences in accuracies 
were small, so it was concluded that all four methods perform classification similarly.  The 
authors also elucidate the biological meaning of the classifiers by showing the connections 
between the genes in the markers and their corresponding cancer types.  For the multi-class 
problems, TSP achieved an average accuracy of 85.12% over 10 problems, somewhat less than 
PAM (88.50%) and SVM (88.10%), which performed the best overall, but used hundreds or 
thousands of genes.    
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 In the initial variant of RXA, Geman et al. showed that the TSP classifier provides 
decision rules that are highly accurate in binary classification problems and involve very few 
genes.  Tan et al. compared the TSP and k-TSP approach to other machine learning techniques on 
a broad source of human cancer gene expression data.  The performance of TSP and k-TSP on 
both binary and multi-class problems were comparable to those of the other techniques, while no 
single method was found to have the best performance across all datasets.  TSP and k-TSP were 
thus shown to have comparable accuracy to state-of-the-art methods, involve fewer genes and 
yield transparent, context-independent classifiers that are invariant to most forms of data 
normalization. 
 Xu et al. integrated three independent microarray datasets containing 358 total samples 
for prediction of distant metastases in breast cancer (Xu, et al., 2008).  All samples in the 
integrated dataset were obtained from lymph-node-negative patients who had not received 
adjuvant systemic treatment.  Gene expression was directly merged using 22,283 probe sets on 
the Affymetrix HG-U133A microarray, and the top 200 “features” were selected as gene pairs 
with the highest TSP scores.  In accordance with clinical treatment guidelines defined by the St. 
Gallen (Switzerland) expert consensus and the NIH, the goal of the authors was to achieve the 
highest possible specificity while maintaining high sensitivity (~90%).  The optimal signature 
size (80 pairs, 112 distinct genes) was determined in k-fold cross-validation, and a likelihood ratio 
test (LRT) for classification based on this signature achieved 88.6% sensitivity and 54.6% 
specificity in an independent external test set of 154 samples.  Since the LRT assumes statistically 
independent gene pairs, the decision rule amounts to weighted voting among the gene pair 
classifiers and hence is very similar to k-TSP. 
 The in vivo efficacy of an orally active small molecule Src inhibitor AZD0530 was 
investigated in a collection of pancreatic tumor xenografts (Rajeshkumar, et al., 2009).  Over-
expression of the Src tyrosine kinase in pancreatic cancer is thought to play a significant role in 
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tumor development and progression.  The k-TSP algorithm was applied to gene expression 
profiles from the tumors in order to identify predictive biomarkers of response to AZD0530.  
Tumor growth index (TGI) was used to morphologically classify xenografts as sensitive (TGI < 
50%) or resistant (TGI > 50%) to AZD0530 treatment.  In the training set of 16 xenografts (3 
sensitive, 13 resistant), the TSP classifier LRRC19 > IGFBP2 most accurately predicted cases as 
sensitive (and correspondingly predicted cases as resistant when LRRC19 ≤ IGFBP2).  
 The k-TSP classifier achieved an estimated LOOCV accuracy of 97.8% on the 
microarray data set.  The two-gene predictor was tested and validated on eight independent 
xenografts not included in the original training set and achieved an overall accuracy of 87.5%, 
specificity of 83.3%, and sensitivity of 100%.  RT-PCR was performed on the two genes in the 
eight independent xenografts, showing the relative expression of LRCC19 and IGFBP2 was the 
same as measured by microarray gene expression in all cases. This stability across different 
measurement platforms is critical for application in the clinic, and represents an advantage of 
methods based on RXA. 
 A two-gene expression ratio (RASGRP1/APTX) has been found that accurately predicts 
response to the drug tipifarnib in patients with acute myeloid leukemia (AML) (Raponi, et al., 
2008).  The TSP algorithm was applied to transcriptional profiles of bone marrow samples from 
newly diagnosed AML patients—including 13 responders and 13 patients with progressive 
disease, achieving 92.3% sensitivity and 100% specificity (96% accuracy) in LOOCV.  External 
validation of the two-gene classifier was performed in an independent dataset of 54 samples from 
patients with relapsed or refractory AML (10 responders, 44 with progressive disease).  When 
applied to the independent test set, the classifier predicted tipifarnib response with sensitivity of 
80% and specificity of 52.3%.  This reduction in accuracy compared to LOOCV may derive from 
the initial very small sample set not being sufficient to represent the amount of variance in the 
population, and thus further data collection and classifier development is needed.  Still, the results 
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are encouraging considering the subtle difference of the phenotypes being considered and the 
small amount of training data. 
3.1.4 RXA methods beyond TSP and k-TSP 
In an effort to identify a robust, universal cancer signature, Xu et al. performed a large-scale 
meta-analysis of cancer gene expression datasets, and validated their signature using a variant of 
RXA to separate cancer from normal samples across a wide range of cancers (Xu, et al., 2008).  
More specifically, the authors integrated nearly 1,500 microarray gene expression profiles from 
26 published cancer data sets across 21 major human cancer types using two different Affymetrix 
microarray platforms.  The authors applied another RXA method, referred to as the top-scoring 
pair of groups (TSPG) classifier, combined with a repeated random sampling strategy (Michiels, 
et al., 2005) to identify of a common cancer signature consisting of 46 genes. The TSPG classifier 
is an extension of the TSP classifier from two individual genes to two groups of genes.  Being an 
RXA method, it is based entirely on the internal ranking of the genes in the signature.  The 
signature is divided into two disjoint groups, and the average rank is computed for each group 
and two averages are compared.  The decision rule is again maximum likelihood; to choose the 
class for which the observed ordering between the two rank averages is most likely.  It can also 
be shown that TSPG is a special case of k-TSP, where k is the product of the two group sizes.  
Given a new expression profile, the classifier was found to discriminate most human cancers 
from normal tissues, including a validation on six different independent test datasets generated 
from different Affymetrix microarray platforms. Upon further validation, this cancer signature 
may be used to improve understanding of cancer pathogenesis and therapeutic targets, and hence 
lead to the development of effective treatment regimens. 
 Lin et al. proposed an extension of TSP which bases prediction entirely upon the relative 
expression ordering among three genes, referred to as the “top-scoring triplets” (TST) (Lin, et al., 
2009).  The decision rule is to select the class which makes the observed ordering the most likely. 
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In many cases, one gene serves as a “reference” whose expression falls between the expressions 
of two differentially expressed genes.  The objective is to achieve a more discriminating decision 
mechanism than TSP but without sacrificing interpretability.  The investigators explored the 
different roles the three genes play in the decision mechanism from previous cancer studies, and 
also applied this methodology to two problems in breast cancer:  a cross study validation based on 
predicting ER status and a clinically relevant application to predicting germ-line BRCA1 
mutations.  Further analysis on protein-protein interactions among the triplets of genes aided in 
understanding the biological roles of the classifiers. 
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3.2 Motivation and development of Top Scoring Pair Lists (TSPL)  
In this section, I describe the motivation behind the development of another classification strategy 
based on relative expression reversals, which we call Top Scoring Pair Lists (TSPL).  Our new 
approach, introduced herein, distinguishes phenotypes using a decision rule composed of many 
top-scoring gene-pairs.  Although this trait alone bears a resemblance to the methodology of k-
TSP, three contrasting points are made. 
3.2.1 Limitations to using small feature sets 
As previously mentioned, one of the major advantages of the classification methods based on 
relative expression reversals (e.g., TSP and k-TSP) is that only a small number of genes are 
involved in phenotype distinction.  This undoubtedly brings convenience into feature validation 
by PCR techniques, and also into any analyses of functional relationships between the classifier 
genes and their respective phenotypes.  However, we see two notable limitations to using small 
feature sets:  
1.  Gene expression measurements, especially from microarray experiments, are known to be 
difficult to reproduce due to myriad factors, including discrepancies in sample 
collection/preparation protocols, microarray platforms, fluorescence instruments, raw data pre-
processing algorithms, and so forth (further discussion on batch effects and proposed methods for 
controlling them is presented in Chapter 6).  These technical issues alone are considerable 
sources of noise and can cause random fluctuations in observed signal (Pavlidis, et al., 2003; Qiu, 
et al., 2006), leading to immense difficulty in obtaining robust and reliable measurements across a 
wide range of clinical settings and/or patient populations.  Thus, limiting feature selection to a 
small number, despite the aforementioned advantages, carries a greater risk of having the 
expression of the chosen classifiers significantly or entirely compromised by such measurement 
instabilities, compared with working with a more expansive set of classifiers. 
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2.  In previous methods, selection of a feature set is prioritized based on the strength of each 
individual gene-pair to differentiate clinical phenotypes.  In TSP and k-TSP, the selected features 
are limited to the best single gene-pair and k gene-pairs, respectively, while all other available 
pairs are neglected.  The rationale behind not having to use additional gene-pairs is due to their 
weak discriminative power, and hence their use does not significantly impact classification 
performance.  Although this is true in the case where each gene-pair is utilized (in the form of a 
decision rule) individually, or through majority-voting as in k-TSP, the gene-pairs that show 
weaker (but giving results much better than random chance), but consistent class discriminative 
signal may still contribute favorably towards overall performance if put to use in a more 
collective manner.  Therefore, we desire to use a more large-scale approach, wherein we utilize 
all available relative expression reversal signal. 
3.2.2 Top Scoring Pair Lists (TSPL) for phenotype classification 
To address the limitations above, we propose a new approach called Top Scoring Pairs Lists 
(TSPL).  Our new method is similar to the methodology of k-TSP, in the sense that it uses 
multiple gene-pairs, which exhibit reversal of ranked gene expression between two phenotypes, in 
a majority-vote.  In contrast, we make three modifications to the original k-TSP algorithm: 
1.  All non-disjoint, gene-pair combinations are initially considered as candidates for feature 
selection. 
2.  Gene-pairs with TSP scores (Geman, et al., 2004) of 0.6 or greater (during the classifier-
learning stage) are chosen as the classifiers.  In general, this results in a list of many classifier 
gene-pairs of moderate to strong predictive value. 
3.  Majority-voting is performed n times, where n is the total number of selected gene-pairs.  The 
n majority votes involve decision rule outcomes from the top one (as in TSP), two, three, ... , n 
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gene-pairs, and the class with the higher number of n total possible votes is selected as the test 
sample’s phenotype. 
 In the next section, we compare classification performances of TSPL and other RXA-
based methods on various transcriptomic datasets. 
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3.3 Classification performance on various transcriptomic datasets 
The general classification performance of TSPL was evaluated on transcriptomic datasets from a 
wide range of clinical phenotypes and measurement platforms.  A total of 19 datasets were 
obtained from the Gene Expression Omnibus (GEO) or from online repositories of previously 
published studies.  Clinical phenotypes, total sample numbers, and GEO references of all datasets 
are shown in Table 3.1.  
 Leave-one-out cross-validation was chosen as the performance metric for binary 
classification.  For comparison with the results from TSPL, Support Vector Machines (SVM) and 
two other RXA-based methods, TSP and k-TSP, were also tested on every dataset.  Cross-
validation accuracies from all four methods are shown in Table 3.2.  TSPL displayed the highest 
average cross-validation accuracy across all datasets (87.3 %), compared to SVM (85.4 %), TSP 
(79.2 %), and k-TSP (87.3 %).  When considering only the RXA-based methods, TSPL 
performed equally as well as, or better than TSP and k-TSP in 13 of 19 cases.   
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Table 3.1 Description of all 19 binary phenotype datasets used in this study. 
 
‘ψ’: expression data from protein lysate array. ‘-’: Datasets from published studies, but not 
available on GEO. 
 
 
 
 
 
 
 
 
 
 
   
GEO dataset
(GDS #)
A Responsive vs. non-responsive breast tumors dataset 1 60 807
B Gastrointestinal stromal tumor vs. Leimyosarcoma 52 -
 C! Gastrointestinal stromal tumor vs. Leimyosarcoma (protein lysate array) 52 -
D Responsive vs. non-responsive breast tumors dataset 2 60 1627
E Head and neck squamous cell carcinoma vs. control tissue 44 2520
F Bipolar disorder vs. control cerebral cortex 61 2190
G Carcinoma-like vs. adenoma-like ovarian tumor 43 2785
H Acute myeloid leukemia vs. acute lymphoblastic leukemia dataset 1 72 -
I Marfan syndrome vs. control subjects 101 2960
J Tumor vs. control prostate 102 2545
K Glioblastoma multiforme vs. anaplastic oligodendroglioma 29 1813
L Melanoma patients vs. control lympocytes 46 2735
M Parkinson vs. control brain dataset 1 47 3129
N Parkinson vs. control brain dataset 2 25 2821
O Tumor vs. normal pancreas epithelial layer 52 -
P Tumor vs. control ovarian tissue 24 3592
Q Adenocarcinoma vs. squamous cell carcinoma NSC lung cancer 58 2771
R Acute myeloid leukemia vs. acute lymphoblastic leukemia dataset 2 63 3057
S Diffuse large B-cell lymphoma vs. follicular lymphoma 77 3516
Total 
sample #Clinical phenotypesDataset
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Table 3.2 Leave-one-out cross-validation accuracies from SVM, TSP, k-TSP, and TSPL.  
 
‘ψ’: expression data from protein lysate array. ‘Φ’: Highest accuracy obtained for each dataset is 
shaded.  
 
 
 
 
 
A
B
  C!
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
Average
Dataset
60
52
52
60
44
61
43
72
101
102
29
46
47
25
52
24
58
63
77
!
Total 
sample # SVM TSP k-TSP TSPL
61.7% 28.3% 55.0% 80.0%
94.2% 86.5% 96.2% 96.2%
92.3% 55.8% 63.5% 88.5%
53.3% 68.3% 66.7% 63.3%
95.5% 84.1% 84.1% 95.5%
47.5% 65.6% 54.1% 60.7%
100.0% 93.0% 100.0% 100.0%
98.6% 87.5% 97.2% 97.2%
94.1% 80.2% 89.1% 92.1%
91.2% 92.2% 89.2% 89.2%
96.6% 72.4% 79.3% 75.9%
67.4% 73.9% 67.4% 78.3%
87.2% 89.4% 83.0% 87.2%
72.0% 68.0% 72.0% 76.0%
86.5% 82.7% 86.5% 92.3%
100.0% 95.8% 100.0% 100.0%
94.8% 87.9% 93.1% 96.6%
93.7% 93.7% 96.8% 98.4%
96.1% 98.7% 97.4% 92.2%
85.4% 79.2% 82.7% 87.3%
Leave-one-out cross-validation accuracy!
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 Next, cross-validation accuracies of TSPL were directly compared to those of SVM (Fig. 
3.1a), TSP (Fig. 3.1b) and k-TSP (Fig. 3.1c).  In 4 of 19 datasets, strong classification 
performance (≥ 90%) was obtained when either method was used.  TSPL performed equally as 
well as, or better than SVM, TSP and k-TSP in 13, 14, and 16 of 19 total cases, respectively.  In 
the datasets where both methods show moderate to poor performances (both accuracies ≤ 80%), 
TSPL had higher accuracies in 5 of 5 (vs. SVM, Fig. 3.1a), 4 of 6 (vs. TSP, Fig. 3.1b), and 4 of 6 
(k-TSP, Fig. 3.1c) datasets.  This shows that, compared to currently available techniques, better 
results may be expected when TSPL is used in cases where a strong distinction between two 
phenotypes does not exist at the transcriptomic level.  That TSPL performs better than SVM in all 
5 cases is highly encouraging, because SVM has been previously shown to perform remarkably 
well compared to other gene-expression microarray classification strategies (Statnikov, et al., 
2005; Tan, et al., 2005).  These results clearly indicate that our large-scale approach of utilizing 
all relative expression reversal signals shows significant promise towards binary phenotype 
classification. 
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Figure 3.1 Comparisons of classification performances between (a) SVM vs. TSPL; (b) TSP vs. 
TSPL; and (c) k-TSP vs. TSPL across all 19 datasets.  Each point on the scatter-plots represents a 
comparison between cross-validation accuracies of two methods for a particular dataset.  
Numerical values of points are shown in Table 3.2.  In approximately a fifth of all datasets, high 
accuracy (≥ 90%) is obtained when either method is used, as indicated by points towards the top-
right of the scatter-plots.  In datasets where both methods show moderate to poor performances 
(both accuracies ≤ 80%, as indicated by green dashed-line), higher accuracies are obtained from 
TSPL in (a) 5 of 5; (b) 4 of 6; and (c) 4 of 6 corresponding datasets.  The gray line has a slope of 
1, and represents a cut-off of accuracies higher in one method than in the other.  
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 In Dataset C, where the measurement platform was a protein lysate array composed of 40 
antibody features per sample (Yang, et al., 2010), TSPL, TSP, and k-TSP have cross-validation 
accuracies of 88.5 %, 55.8 %, and 63.5 %, respectively (Table 3.2).  This observation motivated 
our next analysis, which was to test whether TSPL could outperform other RXA-based methods 
on datasets of small feature sizes.  In contrast to gene-expression microarrays, small feature size 
is generally the case for antibody-based protein chips, which are also known to be highly 
expensive and labor-intensive to produce despite their relatively low measurement throughput. 
(Although there have been recent improvements regarding comprehensiveness (Fan, et al., 2008; 
Sardiu and Washburn, 2011; Song, et al., 2011; Talapatra, et al., 2002), the current technology is 
still far from reaching the entire proteome-scale.)  It would greatly behoove such strategies if the 
advantages of using simple decision rules based on relative expression can be fully utilized in 
protein expression measurements, as long as high classification performance can be consistently 
maintained.   
 We tested this hypothesis by performing cross-validation on the same datasets used 
previously, but on 100 randomly selected features chosen consistently across all samples for a 
particular dataset, over 100 iterations.  Results in Table 3.3 show that, on average, TSPL 
displayed the best classification performance (in cross-validation) among the four methods 
(SVM: 79.9 %; TSP: 72.5 %; k-TSP: 77.1 %; TSPL: 80.1 %).  In addition, TSPL had cross-
validation accuracies equal to, or higher than, the others RXA-based methods in 16 of 18 cases, 
showing again that TSPL clearly performs better than TSP and k-TSP, even on expression data 
for which the total feature size was greatly reduced.  
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Table 3.3 Average leave-one-out cross-validation accuracies from 100 iterations of SVM, TSP, 
k-TSP, and TSPL on datasets of 100 features selected randomly. 
 
‘ψ’: Protein lysate array data has only 40 measured features per sample, and was therefore 
removed from this analysis.  ‘Φ’: Highest accuracy obtained for each dataset is shaded.   
 
 
 
 
 
 
A
B
   C!
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
Average
Dataset
60
52
52
60
44
61
43
72
101
102
29
46
47
25
52
24
58
63
77
!
Total 
sample # SVM TSP k-TSP TSPL
55.0% 56.7% 63.3% 72.0%
91.4% 82.1% 89.2% 90.9%
- - - -
51.1% 47.2% 47.2% 48.8%
90.2% 80.7% 88.9% 88.9%
57.4% 45.9% 45.9% 60.7%
98.2% 91.2% 96.2% 98.2%
80.0% 83.3% 87.8% 89.4%
87.6% 73.6% 79.7% 82.5%
80.0% 74.6% 78.4% 82.7%
96.5% 62.9% 65.0% 70.2%
48.4% 57.8% 56.1% 54.7%
86.8% 76.0% 80.7% 80.7%
72.2% 60.6% 64.3% 70.8%
78.5% 82.1% 85.3% 87.4%
93.5% 85.7% 94.6% 97.0%
90.9% 77.7% 85.6% 87.8%
89.8% 87.1% 92.1% 93.3%
89.8% 79.5% 87.0% 86.3%
79.9% 72.5% 77.1% 80.1%
Leave-one-out cross-validation accuracy!
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3.4 Chapter summary 
The advent of high-throughput measurement technologies for the comprehensive, rapid, and 
inexpensive detection of molecular signatures in human cells, tissues, and serum has led to the 
generation of a tremendous amount of raw, unprocessed information.  However, analyzing and 
interpreting these data in order to enhance our understanding of human health and genetic 
diseases continues to be a challenge in the scientific community.  In the case of gene-expression 
microarray data, standard statistical learning methods have been shown to produce accurate 
classifiers to distinguish disease phenotypes, but still lack the convenience and simplicity desired 
for extracting any underlying biological rationale for the decision rules.  
 To address this issue, Geman et al. developed the TSP and k-TSP classifiers, two 
bioinformatics techniques for the molecular classification of gene expression data based on the 
analysis of relative expression values.  Due to the simplicity of the classifier and ease of 
biological interpretation, as well as its independence to data normalization and parameter-fitting, 
the TSP and k-TSP methods have been applied in several studies to perform molecular 
classification of various pathologies, primarily to cancer.  These methods have been shown to 
display highly accurate classification performance in distinguishing a broad phenotype range of 
case (i.e., disease) vs. controls, cancer subclasses, prognostic outcomes, and so forth.  As we will 
see in Chapter 4, these strategies can be applied towards classification of multiple phenotypes 
based on a decision-tree approach.  
 In addition to the currently available RXA-based classification methods, we introduce a 
new approach called Top Scoring Pair Lists (TSPL), which follows a natural extension of the TSP 
and k-TSP methods by incorporating a wider range of gene-pairs that show moderate to strong 
diagnostic value.  We evaluated the classification performance of TSPL by leave-one-out cross-
validation across 19 datasets.  On average, TSPL outperformed TSP and k-TSP, and also SVM.  
TSPL also performed better than these methods on expression data of small feature size, which is 
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the general case for antibody-based protein detection platforms.  Our results suggest that this 
large-scale approach of utilizing all relative expression reversal signals shows great promise 
towards the identification of more robust molecular diagnostic signatures. 
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Chapter 4. Multi-category classification of clinical 
phenotypes using structured signatures and 
classifiers 
 
4.1 Introduction 
Conventional statistical-learning methods (e.g. k-Nearest Neighbors (k-NN), Neural 
Networks, and Support Vector Machines (SVM)) have been used on high-throughput, 
gene-expression data in the search for disease-phenotype molecular signatures (Burger, 
2002; Eisen, et al., 1998; Nutt, et al., 2003; Yeoh, et al., 2002).  Although such studies 
have reported acceptable to near-perfect performance scores in cross-validation or 
independent hold-out trials, they have largely been limited to binary-classification 
scenarios (e.g. normal vs. cancer, benign vs. malignant tumor, or favorable vs. 
unfavorable prognosis).  A more clinically relevant, yet more challenging task is the 
multi-category classification problem, where unique, class-specific signatures distinguish 
a variety of possible diseases and progression levels.  This especially pertains to 
identifying molecular signatures for screening and monitoring purposes since such 
signatures need to detect and stratify various pathological conditions simultaneously, and 
therefore must be highly specific for a particular disease, as well as tissue of origin.  The 
successful identification of more reliable and efficient molecular signatures will also be 
critical for the blood-based, organ-specific diagnostics envisioned for the future (Hood, et 
al., 2004). 
 For this purpose, investigators have favored the use of multi-class SVM 
(Ramaswamy, et al., 2001; Statnikov, et al., 2005), which, in general, utilizes an 
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exhaustive number of microarray feature-genes for optimal parameter estimation to build 
complex decision rules.  Thereby, this method lacks the ease of meaningful biological 
interpretation of the classification process.  In the clinical setting, a simple classification 
technique that requires the validation of only a few genes to distinguish diseases or their 
progression states would offer a much more rapid and cost-effective strategy.  To address 
this issue, an alternative bioinformatics approach is desired.  
 As reviewed in Chapter 3, relative expression orderings (i.e. ranks) among a 
small number of genes have been used for the supervised classification of biological 
phenotypes (Geman, 2004; Lin, et al., 2009; Tan, et al., 2005).  The Top-Scoring Pair 
(TSP) classifier, which uses a single gene-pair within an expression profile that exhibits a 
characteristic "relative expression reversal" between two phenotypes of interest, has been 
shown to be a highly accurate and robust strategy in the molecular diagnostics of a 
variety of human cancers (Price, et al., 2007; Xu, et al., 2005; Xu, et al., 2008).  The 
power of this two-gene classifier method extends beyond high classification performance; 
by comparing the values of only two genes, this simple classification decision rule has 
remarkably straightforward biological interpretation.  Furthermore, TSP considers only 
the ranks, rather than the absolute expression values, within a profile, which then 
eliminates the need to perform parameter estimation and data normalization.  These are 
important advantages over more sophisticated methods, since building complex decision 
rules entails the risk of over-fitting, and data preprocessing may introduce unwanted bias 
into the dataset.  For the multi-class problem, the logical extension of the TSP classifier 
would be to use this method iteratively in a hierarchical, decision-tree format, as a coarse-
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to-fine search (Fleuret and Geman, 2001; Tibshirani and Hastie, 2007) for the optimal 
solution among several potential candidates.   
 Data-driven, hierarchical approaches to multi-category classification have been 
investigated extensively in machine learning (Amit, et al., 2004; Blanchard and Geman, 
2005).  The basic idea of these methods is first to design a classification framework in the 
form of a tree-structured hierarchy of sets of different categories.  The next step is to 
identify binary classifiers for all decision points (i.e. nodes and/or edges) of the tree.  This 
principle can be applied directly towards molecular diagnostics, wherein all diseases can 
be organized into a global hierarchy of disease sets, where the diseases in each set share 
common expression patterns.  The sets of binary classifiers can be aggregated into a 
classifier marker-panel, which can then direct diagnosis of a previously unseen patient 
sample down the hierarchical structure towards a particular label based on expression of a 
particular set of features.  Therefore, the cumulative expression patterns constitute 
“hierarchically-structured” molecular signatures.  
  In the following sections, we present a simple, automated technique called 
Identification of Structured Signatures And Classifiers (ISSAC).  This method was 
developed to identify molecular diagnostic signatures that accurately and simultaneously 
distinguish a variety of pathological states, and thereby lead to more reliable and efficient 
diagnostic strategies. 
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4.2 Quick guide to Identification of Structured Signatures And 
Classifiers (ISSAC) 
We summarize the overall method of ISSAC into three main steps (Fig. 4.1).  First, 
ISSAC constructs the framework for clinical phenotype classification (Fig. 4.2 and Fig. 
4.3) – a tree-structured hierarchy of all phenotypes built using an agglomerative 
hierarchical clustering algorithm on gene expression training data.  The construction of 
the hierarchy relies on the fact that there exist natural groupings among phenotypes based 
on shared features in their gene expression.  As the set of different phenotypes is 
partitioned into smaller and more homogeneous subsets, the multi-class diagnosis 
problem is thereby decomposed into more tractable sub-problems. 
 Second, ISSAC identifies binary classifiers corresponding to the nodes and edges 
of the diagnostic hierarchy.  Both types of classifiers attempt to distinguish between two 
sets of phenotypes: the objective of a node classifier is to distinguish the set of 
phenotypes associated with the node from all other phenotypes, whereas that of an edge-
based, decision-tree classifier is to distinguish the two sets of phenotypes associated with 
the two child nodes (analogous to decision rules of an ordinary decision-tree).  These 
classifiers are based on comparing the relative expression values (i.e. ranks) between two 
genes, for several pairs of genes within a gene expression profile.  The chosen pairs are 
the ones that best differentiate between the phenotype sets, and are based entirely on the 
reversal of relative expression, as previously reported (Geman, 2004).  Briefly, the 
decision rule by Geman et al. is based on two genes (e.g. gene i and gene j) for 
distinguishing between two phenotypes (e.g. class A and class B): If the expression of  
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Figure 4.1 The overall method of ISSAC can be summarized into three main steps.  A) 
ISSAC constructs the framework for clinical phenotype classification – a tree-structured 
hierarchy of all phenotypes built using an agglomerative hierarchical clustering algorithm 
on gene expression training data.  B) Training on gene-expression data from all 
phenotypes, ISSAC identifies disjoint, gene-pair classifiers at all nodes (excluding the 
root) and edges of the diagnostic hierarchy, and accumulates them into their respective 
marker-panels.  The chosen pairs are the ones that best differentiate between the 
phenotype sets, and are based entirely on the reversal of relative expression.  C) ISSAC 
uses the gene-pair classifiers for class prediction.  Briefly, given a gene expression 
profile, ISSAC executes the node classifiers in a hierarchical, top-down fashion within 
the disease diagnostic hierarchy to identify the phenotype(s) whose class-specific 
signature(s) is present.  In case of multiple class candidates (i.e. node classifiers for 
multiple leaves are positive), the ambiguity is resolved by aggregating all the decision-
tree classifiers into a classification decision-tree, thereby leading any expression 
signature down one unique path toward a single phenotype. 
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Figure 4.2 Phenotypes are grouped into a global diagnostic hierarchy, which allows an 
intuitive representation of the classification process.  The tree structure shown in this 
figure represents a diagnostic hierarchy of several brain cancers, which will be discussed 
in Chapter 5.  The diagnostic hierarchy is built using a data-driven, iterative approach, 
and is free of manual, ad-hoc construction.  In each iteration, two classes, or two groups 
of classes, with the lowest TSP score among all pair-wise comparisons, come together to 
form a node.  This approach optimizes overall classification by placing the more 
challenging decisions further away from the base of the tree (i.e. root), thereby ensuring 
only the minimum misclassifications percolate down the tree.  The final form of the 
diagnostic hierarchy represents a hierarchical structure of nested partitions, where the 
multi-class problem is decomposed into smaller and smaller groups using a sequence of 
diagnostic decision rules.  Phenotype abbreviation (name): EPN (Ependymoma), GBM 
(Glioblastoma Multiforme), MDL (Medulloblastoma), MNG (Meningioma), OLG 
(Oligodendroglioma), PA (Pilocytic astrocytoma), and normal (Normal brain).   
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gene i is greater than that of gene j for a given profile, then the phenotype is classified as 
class A; otherwise, class B.  It has been shown that using such simple decision rules with 
only a small number of gene-pairs can lead to highly accurate supervised classification of 
human cancers (Price, et al., 2007; Tan, et al., 2005).   
 Overall, the collection of node classifiers represent a series of coarse-grained to 
fine-grained explanations of the hierarchical groupings, and are used in diagnosis to 
screen for phenotype-specific expression patterns (described below).  Thus, the hierarchy 
of binary predictors guides classification of an expression profile in a dynamic “coarse-
to-fine” fashion: a classifier is executed if and only if all of its ancestor classifiers have 
been executed and returned a positive response, i.e. predicted the phenotypes in each 
node.  The cumulative outcome of the node classifiers for a given expression profile is 
the set of its candidate phenotypes, corresponding to all the leaves of the hierarchy that 
were reached and tested positively.  This property means that it is possible to traverse 
multiple paths to multiple leaf nodes, and thus multiple diagnoses may be made in this 
step (though in practice it is usually just one).  For tie-breaking purposes, the decision-
tree classifiers at the edges of the diagnostic hierarchy are used to reach a unique 
diagnosis. 
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Figure 4.3 The coarse-to-fine classification process is represented by a hierarchically 
structured grouping of phenotypes. There is a node classifier for each set of phenotypes 
in the hierarchy, which is designed to respond positively if the sample belongs to this set 
of diseases and negatively otherwise. Our diagnostic hierarchy has thirteen nodes in total, 
and seven terminal nodes (i.e. leaves).  The node classifiers are executed sequentially and 
adaptively on a given expression profile; a classifier test for a particular node is 
performed if and only if all of its ancestor tests were performed and deemed positive.  
The node classifiers are used to screen for phenotype-specific signatures.  
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 Finally, ISSAC uses the classifiers for phenotype prediction (Fig. 4.4).  Given a 
gene expression profile, ISSAC executes the node classifiers in a hierarchical, top-down 
fashion within the disease diagnostic hierarchy to identify the phenotype(s) whose class-
specific signature(s) is present.  In case of multiple class candidates (i.e. node classifiers 
for multiple leaves are positive), the ambiguity is resolved by aggregating all the 
decision-tree classifiers into a classification decision-tree, thereby leading any expression 
signature down one unique path toward a single phenotype.  Overall, we generated a 
diagnostic marker-panel whose classifiers allow efficient brain cancer diagnosis and 
straightforward biological interpretation. 
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Figure 4.4 The candidate phenotype(s) of a given expression profile correspond to the 
leaves that have positive classifier outcomes.  If there is no candidate phenotype, the 
expression profile is labeled as ‘Unclassified’.  If only one candidate phenotype is 
identified, the profile is labeled as that phenoe phenotype of the respective leaf.  If the 
profile is considered to consist of multiple phenotype signatures, the ambiguity is 
resolved using the decision-tree classifiers based on the same diagnostic hierarchy.  Here, 
the decision-tree classifiers are executed starting from the root of the tree, directing the 
profile to one of the two child nodes sequentially until it completes a full path towards a 
leaf.  The phenotype label of the final destination corresponds to the unique diagnosis.  
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4.3 Detailed description of the ISSAC algorithm 
In this section, we describe the process of building the tree-structured framework for 
multi-category classification, identifying gene-pair classifiers at all nodes and edges of 
the diagnostic tree, and performing phenotype prediction.  
4.3.1 A tree-structured framework for multi-category classification   
Let L denote the set of phenotype labels.  Given an expression profile x, the objective is 
to determine its true phenotype Y ∈ L.  The main assumption is that there are natural 
groupings L ⊂ L among the phenotypes.  Thus, testing for these groupings can more 
efficiently utilize the available training data, leading to more accurate classification than 
testing for each phenotype individually.  Based on these attributes, the natural structure to 
represent L is then a diagnostic hierarchy in the form of a binary hierarchical decision 
tree T.  Each node t ∈ T is associated with a set of phenotypes Lt ⊂ L.  The root of T 
contains all the phenotypes and each leaf (terminal node) of T delineates a single 
phenotype.  Overall, this representation is nested, in the sense that the set of phenotypes 
at every non-terminal node is the disjoint union of the phenotypes of the two child nodes.  
This tree is built from the training data by agglomerative hierarchical clustering derived 
from features of the profiles, as discussed below. 
4.3.2 Node classifiers are assembled according to the diagnostic hierarchy   
There is a binary classifier ft for every node t ∈ T except for the root.  The classifier ft is a 
function of the expression profile x.  Put simply, ft is a collective “test” for phenotypes in 
Lt versus all other phenotypes.  More formally, the classifier returns two possible 
outcomes: ft (x) = 1 (i.e. positive) signals that we accept the hypothesis that Y ∈ Lt, and ft 
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(x) = 0 (i.e. negative) signals that we reject this hypothesis and conclude that Y ∉ Lt.  In 
particular, ft is not a test for Lt versus the phenotypes in the sibling of t, as would be the 
case with a standard decision tree.  Rather, ft looks for traits within a given profile x 
which characterize all phenotypes in Lt simultaneously, such that a positive result 
signifies that the classifier assumes the true class of x belongs to Lt. 
 Classifier learning begins at the two child nodes of the root, and the classifiers are 
learned from two types of training data.  The positive training data for learning the 
classifier ft for node t are all the expression profiles of the phenotypes in Lt.  The negative 
training data are all the profiles of the phenotypes that are not in Lt.  Being binary, each 
classifier has two performance metrics: the sensitivity of ft is the probability that ft (x) = 1 
given x is from the positive training data, and the specificity of ft is the probability that ft 
(x) = 0 given x is from the negative training data.  Due to the coarse-to-fine, hierarchical 
manner in which the classifiers are processed, we required the sensitivity of ft to be as 
close to unity as possible.  This can be accomplished at the expense of specificity by 
adjusting a threshold, as discussed below. The reason for imposing a high sensitivity on 
each classifier is that if a test profile is rejected from belonging to Lt by the classifier 
when in fact it does belong to Lt, it cannot be recovered.  However, the reduced 
specificity is only local to each node, and the overall specificity increases with testing at 
subsequent nodes.   
4.3.3 A coarse-to-fine screening yields candidate phenotypes 
The strategy for processing any given profile x with the diagnostic hierarchy is breadth-
first, coarse-to-fine.  Starting from the two child nodes of the root, classifiers are 
executed sequentially and adaptively, with ft performed if and only if all its ancestor tests 
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are performed and are positive.  More specifically, ft is performed if and only if fs = 1 for 
every node s ∈ T between t and the root.  As soon as ft = 0 for a non-terminal node t, none 
of the descendant classifiers in the sub-tree rooted at t are performed.  This is because a 
negative response of ft means that the phenotype is unlikely to belong to Lt and the set of 
phenotypes associated with descendant of t, which are necessarily subsets of Lt.  This 
facilitates pruning whole subsets of phenotypes at once. 
 The complete coarse-to-fine screening process for x results in a set of detected 
phenotypes.  We denote this set by L(x) ⊂ L.  These are the phenotypes corresponding to 
a complete chain of positive results for all ft from root to leaf.  Equivalently, L(x) is the 
set of phenotypes that are not ruled out by any test performed.  During the diagnostic 
process, a profile may traverse only one path all the way to the terminal node. In this 
case, L(x) consists of a single phenotype d, and the diagnostic process terminates with Y 
= d as the predicted phenotype.  However, a profile may also traverse multiple branches 
to the terminal nodes of T, in which case L(x) consists of multiple candidate phenotypes 
(see the discussion on resolving ambiguities below).  Moreover, a profile may reach no 
terminal nodes, in which case L(x) is empty.  When no terminal node is reached, the 
profile is determined to be outside of L, and labeled as ‘Unclassified’.   
4.3.4 Resolving ambiguities using a decision-tree approach 
When L(x) consists of multiple phenotypes, it becomes necessary to refine the 
diagnosis.  The ambiguity is resolved by another tree-structured process – an ordinary 
decision tree based on the same diagnostic hierarchy.  For every pair of sibling nodes, we 
learn a classifier gt,s which tests Y ∈ Lt versus Y ∈ Ls, just as in an ordinary decision-tree 
(the process of classifier identification is elaborated below).  Starting from the root of the 
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tree, execution of the decision-tree classifiers directs a profile to one of two sibling nodes 
sequentially until it reaches a terminal node.  Unlike the process of traversing the 
hierarchy of node classifiers, a sample that enters the decision tree is directed to one and 
only one leaf node, and hence uniquely labeled. 
4.3.5 Classifier design and learning 
Every node classifier is based on expression level comparisons between two genes.  Let 
G be the set of all genes for which we have microarray expression data, and denote the 
set of all distinct pairs of genes by P.  For each gene-pair !! ,!! ∈  P, consider the 
Boolean feature !!"(x) ∈ 0, 1  of an expression profile x = !!,! ∈ ! .  !!"(x) assumes 
the value 1 if gene !! is expressed higher than gene !! (i.e. !!! > !!!) in x, and the value 
0 otherwise (i.e. !!! ≤ !!!).  These are the features that have been used in previous work 
on relative expression reversals (Geman, 2004).  Each node classifier f is constructed 
from a small set of gene-pairs P ⊂ P, the binary outcomes of !!" for all !, !  ∈ P, and a 
constant threshold k.  More specifically, f (x) = 1 if !!"   ≥!!,!!∈  ! !, and f (x) = 0 
otherwise.  The threshold k takes values between 1 and |P|.   
 There is a classifier of this nature for every node t ∈ T, except for the root.  The 
set of gene-pairs P =Pt and threshold k = kt depend on the node t.  Hence, for each t, the 
classifier ft = 1 if at least kt of the gene-pair comparisons in Pt are positive !!" = 1 ; 
otherwise, ft =0.  The comparisons are chosen such that, for each pair   !! ,!!  in Pt, we 
expect to see gene !! expressed more than gene !! under the assumption that the 
phenotype of x belongs to Lt, whereas if the phenotype of x does not belong to Lt, we 
expect to see the reverse.  For every node t, every pair of all gene-pair combinations is 
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“scored” by the difference between the probability of the event that !!" = 1 given Y ∈ Lt 
and the probability given Y ∉  Lt.  These probabilities are estimated from the training data, 
and the subset of pairs with the highest scores are chosen.  
Since each positive (resp., negative) comparison is viewed as evidence for Y ∈ Lt 
(resp., Y ∉  Lt), we can then favor sensitivity over specificity by varying the threshold kt.  
That is, by choosing a relatively small value for kt relative to the number of comparisons 
in Pt, we can make it highly likely that the classifier responds positively when in fact the 
sample belongs to the set Lt. We show the sets of gene-pairs Pt for each of the nodes in a 
brain cancer diagnostic hierarchy in Chapter 5.  Finally, the decision tree classifiers gt,s 
are all based on comparisons of single gene-pairs at all edges of the diagnostic hierarchy.  
MATLAB implementations of the ISSAC algorithm and a step-by-step tutorial are 
available to download at http://price.systemsbiology.net/downloads_tmp.php. 
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4.4 Step-by-step descriptions of major processes in ISSAC 
In this section, we provide a step-by-step description of each of the major processes in the ISSAC 
algorithm. 
4.4.1 Construction of the clinical phenotype diagnostic hierarchy 
Let L = !!,… ,!!  be the collection of class labels, where !! denotes phenotype !.  
Using expression profiles of the phenotype classes, we first calculate the Top Scoring 
Pair (TSP) score (∆) of all gene-pair combinations between all pair-wise class 
comparisons.  As previously described (Geman, 2004), the TSP score between two 
classes !! and !!, of two genes, gene ! and gene !, is defined as: 
∆!,! !!,!!   =    !!  !  ! !! − !!  !  ! !!  , 
where !!  !  ! !!  and !!  !  ! !!  denotes the percentage of samples in !! and !!, 
respectively, whose expression of gene ! is higher than that of gene !.  ∆!"# !!,!!  
denotes the maximum ∆!,! between !! and !! over all gene pairs ! and ! 
 Let  ! designate an evolving set of groups of labels that starts off as the set of all 
individual classes !!,… ,!! .  The diagnostic hierarchy was constructed by 
progressively evolving ! towards the set of all groupings in the hierarchy using the 
following steps: 
1.  For all pair-wise comparisons of distinct elements in !, we calculate all ∆!"#.  The 
leaves of the class-pair !! and !! with the smallest value of ∆!"# are merged into the 
first node of the tree, denoted as !!!,!!.  
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2.  ∆!"# of all pair-wise comparisons of the elements in the updated ! are calculated, and 
the pair with the smallest value of  ∆!"# is grouped into the next node of the tree.  Since 
at this point ! contains one non-singleton node and a host of other leaves, the next 
merging can be either between two leaves !! and !!, denoted as !!!,!!, or between a 
node !!!,!!and a leaf !!, denoted as !!!,!!,!!.  Whichever pair with the smallest ∆!"# 
merges to form a new node in !. 
3. This process of finding the minimum ∆!"# for all pair-wise elements in !, and adding 
the new node in !, is iterated until all nodes and leaves are connected to form a tree 
structure.  All classes combine to form the top node !!!,…  ,!! at the top of the diagnostic 
hierarchy (i.e. root). 
4.4.2 Identification of the node marker-panel 
The general idea of the node marker-panel discovery method is to find a classifier at 
every node (excluding the root) and leaf of the diagnostic hierarchy.  The node classifiers 
are based on common expression attributes of phenotypes grouped within a particular 
node; these classifiers consist of a set of gene-pair binary decision rules, whose 
collective ‘true = 1 ’ or ‘false = 0 ’ outcomes are to guide classification of a 
transcriptome test sample towards a brain phenotype.  The gene-pair classifiers of the 
node marker-panel are identified through the following steps: 
1.  Let !! denote all samples included in the training of node t.  These samples 
correspond to phenotypes of either !! ∈ !! or !! ∈ !!!, where !! is the subgrouping of 
classes at t (we start from a child nodes of the root), and !!! represents the set of classes 
that do not belong to !!.  Using all expression profiles in !!, we identify nine disjoint 
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gene-pairs (!! ,!!) with the nine highest values of ∆!,! between !! and !!!.  This set of 
gene-pairs is denoted as !! = !!,… ,!! , where !! is the gene-pair with the mth highest ∆!,!.  Here, for any given transcriptome sample, the two genes of !! comprise the 
following decision rule: If a sample displays the relative expression relation !!! > !!!, 
then the sample is classified as !!; otherwise, the sample is classified as !!!, where !!! 
and !!! are expression levels of gene ! and gene !, respectively.   
 When multiple gene-pairs achieve the same ∆!,!, the gene pairs are preferentially 
selected by the tie-breaking scheme employed by Tan et al. (Tan, et al., 2005).  Note that 
since the classification compares !! and !!! at each node t, the classifiers of the two child 
nodes of the root must necessarily be the same.  This special case occurs in the child 
nodes of the root because every class label is represented either in the left child or the 
right child.   
2.  For the ! gene-pairs in !! with the ! highest TSP scores (! = 1,… ,9), a constant 
threshold !   ! ≤ !  is found, representing the minimum number of gene-pairs required 
to have ‘true = 1 ’ decision rule outcomes in order to have a particular sample classified 
as !!.  The optimal ! gene-pairs and threshold ! are found concurrently: !  is the fewest 
number of gene-pairs that yields classification sensitivity (percentage of !! samples that 
are classified as !! ∈ !! correctly) above a desired value; ! is optimized to be the 
threshold that results in the highest overall accuracy, i.e. percentage of all samples in !! 
that are classified correctly. 
3.  Using the optimal ! gene-pairs and threshold ! found in Step 2, we evaluate all ! 
gene-pair classifiers on every sample of !!, where each classifier’s binary decision rule 
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outcome (on each sample) is either ‘true = 1 ’ or ‘false = 0 ’.  The total number of 
true outcomes for each sample is denoted as !.  If ! ≥ !, the sample is labeled ‘positive’ 
for !! and passes into !!∗ of child node t* of t for further classifier training.  However, if ! < !, the sample is labeled ‘negative’ for !!  and does not pass into !!∗.  In general, 
most samples of !! ∈ !! passes into !!∗, while most samples of !! ∈ !!! do not pass into !!∗.  This updated collection of samples of !!∗ is now to be used in Step 4 by the child 
nodes t*. 
4.  We iterate Steps 1-3 on the sibling node, on its child nodes, and so forth.  The classes 
of !! and !!! are dependent upon the current node.  Step 2 is used to find the optimal ! 
gene-pairs and threshold !.  Step 3 is used to update !!∗ into smaller and smaller sample 
subsets.  We iteratively train on the samples remaining in each successive !!∗ until gene-
pairs and thresholds are found for all nodes and leaves of the diagnostic hierarchy.   
4.4.3 Identification of the decision-tree marker-panel 
At each edge of the diagnostic hierarchy, the group of class labels of the parent node is 
partitioned into class labels of the two children.  A classifier is chosen at each edge to 
direct classification to either one of the child nodes.  This classifier is a gene-pair (!! ,!!) 
that gives ∆!"# !!,!!  between the classes of the two child nodes, !! and !!.  The 
decision rule for each classifier is: IF !!! > !!!, THEN classify as phenotype !!; ELSE 
phenotype !!, where !!! and !!! are expression levels of genes !! and !!, respectively.  
The collection of gene-pair classifiers at all edges of the diagnostic hierarchy is 
accumulated vertically into a decision-tree marker-panel (Chapter 5) to guide 
classification toward a unique leaf in the diagnostic hierarchy.  The cumulative binary 
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outcome for an entire route, from root to leaf, delineates the disease-specific molecular 
signature.   
4.4.4 Diagnosis of transcriptome samples 
The node marker-panel and the diagnostic hierarchy are used for phenotype 
classification.  Specifically, the relative expression orderings of the gene-pair classifiers 
are used to screen for class-specific expression patterns.   
 Starting at either child node of the root, we use the corresponding set of ! gene-
pairs and constant threshold !.  The value of ! for the transcriptome test sample is 
compared with !.  If ! ≥ !, the sample is ‘positive’ for !! and classification proceeds to 
both child nodes.  However, if ! < !, the sample is ‘negative’ for !!  and classification 
stops.  We continue this process on the sibling node, on the child nodes, and so forth, 
unless a sample is deemed ‘negative’ for a particular node.  A test sample can have one of 
three diagnostic outcomes:  
1.  A single class diagnosis, where the sample is ‘positive’ for all the nodes of only one 
entire diagnostic path.  
2.  No diagnosis, where the sample is ‘negative’ for at least one node in every path.  Here, 
the sample is rejected from classification, and determined to be none of the original 
phenotypes in the diagnostic hierarchy. 
3.  Multiple diagnoses, where the sample is ‘positive’ for all the nodes of multiple paths.  
In this case, the classifiers of the decision-tree marker-panel are used as a tie-breaker:  All 
gene-pair classifiers’ decision rules are evaluated on the sample, and the resulting binary 
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outcome is compared to the binary signatures of the class candidates.  The phenotype 
whose binary signature matches that of the test sample is chosen as the unique diagnosis. 
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4.5 Classification performance of ISSAC on transcriptomic datasets 
Herein, we compare the classification performance of ISSAC with those of other multi-
category classification methods on a variety of gene-expression datasets.  A total of 10 
datasets from a range of clinical phenotypes were collected from several published 
sources (Tables 4.1 and 4.2).  
 Six multi-category classification methods were chosen for our analysis: back-
propagation neural networks (BPNN), k-nearest neighbors (kNN), probabilistic neural 
networks (PNN), support vector machines (SVM), prediction analysis of microarrays 
(PAM), and ISSAC.  We evaluated each of these methods on our collection of ten 
transcriptomic datasets using a single iteration of ten-fold cross-validation.  An overview 
on how BPNN, kNN, PNN, SVM, and PAM were used in this study is summarized in 
Table 4.3 and Table 4.4. 
 Classification performances of all six methods are shown in Table 4.5.  The 
average cross-validation accuracy using ISSAC was 88.4%, which was the second 
highest among all accuracies falling short to only that of SVM (91.9%).  This is highly 
encouraging, considering that SVM is widely regarded by current standards the most 
robust and powerful classification method (Statnikov, et al., 2005).  Based on our results, 
we believe ISSAC shows great promise towards the classification of multiple phenotypes, 
and we recommend its use in future studies that involve more diverse conditions and 
larger sample sizes. 
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Table 4.1 Phenotypes and references of datasets used in this study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
11_Tumors 11 various human tumor types
14_Tumors 14 various human tumor types
9_Tumors 8 various human tumor types
Brain_Tumor1 4 malignant glioma types
DLBCL Diffuse large B-cell lymphomas (DLBCL) and follicular lymphomas
Leukemia 1 Acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL) B-cell and ALL T-cell
Leukemia 2 AML, ALL and mixed-lineage leukemia (MLL)
Lung_Cancer 4 lung cancer types and normal tissues
Prostate_Tumor Prostate tumor and normal tissues
SRBCT Small, round blue cell tumors (SRBCT) of childhood
Dataset name Phenotypes
Su et al. (2001)
Ramaswamy et al. (2001)
Stuanton et al. (2001)
Nutt et al. (2003)
Shipp et al. (2002)
Golub et al. (1999)
Armstrong et al. (2002)
Bhattacherjee et al. (2001)
Singh et al. (2002)
Khan et al. (2001)
Reference
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Table 4.2 Total number of samples, features (genes), and classes of each dataset. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
11_Tumors
14_Tumors
9_Tumors
Brain_Tumor1
DLBCL
Leukemia 1
Leukemia 2
Lung_Cancer
Prostate_Tumor
SRBCT
Dataset name
  Number of
Total samples Features (genes) Classes
174 12,533 11
308 15,009 26
60 5,726 9
50 10,367 4
77 5,469 2
72 5,327 3
72 11,225 3
203 12,600 5
102 10,509 2
83 2,308 4
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Table 4.3 Notes on BPNN, kNN, PNN, SVM, and PAM used in this study. 
 
 
 
 
 
 
 
 
 
Method Method overview
BPNN
i. This is similar to probabilistic neural networks in regards to having different layers and the fact that they’re both 
modeled as a perceptron.
ii. Creates an error gradient based on the points, and traverses the multidimensional surface stochastically.
kNN
i.  Arguably the simplest of the classification algorithms.  Genes are considered points in hyper-dimensional 
space, and classification is based on the classes of the closest K points to the test sample.
ii. http://upload.wikimedia.org/wikipedia/commons/e/e7/KnnClassification.svg In this picture, the green point is 
the “test sample”, and using k = 3, the three closest points are 2 red points and 1 blue point.  Hence the test 
sample would be classified as a red triangle.  However, if k = 5 the the 5 closest points are 3 blue squares and 2 
red triangles.  Hence the test sample would be classified as a blue square.  k = 5 was used in our analysis.
PNN
i. This method is similar to K Nearest Neighbors except it uses a concept of perceptrons, where the algorithm is 
divided into layers.  http://voyagememoirs.com/wordpress-voyphar/wp-content/uploads/2008/06/pnn.jpg.  The 
input layers are the genes of the test sample ran through the algorithm.  The Pattern Layer is an activation 
operation based on which genes are the most telling of the sample.  The summation layer takes a mathematical 
sum of the activations (there are two nodes in the summation layer of this picture, which means it is 
discrimination between two classes).  The output layer is the final classification.
ii. The bulk of the algorithm is nested in the activation layer. 
SVM
i. Conceptually, SVM plots all points in hyper-dimensional space and optimize a plane such that the distance 
between the points and plane is maximized. 
ii. There are different versions for SVM, but the one used in our analysis is one-versus-one (OVO), which means 
every binary comparison between two classes is considered.
iii. A linear SVM kernel was used in our analysis.
PAM
i. PAM is a relatively simple algorithm that is based on nearest centroids.  The following link should be a good 
reference: http://www-stat.stanford.edu/~tibs/PAM/Rdist/doc/readme.html
ii. Basically PAM works by normalizing the data (by its own method) and determining the centroid (basically an 
adjusted center) for each gene for each class. 
iii.  In its second step, a threshold value is used to shrink every centroid value towards zero.  For example, if the 
normalized centroid value for one gene is 4.0, and the threshold value is 3.0, the values would be shrunk to 1.0.  
However, if the threshold value is 5.0, the centroid will be shrunken to 0, not -1.0.
iv. If a gene presents a centroid value of 0 for every class, then it is eliminated completely.  This is PAM’s method 
for gene selection.  That is why we cannot specify an exact number to determine the number of genes, rather we 
must use a threshold value which would allow only the top n number of genes to survive.  A threshold of 3.0 was 
used in our analysis.
v. Classification of samples is based on closest squared distance. The class that has the smallest squared 
distance from the sample is classified as such.
vi. Full documentation for PAM functions can be found at: http://cran.r-project.org/web/packages/pamr/pamr.pdf
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Table 4.4 Notes on feature selection methods used in SVM and PAM. 
 
  
 
 
 
 
 
 
Method Feature selection method overview
SVM
i. Recursive feature elimination, used solely for selecting genes in SVM, is considered 
the best method
ii. In order to select genes, SVM must first be trained on the training set with all 
genes. The SVM model that is trained will have support vectors and coefficients for 
corresponding genes. The support vector and coefficients can be multiplied to finding 
the weight vector.
iii. The weight vector is what determines the hyperplane, and the weight vector has 
one value for each gene. So if you have 5000 genes, you will also have 5000 weights
iv. The weight vector values are squared so that you only deal with positive values
v. The gene with the smallest corresponding W^2 value is eliminated. This will mean 
that the gene contributing towards the hyperplane the least will be eliminated. 
Conventionally this method only removes 1 gene at a time. However, for the scale we 
are using the method, it was not computationally feasible. I removed 10% + 1 gene(s) 
per iteration.
vi. With the remaining genes, SVM is trained again and the process continues to loop 
until the top “n” number of genes are found.
PAM
i. This method of gene selection is determined by threshold values.
ii. This method starts off by adjusting a centroid for each gene for class
iii. Threshold values are chosen arbitrarily and they shrink every centroid towards 
zero. For example if you have a centroid value of 4.0 and a threshold value of 3.0, the 
centroid is shrunken to 1.0. Centroid values never go below zero, so if you have a 
centroid value of 4.0 and a threshold value of 5.0, the centroid is shrunken to 0.0, not -
1.0.
iv. If the centroid of a gene for every class is shrunken to 0, that gene is eliminated 
from classification. This is PAM’s method of gene selection.
v. Since you cannot specify the number of genes you want, you must indirectly 
specify a threshold value that corresponds to the correct number of genes. For 
example if the top 50 genes have centroid values over 4.0, and every other gene have 
values lower than 4.0, then you would set the threshold value to about 3.9999.
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Table 4.5 Ten-fold cross-validation accuracies of multi-category classification methods. 
 
 
 
 
 
 
 
 
 
 
 
BPNN kNN PNN SVM PAM ISSAC
11_Tumors 74.5% 85.0% 86.3% 93.5% 90.2% 83.0%
14_Tumors 38.5% 50.8% 48.8% 69.0% 56.0% 60.3%
9_Tumors 88.8% 87.5% 90.0% 92.5% 88.8% 96.3%
Brain_Tumor1 67.4% 83.7% 67.4% 81.4% 74.4% 39.5%
DLBCL 88.3% 88.3% 90.9% 96.1% 79.2% 92.2%
Leukemia 1 92.1% 87.3% 88.9% 95.2% 96.8% 98.4%
Leukemia 2 80.6% 87.5% 90.3% 95.8% 86.1% 90.3%
Lung_Cancer 90.9% 92.9% 92.4% 92.9% 92.9% 91.4%
Prostate_Tumor 83.3% 79.4% 71.6% 92.2% 84.3% 90.2%
SRBCT 79.5% 89.2% 94.0% 100.0% 98.8% 94.0%
Average 79.6% 83.1% 83.7% 91.9% 85.9% 88.4%
Dataset name
Ten-fold cross-validation accuracy
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4.6 Chapter summary 
We developed a novel algorithm called Identification of Structured Signatures And 
Classifiers (ISSAC) that stratifies multiple clinical phenotypes simultaneously based on 
relative expression of biological features (e.g. genes, proteins).  ISSAC uses a data-
driven, hierarchical approach to first organize phenotypes into a global hierarchy, and 
then learn corresponding (binary) classifiers.  The genes appearing in the hierarchy of 
decision rules can then be accumulated into a panel of biomarkers, which can then direct 
classification down the tree to select a particular phenotype.  The cumulative expression 
patterns in the biomarker panel thereby constitute “structured” signatures for a set of 
classes.  Compared with other methods, ISSAC displayed favorable classification 
performance on various transcriptomic datasets, showing great promise towards future 
molecular diagnostics studies wherein comprehensive phenotype distinction is necessary. 
 
(Armstrong, et al., 2002; Bhattacharjee, et al., 2001; Golub, et al., 1999; Khan, et al., 
2001; Shipp, et al., 2002; Singh, et al., 2002; Staunton, et al., 2001; Su, et al., 2001) 
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Chapter 5.  Molecular diagnostic signatures of 
human brain cancers  
 
5.1 Introduction 
The global measurement of biomolecule expression in an organ system can enable the discovery 
of molecular diagnostic signatures that effectively detect organ-specific maladies, especially 
cancer.  In this regard, genome-wide transcriptomic data are a readily available type of high-
throughput biological data, making this a promising source for molecular signatures, as well as a 
good means to study the robustness of signatures across different studies.  During the past decade, 
transcriptomics analyses on clinical patient samples have been widely used to uncover cancer-
associated genes (Gu, et al., 2002) and to discover biomarkers for diagnosis, prognosis prediction, 
and optimal therapy selection (Friedman, et al., 2009; Khan, et al., 2001; Yeoh, et al., 
2002).  Recently, gene transcripts measured in blood have been used as serum-based molecular 
fingerprints of neurological disease (Scherzer, et al., 2007).  Furthermore, with the rapid 
advancement of RNA-seq technologies, the broader inclusion of small RNAs in clinically 
relevant studies is likely to dramatically increase (Wang, et al., 2009).  
 A significant limitation to the field of microarray transcriptomics is the poor overlap in 
biomarker results and limited predictive success across independent studies of equivalent test 
conditions (Dougherty, 2001; Kuo, et al., 2002).  This lack of robustness, even for the most 
promising results, has been reported to be due to a host of factors, including insufficient quantity 
of microarray samples available in clinical studies upon which a classifier is trained, and over-
fitting problems common to overly complex classifiers.  Also, the use of disparate microarray 
platforms and variability in experimental protocols and data preprocessing techniques (i.e. 
normalization) can lead to an inherent bias to the specific data source or laboratory.   
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 To overcome these limitations, a growing trend has been to accumulate gene-expression 
microarray data from independent studies into the form of large meta-analyses (Dreyfuss, et al., 
2009; Dudley, et al., 2009; Segal, et al., 2004).   This integrated strategy allows a natural 
expansion in sample size across diverse sources and conditions, which is essential to the 
development of more robust results.  Therefore, a large-scale, inter-study analysis using all 
currently available microarray gene-expression data for a disease state(s) of interest can be a 
promising method of finding more reliable and robust meta-signatures, as well as to gain new, 
holistic insights about disease not offered by smaller, individual studies.  
 In this chapter, we used ISSAC (Chapter 4) on an integrated dataset of publicly available 
gene expression data to identify molecular signatures that simultaneously distinguish major 
cancers of the human brain.  As shown in the forthcoming sections, ISSAC provided a global 
diagnostic hierarchy and corresponding structured brain cancer signatures composed of gene-pair 
classifier sets.  The signal in the transcriptomics data was sufficient to develop accurate, 
comprehensive signatures when the training set was sampled from the same population as the 
validation set (i.e. cross validation).    
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5.2 Data collection and integration methods 
In this section, we describe the three major steps involved in building our meta-dataset of human 
brain cancer gene-expression.  These steps are: 1) accumulating brain cancer transcriptomes from 
multiple studies into a single dataset; 2) consensus preprocessing using GC-RMA; and 3) 
microarray probe-set filtering using MAS5 calls. 
5.2.1 Multi-study dataset of human brain cancer transcriptomes 
All transcriptomic data used in our analysis are publicly available at the NCBI Gene Expression 
Omnibus (GEO).  We integrated 921 microarray samples of six brain cancers (ependymoma, 
glioblastoma multiforme, medulloblastoma, meningioma, oligodendroglioma, pilocytic 
astrocytoma) and normal brain across 16 independent studies into a transcriptome meta-
dataset.  Importantly, we obtained the raw data (.CEL files) from each of these studies and 
preprocessed them uniformly using identical techniques to greatly reduce extraneous sources of 
technical artifacts (discussed below).  All data manipulation and numerical calculations were 
performed using MATLAB (MathWorks).   
 To ensure data quality and to help control for systemic bias, we used the following strict 
criteria and reasoning for brain phenotype selection: 1) Expression profiles must have been 
conducted on either the Affymetrix Human Genome U133A or U133 Plus 2.0 microarray 
platform.  This allowed maximum microarray sample collection without considerable reduction in 
number of overlapping classifier features (i.e. microarray probe-sets).  2) Transcriptomic datasets 
(i.e. GSE xxx) for each phenotype must have been collected from at least two independent 
sources to help mitigate batch effects.  3) All datasets must have consisted of no fewer than 5 
microarray samples.  4) All datasets must have originated from primary brain tumor or tissue 
biopsies.  Expression profiles from cell-lines or laser micro-dissections were not used in our study 
to better ensure sample consistency.  5) Raw microarray intensity data (.CEL files) must have 
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been available on GEO for consensus preprocessing.  6) Sample preparation protocols must have 
been fully disclosed on GEO.  7) All microarray samples in a dataset of a given phenotype were 
used in order to take into consideration all sources of heterogeneity.  That is, no samples were 
excluded because their gene expression profile were abnormal for its phenotype.  This reduces 
apparent accuracy, but we concluded this to be the most stringent and fairest test.  After an 
exhaustive search on GEO, we identified 921 microarray samples from 16 studies that met the 
above criteria (as of January 2011).  Information on all datasets (e.g. publication sources, 
Affymetrix platforms, GEO dataset IDs, and microarray sample IDs) and GEO microarray sample 
IDs used in our meta-analysis is available in Tables 5.1 and 5.2, respectively.   
 Raw microarray intensity data (.CEL files) were obtained online from GEO and 
preprocessed uniformly.  More specifically, common probe-sets were found across all 
transcriptome samples, and consensus preprocessing was performed on all the raw microarray 
image data to build a consensus dataset.  This step removes one major non-biological source of 
variance between different studies.  These preprocessed samples were used to build a multi-study, 
meta-dataset of human brain cancer and normal brain transcriptomes.  Finally, stringent probe-set 
filtering was used to remove spurious classifier features.  Our consensus preprocessing and probe-
set filtering methods are explained in further detail below.  Our integrated and uniformly pre-
processed meta-dataset is available at http://price.systemsbiology.net/downloads_tmp.php as a 
community resource for those who wish to conduct their own analyses. 
5.2.2 Consensus preprocessing using GC-RMA 
All gene expression data used in our meta-analysis were measurements conducted on either the 
Affymetrix Human Genome U133A or U133Plus2.0 oligonucleotide microarrays.  The 
expression level of a target gene on these two platforms is measured by first quantifying the total 
intensity of fluorescently labeled RNA fragments (from patient specimens) that bind to a probe 
set, or the set of complementary 25-mer oligonucleotide probe sequences.  The intensities of all 
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probe sets (raw measurements in the form of .CEL files) are then adjusted for background 
variability and normalized across all samples to obtain the target genes’ final expression values. 
 Raw .CEL data files were downloaded directly from the Gene Expression Omnibus 
online public repository.  Probe set information used in this study were based on the latest 
Affymetrix annotations (as of January, 2011).  Raw intensity measurements of all microarray 
samples were preprocessed simultaneously (consensus preprocessing) using the MATLAB 
implementation of GC-RMA probe summarization (Wu Z, 2004).  Only the probe sets that map 
to known genes and exist on both Affymetrix platforms (same oligonucleotide sequences) were 
considered for preprocessing.  
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Table 5.1 Description of all GEO microarray datasets used in this study.  
 
ψStudies that have not been published are denoted as ‘-’.  See References for full publication 
citations. 
 
 
 
 
 
 
 
Phenotype name GEO accession #
First author 
(publication year) Ref.
Sample
size Affymetrix array
GSE16155 Donson (2009) S1 19 U133 plus2.0
GSE21687 Johnson (2010) S2 83 U133 plus2.0
GSE 4412 Freije (2004) S3 59 U133A
Glioblastoma GSE 4271 Phillips (2006) S4 76 U133A
Multiforme GSE 8692 Liu (2007) S5 6 U133A
GSE 9171 Wiedemeyer (2008) S6 13 U133 plus2.0
GSE 4290 Sun (2006) S7 77 U133 plus2.0
GSE 10327 Kool (2008) S8 61 U133 plus2.0
GSE 12992 Fattet (2009) S9 40 U133 plus2.0
GSE 4780 Scheck (2006) - 62 U133A/U133 plus2.0
GSE 9438 Claus (2008) S10 31 U133 plus2.0
GSE 16581 Lee (2010) S11 68 U133 plus2.0
GSE 4412 Freije (2004) S3 11 U133A
GSE 4290 Sun (2006) S7 50 U133 plus2.0
Pilocytic GSE 12907 Wong (2005) S12 21 U133A
Astrocytoma GSE 5675 Sharma (2007) S13 41 U133 plus2.0
GSE 3526 Roth (2006) S14 146 U133 plus2.0
GSE 7307 Roth (2007) - 57 U133 plus2.0
Oligodendroglioma
Normal Brain
Ependymoma
Medulloblastoma
Meningioma
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Table 5.2 GEO microarray IDs of all 921 transcriptome samples used in this study. 
 
Phenotype
Name
Phenotype
Label
GEO Accession
Series # GEO Microarray Sample ID
GSE16155
GSM404936,GSM404937,GSM404938,GSM404939,GSM404940,GS
M404941,GSM404942,GSM404943,GSM404944,GSM404945,GSM4
04946,GSM404947,GSM404948,GSM404949,GSM404950,GSM4049
51,GSM404952,GSM404953,GSM404954
GSE21687
GSM541060,GSM541061,GSM541062,GSM541063,GSM541064,GS
M541065,GSM541066,GSM541067,GSM541068,GSM541069,GSM5
41070,GSM541071,GSM541072,GSM541073,GSM541074,GSM5410
75,GSM541076,GSM541077,GSM541078,GSM541079,GSM541080,
GSM541081,GSM541082,GSM541083,GSM541084,GSM541085,GS
M541086,GSM541087,GSM541088,GSM541089,GSM541090,GSM5
41091,GSM541092,GSM541093,GSM541094,GSM541095,GSM5410
96,GSM541097,GSM541098,GSM541099,GSM541100,GSM541101,
GSM541102,GSM541103,GSM541104,GSM541105,GSM541106,GS
M541107,GSM541108,GSM541109,GSM541110,GSM541111,GSM541
112,GSM541113,GSM541114,GSM541115,GSM541116,GSM541117,
GSM541118,GSM541119,GSM541120,GSM541121,GSM541122,GSM
541123,GSM541124,GSM541125,GSM541126,GSM541127,GSM5411
28,GSM541129,GSM541130,GSM541131,GSM541132,GSM541133,G
SM541134,GSM541135,GSM541136,GSM541137,GSM541138,GSM5
41139,GSM541140,GSM541141,GSM541142
GSE 4412
GSM99432,GSM99434,GSM99436,GSM99438,GSM99440,GSM9944
2,GSM99444,GSM99446,GSM99448,GSM99450,GSM99452,GSM99
454,GSM99456,GSM99462,GSM99464,GSM99466,GSM99470,GSM
99472,GSM99474,GSM99476,GSM99478,GSM99480,GSM99482,GS
M99484,GSM99486,GSM99488,GSM99490,GSM99492,GSM99494,G
SM99524,GSM99526,GSM99528,GSM99530,GSM99532,GSM99534,
GSM99536,GSM99538,GSM99540,GSM99542,GSM99544,GSM9954
6,GSM99548,GSM99550,GSM99552,GSM99554,GSM99556,GSM99
558,GSM99560,GSM99562,GSM99564,GSM99572,GSM99576,GSM
99578,GSM99580,GSM99582,GSM99584,GSM99586,GSM99588,GS
M99590
Glioblastoma GBM
GSE 4271
GSM96950,GSM96951,GSM96952,GSM96953,GSM96954,GSM9695
5,GSM96956,GSM96957,GSM96958,GSM96959,GSM96960,GSM96
961,GSM96962,GSM96963,GSM96964,GSM96965,GSM96966,GSM
96967,GSM96968,GSM96969,GSM96970,GSM96971,GSM96972,GS
M96973,GSM96974,GSM96975,GSM96976,GSM96977,GSM96978,G
SM96979,GSM96980,GSM96981,GSM96982,GSM96983,GSM96984,
GSM96985,GSM96986,GSM96987,GSM96988,GSM96989,GSM9699
0,GSM96991,GSM96992,GSM96993,GSM96994,GSM96995,GSM96
996,GSM96997,GSM96998,GSM96999,GSM97000,GSM97001,GSM
97002,GSM97003,GSM97004,GSM97005,GSM97006,GSM97007,GS
M97008,GSM97009,GSM97010,GSM97011,GSM97014,GSM97018,G
SM97021,GSM97024,GSM97028,GSM97031,GSM97032,GSM97037,
GSM97040,GSM97041,GSM97042,GSM97044,GSM97048,GSM9704
9
Multiforme
GSE 8692 GSM215420,GSM215422,GSM215423,GSM215425,GSM215426,GSM215427
GSE 9171
GSM231695,GSM231696,GSM231697,GSM231698,GSM231699,GS
M231700,GSM231701,GSM231702,GSM231703,GSM231704,GSM2
31705,GSM231706,GSM231707
GSE 4290
GSM97794,GSM97796,GSM97797,GSM97798,GSM97801,GSM9780
6,GSM97808,GSM97813,GSM97814,GSM97818,GSM97819,GSM97
821,GSM97829,GSM97832,GSM97839,GSM97844,GSM97847,GSM
97851,GSM97852,GSM97856,GSM97859,GSM97861,GSM97863,GS
M97869,GSM97870,GSM97871,GSM97877,GSM97882,GSM97885,G
SM97886,GSM97887,GSM97888,GSM97889,GSM97891,GSM97892,
GSM97893,GSM97894,GSM97895,GSM97896,GSM97898,GSM9790
3,GSM97905,GSM97906,GSM97908,GSM97912,GSM97914,GSM97
915,GSM97917,GSM97918,GSM97919,GSM97922,GSM97924,GSM
97926,GSM97930,GSM97931,GSM97935,GSM97936,GSM97938,GS
M97940,GSM97942,GSM97945,GSM97946,GSM97948,GSM97950,
GSM97952,GSM97953,GSM97954,GSM97955,GSM97959,GSM9796
1,GSM97963,GSM97965,GSM97966,GSM97967,GSM97968,GSM97
969,GSM97971
EPNEpendymoma
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Table 5.2 (Continued) GEO microarray IDs of all 921 transcriptome samples used in this study. 
 
GSE 10327
GSM260959,GSM260960,GSM260961,GSM260962,GSM260963,GS
M260964,GSM260965,GSM260966,GSM260967,GSM260968,GSM2
60969,GSM260970,GSM260971,GSM260972,GSM260973,GSM2609
74,GSM260975,GSM260976,GSM260977,GSM260978,GSM260979,
GSM260981,GSM260982,GSM260983,GSM260984,GSM260985,GS
M260986,GSM260987,GSM260988,GSM260989,GSM260990,GSM2
60991,GSM260992,GSM260993,GSM260994,GSM260995,GSM2609
96,GSM260997,GSM260998,GSM260999,GSM261000,GSM261001,
GSM261002,GSM261003,GSM261004,GSM261005,GSM261006,GS
M261007,GSM261008,GSM261009,GSM261010,GSM261011,GSM26
1012,GSM261013,GSM261014,GSM261015,GSM261016,GSM26101
7,GSM261018,GSM261019,GSM261020
GSE 12992
GSM324062,GSM324063,GSM324064,GSM324065,GSM324066,GS
M324067,GSM324068,GSM324069,GSM324082,GSM324083,GSM3
24084,GSM324085,GSM324090,GSM324091,GSM324092,GSM3240
93,GSM324104,GSM324111,GSM324112,GSM324113,GSM324115,G
SM324119,GSM324137,GSM324138,GSM324139,GSM324140,GSM
324141,GSM324508,GSM324512,GSM324513,GSM324514,GSM324
515,GSM324516,GSM324517,GSM324526,GSM325233,GSM325278
,GSM325280,GSM325281,GSM325282
GSE 4780 
GSM108014,GSM108015,GSM108016,GSM108017,GSM108018,GS
M107987,GSM107988,GSM107989,GSM107990,GSM107991,GSM1
07992,GSM107993,GSM107994,GSM107995,GSM107996,GSM1079
97,GSM107998,GSM107999,GSM108000,GSM108001,GSM108002,
GSM108003,GSM108004,GSM108005,GSM108006,GSM108007,GS
M108008,GSM108009,GSM108010,GSM108011,GSM108012,GSM10
8013,GSM108019,GSM108020,GSM108021,GSM108022,GSM10802
3,GSM108024,GSM108025,GSM108026,GSM108027,GSM108028,G
SM108029,GSM108030,GSM108031,GSM108032,GSM108033,GSM
108034,GSM108035,GSM108036,GSM108037,GSM108038,GSM108
039,GSM108040,GSM108041,GSM108042,GSM108043,GSM108044
,GSM108045,GSM108046,GSM108047,GSM108048
GSE 9438
GSM239770,GSM239771,GSM239772,GSM239773,GSM239774,GS
M239775,GSM239776,GSM239777,GSM239778,GSM239779,GSM2
39780,GSM239781,GSM239782,GSM239783,GSM239784,GSM2397
85,GSM239786,GSM239787,GSM239788,GSM239789,GSM239790,
GSM239791,GSM239792,GSM239793,GSM239794,GSM239795,GS
M239796,GSM239797,GSM239798,GSM239799,GSM239800
GSE 16581
GSM416798,GSM416799,GSM416800,GSM416801,GSM416802,GS
M416803,GSM416804,GSM416805,GSM416806,GSM416807,GSM4
16808,GSM416809,GSM416810,GSM416811,GSM416812,GSM4168
13,GSM416814,GSM416815,GSM416816,GSM416817,GSM416818,
GSM416819,GSM416820,GSM416821,GSM416822,GSM416823,GS
M416824,GSM416825,GSM416826,GSM416827,GSM416828,GSM4
16829,GSM416830,GSM416831,GSM416832,GSM416833,GSM4168
34,GSM416835,GSM416836,GSM416837,GSM416838,GSM416839,
GSM416840,GSM416841,GSM416842,GSM416843,GSM416844,GS
M416845,GSM416846,GSM416847,GSM416848,GSM416849,GSM4
16850,GSM416851,GSM416852,GSM416853,GSM416854,GSM4168
55,GSM416856,GSM416857,GSM416858,GSM416859,GSM416860,
GSM416861,GSM416862,GSM416863,GSM416864,GSM416865
GSE 4412 GSM99458,GSM99460,GSM99510,GSM99512,GSM99514,GSM99516,GSM99518,GSM99520,GSM99522,GSM99570,GSM99598
GSE 4290
GSM97799,GSM97822,GSM97823,GSM97824,GSM97830,GSM9783
1,GSM97835,GSM97838,GSM97841,GSM97842,GSM97845,GSM97
854,GSM97857,GSM97860,GSM97862,GSM97864,GSM97865,GSM
97866,GSM97867,GSM97868,GSM97872,GSM97873,GSM97874,GS
M97875,GSM97876,GSM97880,GSM97881,GSM97883,GSM97884,G
SM97897,GSM97900,GSM97901,GSM97902,GSM97904,GSM97907,
GSM97909,GSM97911,GSM97923,GSM97925,GSM97928,GSM9792
9,GSM97933,GSM97934,GSM97944,GSM97947,GSM97949,GSM97
956,GSM97962,GSM97964,GSM97970
Medulloblastoma MDL 
Meningioma MNG
Oligodendroglioma OLG
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Table 5.2 (Continued) GEO microarray IDs of all 921 transcriptome samples used in this study. 
 
 
 
 
 
GSE 12907
GSM322969,GSM323054,GSM323523,GSM323524,GSM323525,GS
M323526,GSM323527,GSM323528,GSM323529,GSM323530,GSM3
23531,GSM323554,GSM323555,GSM323557,GSM323558,GSM3235
59,GSM323560,GSM323561,GSM323562,GSM323563,GSM323564
GSE 5675
GSM132714,GSM132715,GSM132716,GSM132717,GSM132718,GS
M132719,GSM132720,GSM132722,GSM132723,GSM132728,GSM1
32729,GSM132730 ,GSM132733,GSM132736,GSM132738 
,GSM132741 ,GSM132744,GSM132747,GSM132748,GSM132750 
,GSM132751,GSM132752,GSM132753,GSM132754,GSM132759,GS
M132761,GSM132763,GSM132765,GSM132768,GSM132769,GSM1
32770,GSM132771,GSM132772,GSM132773,GSM132774,GSM1327
75,GSM132776,GSM132777,GSM132778,GSM132779,GSM132780
GSE 3526
GSM80565,GSM80566,GSM80567,GSM80568,GSM80569,GSM8057
0,GSM80571,GSM80572,GSM80573,GSM80574,GSM80575,GSM80
581,GSM80585,GSM80586,GSM80587,GSM80591,GSM80592,GSM
80593,GSM80594,GSM80595,GSM80596,GSM80597,GSM80598,GS
M80599,GSM80600,GSM80601,GSM80616,GSM80617,GSM80618,
GSM80619,GSM80620,GSM80621,GSM80622,GSM80623,GSM8062
6,GSM80627,GSM80628,GSM80636,GSM80637,GSM80638,GSM80
639,GSM80640,GSM80641,GSM80642,GSM80643,GSM80644,GSM
80645,GSM80646,GSM80647,GSM80650,GSM80651,GSM80652,GS
M80653,GSM80660,GSM80661,GSM80662,GSM80663,GSM80664,
GSM80665,GSM80666,GSM80667,GSM80668,GSM80669,GSM8067
0,GSM80671,GSM80675,GSM80676,GSM80677,GSM80678,GSM80
679,GSM80680,GSM80681,GSM80682,GSM80683,GSM80684,GSM
80690,GSM80691,GSM80692,GSM80693,GSM80699,GSM80700,GS
M80701,GSM80702,GSM80703,GSM80704,GSM80705,GSM80706,
GSM80708,GSM80709,GSM80711,GSM80713,GSM80714,GSM8071
5,GSM80721,GSM80722,GSM80723,GSM80724,GSM80744,GSM80
745,GSM80746,GSM80747,GSM80752,GSM80754,GSM80756,GSM
80760,GSM80761,GSM80762,GSM80763,GSM80766,GSM80767,GS
M80772,GSM80773,GSM80774,GSM80775,GSM80800,GSM80801,
GSM80802,GSM80803,GSM80804,GSM80817,GSM80818,GSM8081
9,GSM80830,GSM80831,GSM80832,GSM80833,GSM80834,GSM80
835,GSM80836,GSM80837,GSM80838,GSM80839,GSM80840,GSM
80841,GSM80847,GSM80848,GSM80849,GSM80851,GSM80852,GS
M80855,GSM80858,GSM80859,GSM80860,GSM80861,GSM80862,
GSM80863
GSE 7307
GSM175842,GSM175843,GSM175844,GSM175845,GSM175849,GS
M175850,GSM175851,GSM176153,GSM175852,GSM175853,GSM1
75854,GSM176048,GSM175855,GSM175856,GSM175857,GSM1758
58,GSM175846,GSM175847,GSM175848,GSM176150,GSM175871,
GSM175872,GSM175873,GSM176059,GSM175874,GSM175875,GS
M175876,GSM175877,GSM176215,GSM175901,GSM175902,GSM1
75903,GSM175904,GSM175987,GSM175988,GSM176174,GSM1761
75,GSM175989,GSM175990,GSM176170,GSM176171,GSM176172,
GSM176173,GSM176178,GSM176179,GSM176180,GSM176181,GS
M176182,GSM176183,GSM176184,GSM176185,GSM176161,GSM1
76162,GSM176163,GSM176164,GSM176056,GSM176073
Normal Brain normal
PAPilocyticAstrocytoma
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5.2.3 Probe set filtering using MAS5 calls 
Probe sets of Affymetrix microarrays have ‘perfect match’ probes that are perfectly 
complementary to the target gene’s mRNA sequence.  They also have ‘mismatch’ probes that 
contain a mismatched nucleotide halfway along the probe sequence, and are used to estimate the 
degree of non-specific binding.  To ensure that a probe set is reliably detected, the measurements 
of the ‘perfect match’ probes must be significantly greater than those of the ‘mismatch’ probes.  
This is usually assessed based on statistical measures.  The MAS5 preprocessing software makes 
expression quality calls based on the nonparametric Wilcoxon signed-rank test.  The ‘absent’ call 
is made when the p-value is greater than 0.06, representing no significant difference between the 
measurements of the ‘perfect match’ and those of the ‘mismatch’ probes (Irizarry, et al., 2003).  
We eliminated probes that were determined to be ‘absent’ in all samples of the consensus dataset.  
After this probe set filtering step, 19,656 probe sets (corresponding to target genes) within each 
microarray sample were kept for further analysis. 
 GC-RMA preprocessing and MAS5 probe set filtering procedures were conducted 
separately for training and test set samples, i.e. inside each cross-validation or hold-out 
loop, in order to avoid possible cross-talk between the two datasets.  Genes that were 
excluded based on the MAS5 ‘absent’ calls on the training data were also removed from 
the corresponding test data. 
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5.3 Node and edge based classifiers of the brain cancer diagnostic 
hierarchy 
From our integrated dataset of publicly available gene expression data, ISSAC provided a global 
brain cancer diagnostic hierarchy and corresponding phenotype molecular signatures composed 
of gene-pair classifier sets.  The node and edge classifiers (Figs. 5.1 and 5.2, respectively) were 
assembled into node and decision-tree marker-panels (Tables 5.3 and 5.4, respectively).  Our 
marker-panels consist of 39 total gene-pairs and 44 unique genes (46 unique Affymetrix 
microarray probe IDs).  (details on how gene-pair sets are selected as classifiers, and how they are 
used for phenotype prediction, can be found in Chapter 4).  
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Figure 5.1 Gene-pair sets of the node marker-panel are shown at their corresponding twelve 
nodes in the brain cancer diagnostic hierarchy.  Gene i (left) and Gene j (right) are the genes 
expressed higher and lower within each gene-pair, respectively.  A transcriptome test sample is 
classified as the phenotype(s) of the node if the number of corresponding gene-pairs with a 'true' 
outcome for the statement “Gene i is expressed higher than Gene j” is greater than or equal to a 
threshold k defined for that node. 
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Figure 5.2 Gene-pairs of the decision-tree marker-panel are shown at their corresponding edges 
in the brain cancer diagnostic hierarchy.  Gene i and Gene j are the genes expressed higher and 
lower within the gene-pair, respectively.  For a given test sample, the direction of its classification 
down the diagnostic hierarchy is based on the gene-pair classifiers’ true/false outcomes (left/right, 
respectively) for the statement “Gene i is expressed higher than Gene j”. 
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Table 5.3 Node marker-panel for brain cancer and normal transcriptome classification. 
 
Node #: Corresponds to numerical labels shown in the brain phenotype diagnostic hierarchy (Fig. 
5.1).  Brain phenotype abbreviation (name): ALZ (Alzheimer's), GBM (Glioblastoma 
multiforme), MDL (Medulloblastoma), MNG (Meningioma), normal (Normal brain), OLG 
(Oligodendroglioma), and PA (Pilocytic astrocytoma).  Gene i / Gene j: the gene expressed higher 
and lower in the gene-pair, respectively, within each corresponding phenotype.  Gene name / 
Chromosome locus: according to Entrez Gene.  Affymetrix Probe ID: For both Affymetrix 
Human Genome U133A and U133Plus2.0 Arrays.  k: The minimum number of gene-pair 
classifiers whose decision rule outcomes for a test sample are required to be ‘true (= 1)' for the 
sample to be classified as the phenotype(s) of the corresponding node. 
 
  Gene symbol Gene name Chomosomelocus
Affymetrix
Probe ID Gene symbol Gene name
Chomosome
locus
Affymetrix
Probe ID
 EPN  GBM  MDL  
 MNG  OLG  PA
3  normal   PURA Purine-rich element binding protein A 5q31 204021_s_at PRPF40A PRP40 pre-mRNA processing factor 40 homolog A  (S. cerevisiae) 2q23.3 218053_at 1
 EPN  GBM  MDL
  NRCAM Neuronal cell adhesion molecule 7q31 204105_s_at ISLR Immunoglobulin superfamily containing leucine-rich repeat 15q23-q24 207191_s_at
 OLG  PA
  IDH2 Isocitrate dehydrogenase 2 (NADP+), mitochondrial 15q26.1 210046_s_at GMDS GDP-mannose 4,6-dehydratase 6p25 214106_s_at
5  MNG   ISLR Immunoglobulin superfamily containing leucine-rich repeat 15q23-q24 207191_s_at NRCAM Neuronal cell adhesion molecule 7q31 204105_s_at 1
  SALL1 Sal-like 1 (Drosophila) 16q12.1 206893_at PAFAH1B3 Platelet-activating factor acetylhydrolase 1b, catalytic subunit 3 19q13.1 203228_at
  SRI Sorcin 7q21 208920_at NBEA Neurobeachin 13q13 221207_s_at
  DDR1 Discoidin domain receptor tyrosine kinase 1 6p21.3 210749_x_at TIA1 TIA1 cytotoxic granule-associated RNA binding protein 2p13 201447_at
  DDR1 Discoidin domain receptor tyrosine kinase 1 6p21.3 208779_x_at MAB21L1 Mab-21-like 1 (C. elegans) 13q13 206163_at
  ITPKB Inositol 1,4,5-trisphosphate 3-kinase B 1q42.13 203723_at PDS5B PDS5, regulator of cohesion maintenance, homolog B (S. cerevisiae 13q12.3 204742_s_at
  PAFAH1B3 Platelet-activating factor acetylhydrolase 1b, catalytic subunit 3 19q13.1 203228_at SALL1 Sal-like 1 (Drosophila) 16q12.1 206893_at
  NBEA Neurobeachin 13q13 221207_s_at SRI Sorcin 7q21 208920_at
  TIA1 TIA1 cytotoxic granule-associated RNA binding protein 2p13 201447_at DDR1 Discoidin domain receptor tyrosine kinase 1 6p21.3 210749_x_at
  MAB21L1 Mab-21-like 1 (C. elegans) 13q13 206163_at DDR1 Discoidin domain receptor tyrosine kinase 1 6p21.3 208779_x_at
  PDS5B PDS5, regulator of cohesion maintenance, homolog B (S. cerevisiae 13q12.3 204742_s_at ITPKB Inositol 1,4,5-trisphosphate 3-kinase B 1q42.13 203723_at
  NUP62CL Nucleoporin 62kDa C-terminal like Xq22.3 220520_s_at ZNF280A Zinc finger protein 280A 22q11.22 216034_at
  GALNS Galactosamine (N-acetyl)-6-sulfate sulfatase 16q24.3 206335_at WAS Wiskott-Aldrich syndrome (eczema-thrombocytopenia) Xp11.4-p11.21 38964_r_at
  CELSR1 Cadherin, EGF LAG seven-pass G-type receptor 1 (flamingo homolog, Drosophila) 22q13.3 41660_at OR10H3
Olfactory receptor, family 10, subfamily H, 
member 3 19p13.1 208520_at
  TLE4 Transducin-like enhancer of split 4 (E(sp1) homolog, Drosophila) 9q21.31 216997_x_at OLIG2 Oligodendrocyte lineage transcription factor 2 21q22.11 213824_at
9  GBM  OLG  PA   ZNF280A Zinc finger protein 280A 22q11.22 216034_at NUP62CL Nucleoporin 62kDa C-terminal like Xq22.3 220520_s_at 1
  DDX27 DEAD (Asp-Glu-Ala-Asp) box polypeptide 27 20q13.13 215693_x_at KCNMA1
Potassium large conductance calcium-
activated channel, subfamily M, alpha member 
1
10q22.3 221584_s_at
  COX7A2 Cytochrome c oxidase subunit VIIa polypeptide 2 (liver) 6q12 217249_x_at GNPTAB
N-acetylglucosamine-1-phosphate transferase, 
alpha and beta subunits 12q23.2 212959_s_at
  KCNMA1 Potassium large conductance calcium-activated 
channel, subfamily M, alpha member 1
10q22.3 221584_s_at DDX27 DEAD (Asp-Glu-Ala-Asp) box polypeptide 27 20q13.13 215693_x_at
  GNPTAB N-acetylglucosamine-1-phosphate transferase, alpha and beta subunits 12q23.2 212959_s_at NDUFS2
NADH dehydrogenase (ubiquinone) Fe-S 
protein 2, 49kDa (NADH-coenzyme Q 
reductase)
1q23 201966_at
  APOD Apolipoprotein D 3q26.2-qter 201525_at PPIA Peptidylprolyl isomerase A (cyclophilin A) 7p13 211378_x_at
  CD59 CD59 molecule, complement regulatory protein 11p13 212463_at SNRPB2 Small nuclear ribonucleoprotein polypeptide B 20p12.1 202505_at
  SEMA3E Sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3E 7q21.11 206941_x_at ADAMTS3
ADAM metallopeptidase with thrombospondin 
type 1 motif, 3 4q13.3 214913_at
  CD59 CD59 molecule, complement regulatory protein 11p13 200985_s_at HINT1 Histidine triad nucleotide binding protein 1 5q31.2 208826_x_at
  BAMBI BMP and activin membrane-bound inhibitor homolog (Xenopus laevis) 10p12.13-p11.2 203304_at CIAPIN1 Cytokine induced apoptosis inhibitor 1 16q13-q21 208968_s_at
  FLNA Filamin A, alpha Xq28 214752_x_at TNKS2 Tankyrase, TRF1-interacting ankyrin-related ADP-ribose polymerase 2 10q23.3 218228_s_at
  ITGB3BP Integrin beta 3 binding protein (beta3-endonexin) 1p31.3 205176_s_at RB1CC1 RB1-inducible coiled-coil 1 8q11 202034_x_at
  DDX27 DEAD (Asp-Glu-Ala-Asp) box polypeptide 27 20q13.13 215693_x_at TRIM8 Tripartite motif-containing 8 10q24.3 221012_s_at
13  OLG   LARP5 La ribonucleoprotein domain family, member 4B 10p15.3 208953_at ANXA1 Annexin A1 9q12-q21.2 201012_at 1
8
10
11
12
Node #
2
4
6
7
 GBM  OLG
 PA
k
 EPN  GBM
 OLG  PA
 MDL
 EPN
Purine-rich element binding protein A 5q31 204021_s_at  PRPF40A PRP40 pre-mRNA processing factor 40 homolog A  (S. cerevisiae) 2q23.3 218053_at      PURA
Gene i
2
1
 GBM 1
Gene j
4
3
1
2
1
  Node phenotype 
  classes
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Table 5.4 Decision-tree marker-panel for brain cancer and normal transcriptome classification. 
 
For each classifier decision rule (i.e. Is Gene i > Gene j ?), 1 and 0 delineates 'true' and 'false', 
respectively, and ' - ' denotes that the outcome is not used for classification.  The vertical binary 
pattern under each class label corresponds to a phenotype-specific molecular signature.  
 
 
 
 
 
 
 
 
 
 
Gene symbol AffymetrixProbe ID Gene symbol
Affymetrix
Probe ID EPN GBM MDL MNG OLG PA normal
PRPF40A 218053_at PURA 204021_s_at 1 1 1 1 1 1 0
NRCAM 204105_s_at ISLR 207191_s_at 1 1 1 0 1 1 -
SRI 208920_at NBEA 221207_s_at 1 1 0 - 1 1 -
NUP62CL 220520_s_at OR10H3 208520_at 1 0 - - 0 0 -
DDX27 215693_x_at KCNMA1 221584_s_at - 1 - - 1 0 -
FLNA 214752_x_at TNKS2 218228_s_at - 1 - - 0 - -
Gene i Gene j Brain phenotype binary signature
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5.4 Marker-panel genes have significant connections to cancer biology 
In addition to predictive power, the clarity of biological interpretation contributes to the practical 
value and utility of molecular diagnostic signatures.  The classification scheme from ISSAC is 
based on comparing the relative expression quantities within gene-pairs framed around a 
phenotype hierarchy, which can have straightforward implications for characterizing the 
underlying cellular biology.  We examine below the genes and gene-pairs that compose our 
structured signatures of brain cancer. 
 Several genes in our marker-panel are strongly associated with brain cancers, supporting 
the rationale that these genes may reflect the underlying pathophysiology of their corresponding 
phenotypes.  One such gene is NRCAM, which was reported as a marker for high-risk 
neuroblastoma (Liu, et al., 2008) and poor prognostic ependymoma (Lukashova-v Zangen, et al., 
2007).  NRCAM was also found to be over-expressed in cell lines derived from astrocytomas, 
gliomas and glioblastoma multiforme tumors (Sehgal, et al., 1998).  DDR1, a receptor tyrosine 
kinase (RTK), was found to be over-expressed in high-grade gliomas and to promote tumor cell 
invasion (Weiner, et al., 2000) and contribute towards glioma cell invasion (Ram, et al., 2006).  
FLNA was detected in the serum of high-grade astrocytoma patients (Alper, et al., 2009), and 
ANXA1, a gene that encodes an anti-inflammatory phospholipid binding protein, was implicated 
in astrocytoma progression (Schittenhelm, et al., 2009); these reports are consistent with our 
identification of FLNA and ANXA1 as two classifier genes expressed higher in glioblastoma than 
in oligodendroglioma.  The basic helix-loop-helix (bHLH) transcription factor OLIG2 is innately 
expressed in oligodendrocytes and was recently characterized as a key antagonist of p53 function 
in neural stem cells and malignant gliomas (Mehta, et al.).  In accordance with lower expression 
of OLIG2 as an ependymoma classifier, OLIG2 expression was used as a negative marker to 
differentiate ependymoma from other gliomas (Ishizawa, et al., 2008).  SEMA3E, one of several 
classifier genes for pilocytic astrocytoma, has been reported to drive invasiveness of melanoma 
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cells in mice (Casazza, et al.).  And finally, mutation to IDH2 in glioblastoma is well known, with 
occurrence reported in 80% of secondary glioblastomas (Gross, et al.; Yan, et al., 2009).  
 That the genes in our marker-panel have previously confirmed ties to brain cancers raises 
the more intriguing question of what is the underlying molecular framework surrounding the 
generation of gene-pair classifiers.  Among the gene-pairs in our marker-panel, we focus on three 
pairs in which the genes’ common functional roles or relevance to cancer suggest putative 
relationships to its corresponding pathology. 
 One of the classifier gene-pairs involved in the differentiation between meningioma and 
the remaining five brain cancers (ependymoma, glioblastoma, medulloblastoma, 
oligodendroglioma, pilocytic astrocytoma) are two metabolic enzymes, IDH2 and GMDS (Node 4 
in Figure 2 and Table 1).  IDH2 converts isocitrate to α-ketoglutarate within the TCA cycle.  This 
reaction produces NADPH, which not only is an essential cofactor for many metabolic reactions, 
but also helps to protect the cell against oxidative damage (Reitman and Yan, 2010).  Moreover, 
GMDS aids the biosynthesis of GDP-fucose from GDP-mannose in mannose metabolism, in 
which NADPH is produced (Becker and Lowe, 2003).  That the enzymatic activities of both 
IDH2 and GMDS participate in the conversion between NADP+ and NADPH is interesting, 
considering the well-known alteration to cellular metabolism and deregulated redox balance in 
cancer (Hanahan and Weinberg, 2011).  Possible meningioma-specific mutations in IDH2 and/or 
GMDS, or changes in the regulatory network that controls the expression of these two genes, may 
affect cellular redox balance and functions of other metabolic enzymes.  
 The DDR1 and TIA1 gene-pair is a classifier that differentiates medulloblastoma from 
ependymoma, glioblastoma, oligodendroglioma, and pilocytic astrocytoma (Nodes 6 and 7 in 
Figure 2 and Table 1).  DDR1 was found to be alternatively-spliced into five isoforms (DDR1a-e) 
in myelin oligodendrocytes, facilitated in part through its interaction with the heterogeneous 
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nuclear ribonucleoprotein (hnRNP) A2/B1 (Roig, et al., 2012).  The TIA-1 gene product was 
shown to directly influence splicing of a number of genes through a motif that recognizes U-rich 
sequences downstream of 5’ splice sites (Singh, et al., 2011).  That the relative abundance of 
DDR1 becomes lower than that of TIA1 in medulloblastoma may suggest alternate splicing 
mechanisms influenced by TIA-1, in this pathology.  
 The TLE4 and OLIG2 gene-pair is used to differentiate ependymoma from glioblastoma, 
oligodendroglioma, and pilocytic astrocytoma (Node 8 in Figure 2 and Table 1).  TLE4, a human 
homolog of the Drosophila Groucho protein, represses the Wnt and FGF developmental signaling 
pathways (Ahn, et al., 2008; Burks, et al., 2009; Esain, et al., 2010) by recruiting deacetylases to 
histones H3 and H4 (Winkler, et al.).  FGF receptor signaling was reported to control neuronal 
and glial cell development by regulating OLIG2 expression in zebrafish (Esain, et al., 
2010).  This connection between these two genes in regards to brain cell development could be 
reflective of the extent of cell-type differentiation (a hallmark of cancer), or lack thereof, unique 
to ependymoma compared with the other gliomas. 
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5.5 Statistical enrichment analysis on global sets of gene-pairs classifiers 
Our aforementioned analysis on a number of marker-panel genes has offered insight into their 
role in particular diseases, but as to why the genes are involved in phenotype distinction remains 
unclear.  Rather than focusing on a limited number of genes (such as those only in our marker-
panel), we extended our analysis to large sets of gene-pair classifiers that distinguish 
Glioblastoma Multiform (GBM) from Oligodendroglioma (OLG).  We hypothesized that this 
would offer more direct insight into the basis of the classifiers' relative expression reversal 
behavior by being able to associate their global patterns with differences between major 
properties of the two phenotypes. 
 Hereon for simplicity, the collection of genes that are expressed relatively higher and 
lower in each TSP for Class 1 will be referred to as 'gene-set i' and 'gene-set j', respectively.  For 
500, 1,000, and 1,500 TSPs for GBM (Class 1) and OLG (Class 2), we performed an enrichment 
analysis on the biological process ontologies of 'gene-set i' (expressed higher in GBM and lower 
in OLG) and on those of 'gene-set j' (expressed lower in GBM and higher in OLG) to find the 
most consistently enriched category.  
 Biological processes and chromosome numbers of genes are available in the PANTHER 
database (Thomas, et al., 2003).  Enrichment was evaluated by Z-scores, which are defined in our 
analysis as: 
 
where n is the total number of measured features on the microarray, while and  are the 
proportion of features characterized by category in a given gene set (e.g. 500, 1,000, or 1,500 
genes in gene-set i or j) and in all features, respectively.  
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 Among 30 major biological processes in the PANTHER database (Thomas, et al., 2003), 
'Immunity and Defense' was the most strongly enriched biological process in gene-set i (Fig. 5.3, 
top).  Strong enrichment in 'Immunity and Defense' for the genes expressed relatively higher in 
GBM reflects the frequently observed presence of chronic inflammation in highly malignant 
cancers (Coussens and Werb, 2002), such as in GBM (Murat, et al., 2009).  In a tumor-associated 
inflammatory micro-environment, immune cells penetrate inside the tumor and secrete reactive 
oxygen species.  This can cause further oxidative DNA damage and oncogenic mutations, 
including amplification of oncogenes or deletion of cell-cycle regulators, and thereby facilitate 
cancer progression, survival, and migration.  Our results show that a relatively higher inflamed 
tumor environment, composed of a deep infiltration of immune cells and tumor cells exhibiting 
functions to embattle such oxidative conditions, is the most representative pathophysiological 
trait that differentiates GBM from OLG.   
 'Neuronal Activities' was the most enriched biological process in gene-set j, or the group 
of genes that are expressed lower in GBM compared to OLG (Fig. 5.3, bottom).  This functional 
category includes basic activities of the nerve or neuron behavior, such as synaptic transmission, 
neurotransmitter release, and action potential propagation.  It has been shown that GBM cells 
release glutamate, an amino-acid neurotransmitter (Takano, et al., 2001; Ye and Sontheimer, 
1999).  Elevated levels of extracellular glutamate concentrations is followed by an acute 
degeneration and death of neurons (Takano, et al., 2001; Ye, et al., 1999; Ye and Sontheimer, 
1999), a process known as excitotoxicity, and is one of the underlying causes of tumor-associated 
epileptic seizures and neuro-cognitive deficiencies in glioblastoma patients (Krex, et al., 2007).  
This glutamate excitotoxicity compromises normal synaptic transmission and neural function, as 
is suggested by our enrichment results for gene-set j.  Glutamate neurotoxicity has also been 
implicated in many neurodegenerative diseases, including stroke and Alzheimer’s disease (Hynd, 
et al., 2004). 
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 Applying the same enrichment analysis strategy described above for chromosome 
number, we looked for associations between our expression data and gene copy-number 
alterations frequently observed in GBM and OLG.  The genes in gene-set i and gene-set j were 
the most enriched in Chromosome 1 (Fig. 5.4, top) and Chromosome 10 (Fig. 5.4, bottom), 
respectively.  The loss of Chromosome 10 is one of the most frequent genetic aberrations in GBM 
(Fults and Pedone, 1993; Pershouse, et al., 1993), causing the expression of its genes to be 
heavily suppressed.  This offers a possible explanation for the over-representation of 
Chromosome 10 genes in the gene-set that is expressed relatively less in GBM ('gene-set j'), and 
thus higher in OLG.  The deletion of the short-arm of Chromosome 1 is a hallmark feature of 
OLG (Burger, et al., 2001; Gresner, et al., 2006), which is what we suspect to have caused the 
over-representation of Chromosome 1 genes in the set that is expressed relatively less in OLG 
('gene-set i'), and thus higher in GBM.   
 The results from our global enrichment analysis in biological processes and chromosome 
numbers display the relative differences between the collective properties of the two diseases.  
This offers a holistic view of the underlying reason behind the classifiers' relative expression 
reversal behavior, which could not have been detected by studying the gene-pairs in Tables 5.3 or 
5.4.  We did not observe the same enrichment patterns in the GBM-node classifiers in Table 5.3.  
This reflects an obvious limit to the extent to which disease properties can be explained by using 
only a small number of genes, since the gene-pairs were chosen only in the interest of selecting 
the smallest set of genes with the highest predictive accuracy, regardless of biological relevance.   
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Figure 5.3 Statistical enrichment analysis on biological processes of the TSP classifiers of 
glioblastoma and oligodendroglioma.  ‘Immunity and Defense’ was the most enriched biological 
process for 'gene-set i' (top), reflecting chronic inflammation common to malignant cancer, while 
‘Neuronal Activities’ was the most enriched biological process for for 'gene-set j' (bottom).  Ψ 
delineates the most enriched category.  aBiological process abbreviation (name): AM (Amino acid 
metabolism), CM (Carbohydrate metabolism), CA (Cell adhesion), CC (Cell cycle), CSM (Cell 
structure and motility), H (Homeostatis), ID (Immunity and Defense), IPT (Intracellular protein 
transport), MC (Muscle contraction), NA (Neuronal activities), NAM (Nucleic acid metabolism), 
PM (Protein metabolism and modification), SM (Sulfur metabolism), and T (Transport). 
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Figure 5.4 The genes in 'gene-set i' and 'gene-set j' were the most enriched in Chromosome 1 and 
Chromosome 10, respectively, reflecting the major chromosome aberrations of the two diseases.  
Ψ delineates the most enriched category.  
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5.6 Diagnostic marker-panel achieves high classification performance in 
cross-validation 
We used ten-fold cross-validation to evaluate the classification performance of our brain cancer 
diagnostic marker-panel (Fig. 5.5).  Our marker-panel achieved a 90% average of phenotype-
specific classification accuracies (Table 5.5), showing strong promise against a multi-category, 
multi-dataset background at the gene expression level (Fig. 5.6).  In addition, we observed higher 
classification accuracy (93%) among the expression profiles for which a unique diagnosis was 
obtained without subsequent disambiguation from the decision-tree (Table 5.6).    
 Four brain cancers (ependymoma, medulloblastoma, meningioma, and pilocytic 
astrocytoma) have estimated accuracies of at least 91%, suggesting clear differences between 
them and the other phenotypes at the transcriptomic level.  The anatomical region specificity of 
these four cancers may have contributed toward their highly accurate separation – as there are 
regional areas of unique gene expression patterns.  Roth et al. analyzed gene expression of 20 
anatomically distinct regions of the central nervous system (Roth, et al., 2006) and clustered all 
anatomical sites into distinct groups, providing evidence of region-specific expression patterns.   
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Figure 5.5 Performance evaluation using ten-fold cross-validation.  Ten-fold cross-validation is 
conducted ten times to obtain the average accuracy.  In each iteration of cross-validation, the 
order of samples within a particular class is randomly permuted before training/test set 
allocations.  
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Table 5.5 Classification performance of diagnostic marker-panel in ten-fold cross-validation. 
 
aAccuracies reflect average performance in ten-fold cross-validation conducted ten times.  The 
main diagonal gives the average classification accuracy of each class (bold), and the off-diagonal 
elements show the erroneous predictions.  bUC (Unclassified samples). When using the node 
classifiers, expression profiles that did not exert a signature of any phenotype (i.e. did not 
percolate down to at least one positive terminal node) were rejected from classification.  In this 
case, the Unclassified sample is treated as a misclassification. 
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Figure 5.6 Our marker-panel achieved a 90.4% average of phenotype-specific classification 
accuracies, showing strong promise against a multi-category, multi-dataset background at the 
gene expression level.  
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Table 5.6 Ten-fold cross-validation accuracies when only the node marker-panel was required to 
reach unique diagnoses. 
 
Sample size: Average proportion of total samples that reached unique diagnoses via node marker-
panel.  Accuracy: Reflects average performance in ten-fold cross-validation conducted ten times.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Phenotype Total samples Sample size (%) Accuracy (%)
  EPN 102 93.1 95.8
  GBM 231 88.9 92.7
  MDL 101 95.0 95.8
  MNG 161 98.8 97.5
  OLG 61 77.0 74.5
  PA 62 90.3 96.4
  Normal 203 97.9 99.5
  Average - 91.6 93.2
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 However, results from another study analyzing gene expression data from distinct brain 
regions suggested that clustering disparities might also be due to activity of distinct brain cell 
types, rather than solely on region (Khaitovich, et al., 2004; Oldham, et al., 2008).  Furthermore, 
if region specificity played a dominant role in classification, we would expect to see a high 
number of misdiagnoses to occur between the normal brain, which was derived from 25 different 
locations (Roth et al. (2006, GSE3526) and Roth et al. (2007, GSE7307): Accumbens, amygdala, 
brain stem, caudate, cerebellum, cerebral cortex, entorhinal cortex, frontal lobe, hippocampus, 
hypothalamus, lateral ventricle, medulla, middle temporal gyrus, occipital lobe, optic nerve, 
posterior cingulate cortex, prefrontal cortex, posterior fossa, parietal lobe, putamen, superior 
frontal gyrus, substantia nigra, thalamus, temporal lobe, and visual cortex), and the six 
cancers.  Such a trend was not observed in Table 5.5.  Therefore, our diagnostic results suggest a 
stronger contribution from underlying cell-type specific and disease-intrinsic elements than from 
region effects alone. 
 The cross-validation accuracies for glioblastoma and oligodendroglioma, two high-grade 
gliomas, were 84.8% and 74.6%, respectively.  Their lower performance was mainly a 
consequence of the limited ability of the marker-panel to correctly differentiate these two cancers 
from each other.  Indeed, the distinction of these two phenotypes from transcriptomics seems to 
be rather difficult in general, and our accuracies here are comparable to those reported previously 
in two-phenotype comparison studies (Kim, et al., 2002; Nutt, et al., 2003).  Furthermore, our 
signatures did show an excellent degree of sensitivity (96.4%) and specificity (97.4%) for 
distinguishing these two well-progressed gliomas as a set from all other brain phenotypes.  There 
exist genetic tests and methods that differentiate glioblastoma and oligodendroglioma well, such 
as the combined loss of chromosome arms 1p and 19q (Burger, et al., 2001), and over-expression 
of the transcription factor protein Olig2 (Ligon, et al., 2004).  
A(Donson, et al., 2009)a(Johnson, et al., 2010)a(Freije, et al., 2004)a(Phillips, et al., 2006)a(Liu, et al., 2007)a(Wiedemeyer, et al., 
2008)a(Sun, et al., 2006)a(Kool, et al., 2008)a(Fattet, et al., 2009)a-a(Claus, et al., 2008)a(Lee, et al., 2010)a(Wong, et al., 
2005)a(Sharma, et al., 2007)a(Roth, et al., 2006) 
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5.7 Diagnostic signatures based on putative blood borne biomolecules  
The work reported herein has focused on identifying a transcriptomic, structured signature that 
can separate major brain cancers simultaneously, as well as on evaluating issues related to 
reproducibility in molecular diagnostic signatures from large meta-analyses.  However, our long-
term motivation for wanting diagnostic signatures of an organ system is ultimately to find 
corresponding signatures in the blood, where they can be assayed non-invasively.  Blood bathes 
virtually all organs, which secrete proteins and nucleic acids.  Subsets of these secreted 
biomolecules can potentially constitute disease signatures for molecular diagnostics.  Moreover, 
the blood is easily accessible in contrast to biopsies of diseased organs for obtaining transcript or 
protein profiles.  In this regard, the brain represents an organ system where a critical need exists 
to develop non-invasive techniques to monitor its health state through secreted proteins. 
 We (LH) have previously demonstrated the presence of organ-specific proteins in the 
blood, and when these proteins changed in concentration or chemical structure, we were able to 
identify the tissue origin of this change (Lausted, et al., 2008).  For blood-based, organ-specific 
diagnostics, molecular signatures need to detect and stratify various possible cancers and other 
pathological conditions simultaneously.  In the context of this current study, an intriguing 
question is if training ISSAC on shed or secreted blood borne biomolecule measurements 
identifies diagnostic signatures that allow us to distinguish health from disease; and if diseased, 
which one and how far has it progressed?  Thus, the approach laid out herein for transcriptomics 
is a foundation for identifying similar signatures from blood proteins as these measurements 
become more abundant. 
 As proof of concept and to provide candidates for targeted proteomics analysis, we 
performed the above transcriptomic meta-analysis of finding brain cancer signatures using only 
the genes that are annotated to encode extracellular proteins.  Our new brain cancer marker-panel 
(Fig. 5.7) obtained an average classification accuracy of 87% in 10-fold cross-validation (Table 
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5.7), which compares favorably to the average accuracy we previously achieved using all the 
genes in the microarray (90%).  This suggests that strong signal may possibly persist for 
phenotype distinction even when using secreted biomolecules from diseased organs.  If indeed 
there are enough biomolecules secreted into the blood at concentrations that can be accurately and 
consistently detected by e.g. targeted mass spectrometry, then there is the very exciting possibility 
that organ-specific pathologies, such as those described above, can be detected from the blood.  
This would truly make blood a “window into health and disease”.  
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Figure 5.7 Gene-pair classifiers based on only the genes that encode extracellular products.  
Gene-pairs are shown at their corresponding nodes in the brain disease diagnostic hierarchy.  The 
corresponding node-based marker-panel consists of 41 classifier pairs and 71 unique classifier 
features.  
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Table 5.7  Ten-fold cross-validation accuracies of gene-pair classifiers composed of genes that 
encode extracellular products. 
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5.8 Chapter summary 
The identification of molecular signatures from either tissues or blood to accurately reflect the 
major cancers of an organ system would be a significant advance in molecular cancer diagnostics.  
Towards this goal, we identified comprehensive diagnostic signatures of major cancers of the 
human brain from a multi-study, integrated transcriptomic dataset.  These signatures are based on 
comparing ranked expression values of gene-pair sets, which are aggregated into a brain cancer 
marker-panel of 44 unique genes.  Many of these genes have established relevance to the brain 
cancers tested herein, with others having known roles in cancer biology.  Phenotype prediction 
follows a diagnostic hierarchy, and the corresponding hierarchically-structured signatures 
achieved 90% classification accuracy against a multi-disease alternative hypothesis when training 
and validation sets were drawn from the same population distribution (cross validation).   
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Chapter 6. Multi-study dataset integration 
improves robustness of molecular signatures  
 
6.1 Introduction 
Microarray transcriptomes are currently the most global and readily available type of high-
throughput data on biological systems, making it a promising resource for molecular signatures.  
However, a significant drawback to the widespread clinical use of such high-throughput data is 
the limited reproducibility of performance accuracy that is often observed across independent 
studies of what are considered the same disease phenotype.  This lack of robustness, even for 
promising results, can be due to myriad factors, which include molecular heterogeneity within 
tumors or other diseased tissue-samples (Navin, et al., 2011; Park, et al., 2010), complex disease 
subtypes, various patient demographics, and/or other biologically relevant factors.  Another major 
issue is batch effects, which arise from differences or inconsistencies in experimental protocols, 
data quality, data-processing techniques, and laboratory conditions and personnel (Leek, et al., 
2010).    
 A promising method to address some of these limitations in diagnostic signature 
robustness is to accumulate and combine data from many independent studies into large meta-
analyses (Dudley, et al., 2009; Miller, et al., 2010).  This approach naturally expands sample 
numbers across diverse sources and conditions.  More importantly, such an integrated strategy 
can provide more reliable disease signatures, as phenotype-associated signals become stronger in 
comparison with noise from batch effects and other sources of variance.  The potential value of 
clinical meta-analyses is shown in Chapter 5, wherein our marker-panel displayed high 
performance in brain cancer diagnostics within cross-validation. 
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 Despite its common use to assess performance of diagnostic signatures, even the most 
promising cross validation results are insufficient to show clinical validity because this technique 
is contingent upon having the training and validation sets drawn from the same population 
distribution.  This is not a condition that is guaranteed (or often likely) to be true for newly 
acquired biological datasets.  Thus, transcriptomics-based molecular signatures, as with all 
clinical biomarkers, need to be validated on data that are independent of the training set (i.e., from 
a different institution and set of investigators studying the same clinical problem).  Such 
independent validation is a more stringent, yet necessary, measure of classifier performance 
compared with cross-validation.   
 In this chapter, we study how learning across multiple datasets from different laboratories 
affects independent validation results.  Our analyses are focused on glioblastoma (GBM), for 
which we have the highest number of datasets and transcriptome samples.   
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6.2 GBM signatures from multi-study, integrated datasets have higher 
average performance than those from individual datasets 
We trained ISSAC on each of the five transcriptomic datasets (i.e. GSE ####) of glioblastoma 
individually, coupled in each case to all the data from the other brain phenotypes.  The full multi-
class signatures were completely relearned (every step) with the only difference in each case 
being which single glioblastoma dataset was included in the training stage.  We then assessed the 
accuracy of correctly classifying glioblastoma transcriptomes measured in the four held-out 
datasets from all other possible phenotypes.  We term this evaluation method as “hold-one-lab-in 
validation”. 
 The overall hold-one-lab-in validation performance, or the average of all classification 
accuracies in Figure 6.1, was 37.6%.  This shows that, in general, individual datasets do not 
consistently yield robust diagnostic signatures.  For example, GBM signatures from GSE8692 (6 
samples,(Liu, et al., 2007)) and GSE9171 (13 samples, (Wiedemeyer, et al., 2008)) led to average 
accuracies of 22% and 0.0%, respectively.  These significantly low performance results are not 
surprising given the very small sample numbers.  However, that glioblastoma signatures from 
GSE9171 could not classify even a single sample from any other GBM study correctly is an 
intriguing observation.  After searching through sample preparation and handling protocols 
provided in the publications of all five glioblastoma studies, we were not able to identify any 
obvious steps unique to the GSE9171 study that could have led to this result.  We suspect that, 
rather than from a single aspect, this case may have been caused by many factors, from the lack 
of variance in the biology of the patient samples studied, to batch effects that compromised 
transcriptomic measurements, and to possibly unreported variations in standard protocol.   
 To an extent, relatively larger datasets can indeed yield disease signatures of higher 
average accuracy.  However, sample size is really not a sole determining factor of signature 
performance.  For example, training on GSE4412 (59 samples, (Freije, et al., 2004)) gave an 
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average accuracy of 23.1% (Fig. 6.1).  Interestingly, the average accuracies from training sets 
GSE4412 and GSE8692 (23.1% and 22.3%, respectively) were very similar despite almost ten-
fold difference in sample sizes (59 and 6 samples, respectively).  As a notable exception, training 
on GSE4271 (76 samples, (Phillips, et al., 2006)) resulted in the best overall average accuracy 
(87.1%) in correctly classifying samples from the four held-out glioblastoma datasets, with 
individual validation set accuracies ranging from 77.9% to 100% (Table 6.1).  These favorable 
outcomes are likely due to the molecular heterogeneity within and across transcriptomes in this 
particular dataset adequately encompassing broad, population-level characteristics.  However, 
when GSE4290 (77 samples, (Sun, et al., 2006)) was used as the training set, a decrease of more 
than 30% in glioblastoma classification accuracy occurred (55.5%) despite the nearly identical 
sample size with GSE4271.    
 We found considerable discrepancy between the minimum and maximum validation set 
accuracies for training sets GSE4412 (0.0% and 83.3%) and GSE4290 (16.7% and 92.3%) (Table 
6.1).  This shows that batch effects, as well as potential biological discrepancies between 
populations studied at different sites, can lead to remarkable variation among transcriptomic 
datasets of supposedly the same phenotype.  This “dataset variation” is widespread in large-scale 
expression studies, causing inconsistencies in diagnostic signature identification and performance 
reproducibility (Allison, et al., 2006).  Large variation within and across transcriptomic datasets 
of glioblastoma is not surprising, given that glioblastoma is known to have various molecular 
subtypes (Mischel, et al., 2003).  Therefore, as mentioned above, diagnostic signatures from any 
single dataset need to be approached with caution.  
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Figure 6.1 Hold-one-lab-in validation results for each of the five GBM datasets.  GBM signatures 
from larger datasets (GSE4271, GSE4290) had better average classification accuracy than those 
from smaller datasets (GSE8692, GSE9171), but significant dataset variance across GBM 
datasets limited overall performance.  Gray line indicates average accuracy on the four test sets.   
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Table 6.1 Hold-one-lab-in validation accuracies of glioblastoma signatures. 
 
 
 
 
 
GBM training set (sample size) GBM test set (sample size)
UC EPN GBM MDL MNG OLG PA Total
GSE4271 (76) 2.63% 57.89% 9.21% 17.11% 5.26% 1.32% 6.58% 76
2 44 7 13 4 1 5 76
GBM MNG Total
GSE8692 (6) 83.33% 16.67% 6
5 1 6  
EPN GBM MNG Total
GSE9171 (13) 92.31% 0.00% 7.69% 13
12 0 1 13
EPN GBM MDL MNG PA Total
GSE4290 (77) 85.71% 0.00% 2.60% 5.19% 6.49% 77
66 0 2 4 5 77
UC GBM PA normal Total
GSE4412 (59) 11.86% 77.97% 8.47% 1.69% 59
7 46 5 1 59
GBM Total
GSE8692 (6) 100.0% 6
6 6
GBM 6 Total
GSE9171 (13) 92.31% 7.69% 13
12 1 13
UC GBM MNG PA Total
GSE4290 (77) 5.19% 77.92% 1.30% 15.58% 77
4 60 1 12 77
UC EPN GBM MDL MNG PA normal Total
GSE4412 (59) 5.08% 13.56% 47.46% 1.69% 3.39% 27.12% 1.69% 59
3 8 28 1 2 16 1 59
UC EPN GBM MDL PA normal Total
GSE4271 (76) 9.21% 32.89% 18.42% 5.26% 32.89% 1.32% 76
7 25 14 4 25 1 76
EPN GBM MDL PA Total
GSE9171 (13) 61.54% 15.38% 15.38% 7.69% 13
8 2 2 1 13
UC EPN GBM MDL MNG PA normal Total
GSE4290 (77) 14.29% 42.86% 7.79% 1.30% 1.30% 25.97% 6.49% 77
11 33 6 1 1 20 5 77
Predicted phenotype / % of test set / samples of test set
GSE4412 (59)
GSE4271 (76)
GSE8692 (6)
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Table 6.1  (Continued) Hold-one-lab-in validation accuracies of glioblastoma signatures. 
 
 
 
 
 
 
 
 
 
UC EPN GBM MDL MNG PA Total
GSE4412 (59) 35.59% 13.56% 0.00% 1.69% 5.08% 44.07% 59
21 8 0 1 3 26 59
UC EPN GBM MDL MNG PA Total
GSE4271 (76) 19.74% 38.16% 0.00% 6.58% 3.95% 31.58% 76
15 29 0 5 3 24 76
UC GBM MNG PA Total
GSE8692 (6) 66.67% 0.00% 16.67% 16.67% 6
4 0 1 1 6
UC EPN GBM MDL PA normal Total
GSE4290 (77) 10.39% 40.26% 0.00% 1.30% 46.75% 1.30% 77
8 31 0 1 36 1 77
UC GBM NB PA normal Total
GSE4412 (59) 5.08% 52.54% 27.12% 13.56% 1.69% 59
3 31 16 8 1 59
UC EPN GBM MDL OLG PA Total
GSE4271 (76) 1.32% 1.32% 60.53% 3.95% 15.79% 17.11% 76
1 1 46 3 12 13 76
UC GBM NB PA Total
GSE8692 (6) 33.33% 16.67% 16.67% 33.33% 6
2 1 1 2 6
UC GBM Total
GSE9171 (13) 7.69% 92.31% 13
1 12 13
GSE4290 (77)
GSE9171 (13)
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 We next analyzed how the multi-study integration approach affects performance 
robustness.  One of each of the five datasets of glioblastoma was sequentially withheld as the 
validation set, while all remaining gene expression data (including those from all other 
phenotypes) were used for training.  The glioblastoma signature was then evaluated on the held-
out validation set.  We term this strategy as “leave-one-lab-out validation”. 
 Classification accuracies ranged from 63.2% (GBM training set: 155 samples across four 
datasets; validation set: GSE4271, 76 samples) to 100% (GBM training set: 225 samples across 
four datasets; validation set: GSE8692, 6 samples) (Fig. 6.2).  The average accuracy of the five 
leave-one-lab-out validations was 83.3%, which is considerably higher than that obtained from 
training on individual glioblastoma datasets (37.6%), and is comparable to the glioblastoma 
accuracy seen in cross-validation (84.8%).  Indeed, the fact that the glioblastoma classification 
accuracies from cross-validation and the leave-one-lab-out strategy are so close suggests that the 
effects of variability among the datasets from different institutions and time-points have been 
mostly overcome by integration across multiple training studies.  We conjecture that this result is 
due to the underlying variation in the training sets better representing the true variation in the 
population, both by achieving a greater sample size, as well as by having the samples come from 
a broader range of situations.  Leave-one-lab-out validation results for datasets of all phenotypes 
are shown in Figure 6.3.  Classification accuracies within and across different brain phenotypes 
varied significantly. 
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Figure 6.2 Leave-one-lab-out validation results for each of the five GBM datasets.  Blue, gray, 
and red line indicates average classification accuracy of GBM signatures from ten-fold cross-
validation (CV), leave-one-lab-out (L1LO) validation, and hold-one-lab-in (H1LI) validation, 
respectively.  On average, combining datasets considerably increased GBM signature 
performance.   
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Figure 6.3 Leave-one-lab-out validation results for datasets of all phenotypes.   
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 To evaluate how multi-study dataset integration alone affects performance robustness 
independent of sample size, we performed hold-one-lab-in and leave-one-lab-out validations for 
the studies with the largest number of samples, GSE4412, GSE4271, and GSE4290 (59, 76, and 
77 samples, respectively) while training on the same number of samples for glioblastoma.  More 
specifically, the same steps in the analyses of Figures 6.1 and 6.2 were used, while glioblastoma 
signatures were learned from a glioblastoma training set of exactly 50 samples chosen randomly 
from either an individual dataset or across four combined datasets.  This process was conducted 
ten times for each glioblastoma training set.   
 The average performances of hold-one-lab-in and leave-one-lab-out validations were 
47.3% and 70.2%, respectively.  Overall, the results were consistent with our two aforementioned 
conclusions: 1) when a diagnostic signature is learned from an individual dataset, its ability to 
accurately and precisely represent phenotype features across a broad population highly varies 
depending on the particular dataset used for training (Fig. 6.4 and Table 6.2); and 2) combining 
datasets considerably increased average accuracy (Fig. 6.5 and Table 6.2).  Thus, dataset 
integration across multiple studies, even without change in sample size, can lead to significant 
improvements in diagnostic performance. 
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Figure 6.4 H1L1 validation to test GBM signatures from GSE4412, GSE4271, and GSE4290, 
while keeping the number of samples in the GBM training set the same.  50 samples were 
randomly selected from each GBM dataset for signature learning.  H1LI validation was executed 
ten times for each of the three GBM datasets.  Bars indicate average classification accuracies with 
standard deviations.   
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Figure 6.5 L1LO validation to test GBM signatures on GSE4412, GSE4271, and GSE4290 test 
sets, while 50 total samples were randomly selected from the other four GBM datasets for 
signature learning.  L1LO validation was executed ten times.   
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Table 6.2 Hold-one-lab-in (H1LI) and leave-one-lab-out (L1LO) validation accuracies of 
glioblastoma signatures when training data were constrained to 50 total samples
 
H1LI and L1LO validations were performed ten times for each category of training data.  In each 
validation trial, 50 samples were randomly selected from the single microarray dataset (for H1L1) 
or from the multi-study, combined dataset (for L1LO).   
 
 
 
 
 
 
 
 
GBM prediction 
Average accuracy St. dev.
  GSE4271 40.26% 14.98%
  GSE8692 96.67% 7.03%
  GSE9171 6.15% 3.24%
  GSE4290 2.47% 2.10%
  GSE4412 58.98% 21.64%
  GSE8692 74.00% 11.43%
  GSE9171 73.08% 10.41%
  GSE4290 49.48% 26.56%
  GSE4412 38.47% 10.23%
  GSE4271 43.13% 16.12%
  GSE8692 23.33% 9.08%
  GSE9171 57.70% 16.79%
GSE4271, GSE8692, 
GSE9171, GSE4290   GSE4412 82.20% 10.39%
GSE4412, GSE8692, 
GSE9171, GSE4290   GSE4271 54.87% 7.18%
GSE4412, GSE4271, 
GSE8692, GSE9171   GSE4290 72.08% 15.29%
L1LO
GSE4412
GSE4271
GSE4290
36.39%
63.89%
40.66%
69.72%
GBM training set
(50 samples)   GBM test setMethod
H1LI
Average
performance
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 Lastly, we used the results in Figure 6.4 and Figure 6.5 to compare performances of 
different glioblastoma signatures on the same validation set (Fig. 6.6).  In all cases, glioblastoma 
signatures from combined datasets had, on average, higher classification accuracy than those 
from any of the individual datasets – even though the same number of samples was used in the 
training sets and were tested on a validation set independent of the training set.  These results 
were then used to evaluate the precision of a glioblastoma signature’s classification accuracy by 
calculating its “signal-to-noise ratio (SNR)”.  SNR in the accuracy estimate was calculated herein 
as the ratio of average classification accuracy to standard deviation in the accuracy estimate 
across studies.  We found that, for all validation set cases, glioblastoma signatures developed on 
the basis of multiple datasets had SNRs greater by at least two fold than those from individual 
data sets.  This clearly shows that learning on integrated, meta-datasets leads to diagnostic 
signatures that have higher and more consistent diagnostic performance (Fig. 6.7). 
 As shown by our hold-one-lab-in validations, when we performed the stringent test of 
obtaining a diagnostic signature from a single dataset of glioblastoma, we found the variation 
among individual studies often have a larger effect on the transcriptome than did phenotype 
differences, resulting in dramatically decreased average accuracy.  However, we found that 
learning signatures across multiple datasets significantly improved average accuracy with 
concomitant reduction in performance variance, even when keeping the size of the training set the 
same.  This was most likely due to the meta-signature encompassing more of the heterogeneity 
across different sources and conditions, while amplifying signal from the repeated global 
phenotype characteristics. 
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Figure 6.6 Data from Figs. 6.3 and 6.4 are used to show GBM signatures’ classification 
accuracies on GSE4412, GSE4271, and GSE4290 test sets when the GBM training data were 
from individual or combined GBM datasets.  Ψ, Φ, and Ω indicate statistical significance relative 
to GSE4271, GSE4290, and GSE4412, respectively (Tukey’s post-hoc test, p < 0.01).  
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Figure 6.7 Signal-to-noise ratios (SNRs) from data in Fig. 6.5.  SNR was calculated as the ratio 
of average classification accuracy to standard deviation.  SNR values of GBM signatures show 
that learning on integrated, meta-datasets across multiple studies leads to disease signatures that 
have higher and more consistent classification performance.  
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6.3 Chapter summary 
Accurately distinguishing among phenotypes in single-population cross-validation is a necessary, 
but not sufficient, test of diagnostic performance of molecular signatures.  Molecular signatures 
must remain robust even across more heterogeneous populations to justify their broad clinical 
use.  To address this issue, we performed variants of holdout analyses (i.e. hold-one-lab-in and 
leave-one-lab-out techniques) for the different datasets of glioblastoma multiforme.  We found 
that sufficient dataset integration across multiple studies greatly enhanced disease signatures’ 
reproducibility and accuracy in diagnostic performance on truly independent validation sets, 
whereas signatures learned from one dataset typically had high error on independent validation 
sets.  Indeed, our meta-analysis approach holds significant promise for developing robust, 
disease-specific molecular signatures. 
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Chapter 7. Matching expression patterns between 
mRNA and protein profiles predict relative 
feature abundance 
 
7.1 Introduction 
As discussed in Chapter 1, our ultimate goal is to track the perturbations in the 
underlying networks that lead to the disease phenotype using secreted protein profiles in 
the blood.  The focus now is to move beyond simply finding markers of disease to 
developing a fundamentally new approach to studying human disease in vivo.  For this, 
we need to better understand the cross-talk between heterogeneous data types, 
particularly how one data type translates into another.  This would allow us to 1) make 
predictions of feature abundance across heterogeneous data types, especially after 
targeted molecular perturbations; 2) use one data type as a proxy to infer biological 
information concerning another data type and/or monitor cellular behavior; 3) elucidate 
expression mechanisms of various intracellular biomolecules.  Thus, finding a model that 
estimates feature abundances across two data types – in our case, measurements of 
intracellular mRNA and proteins secreted into the blood – is imperative to accomplishing 
the goals set in this dissertation. 
 To date, there have been only a handful of efforts to find correlations between 
mRNA and protein expression levels, most notably in yeast and human cancer cells 
(Chen, et al., 2002; Greenbaum, et al., 2003; Gygi, et al., 1999; Vogel, et al., 2010).  For 
the most part, they have reported only minimal global correlations, and limited 
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information on the causal relationships between mRNA and protein expression.  Despite 
this incomplete understanding of the mRNA-protein expression relationship, we 
developed a novel method herein called SOMERA (Signatures of Matching Expression 
to estimate Relative Abundances), which can predict relative feature abundance across 
heterogeneous data types reasonably well.  In our study, we demonstrate the use of 
SOMEIRA on mRNA and protein expression profiles that were taken from the same 
tumor biopsy of human Gastrointestinal Stromal Tumors (GISTs) and Leiomyosarcomas 
(LMSs).  
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7.2 Material and methods 
7.2.1 mRNA and protein expression profiles 
Published datasets of mRNA profiles (Price, et al., 2007) and protein profiles (Yang, et 
al., 2010) from GIST and LMS biopsies (from matching patients) were a kind gift from 
colleagues at the MD Anderson Cancer Center (Dallas, TX).  Each protein profile was 
composed of 40 protein measurements from a reverse-phase protein lysate array, and 
each mRNA profile from Agilent microarrays were limited to the 2,094 features that map 
to all pathways in the BioCarta database (used in DIRAC, as discussed later).  Detailed 
information on the measurement platforms and patient samples can be found in their 
respective publications. 
 
7.2.2 Description of method to predict relative feature abundance 
SOMEIRA identifies matching expression patterns in two heterogeneous data types, and 
uses those patterns to infer an expression profile of one data type from another.  First, 
mRNA and protein datasets are binarized, and common expression patterns of two-
mRNA and two-protein comparisons across patient profiles are found.  Each relative 
expression comparison of mRNA i and mRNA j (gi > gj), or that of protein i and protein j 
(pi > pj) for a particular sample results in either a ‘true (= 1)’ and ‘false (= 0)’ outcome.  
For each mRNA-pair and protein-pair, a percentage is obtained that represents the 
proportion of total samples for which the mRNA/protein-pair comparison results in the 
same outcome.  100% matching mRNA-pair and protein-pair sets identified can have 
binary outcomes that stay the same (always 1 or 0) or vary across all samples.  We term 
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these as “invariant” and “variant” mRNA/protein-pair sets, respectively. These binary 
patterns were found for all matching samples across respective phenotypes. 
 Training and performance testing of SOMEIRA followed a leave-one-out cross-
validation approach, in the sense that conserved expression patterns between pairs of 
mRNAs and pairs of proteins (which form the framework for predicting relative feature 
abundances across heterogeneous datasets) were learned on all but one sample.  The 
remaining protein profile was used to predict relative levels of the corresponding mRNA 
profile from the same biopsy source. 
 Prediction of an expression profile follows two main steps: 1. Obtaining binary 
expression profile of test sample from other test; and 2. Turning a binary expression 
profile into ranked expression.  In the first step, a protein test profile is ranked and 
binarized.  The mode of the protein-pair indices that were found to have matching 
patterns was labeled as the mode of the corresponding mRNA-pair indices.  This was 
iterated for all protein-pair/mRNA pair sets.  At the end, a binary profile of an mRNA 
profile is inferred.  Next, for all mRNA-pairs of the binary expression profile, if the 
binary outcome for an mRNA-pair is a 1, then increase the rank of mRNA i by 1.  If the 
outcome is a 0, then increase the rank of mRNA j by 1.  This is done for all mRNA-pairs, 
and the final results will be ranks of all mRNAs in a profile.  In case of ties in ranks, this 
process is conducted with only the mRNA involved in those tied pairs. 
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7.3 Results and discussion 
In Figure 7.2, we show the relative expression levels of mRNAs and proteins 
corresponding to the same gene.  In short, no significant correlation exists directly 
between mRNA and protein expression.   
 The predictive performance of SOMEIRA was evaluated on mRNA and protein 
profiles of GIST and LMS.  In Table 7.2, we show average correlations of actual mRNA 
(or protein) expression profiles and predicted mRNA (or protein) profiles from protein 
(or mRNA) expression.  For all cases of matching mRNA and protein profiles, the 
average correlation coefficient between actual and predicted mRNA profiles was 0.91, 
while the average correlation coefficient between actual and predicted protein profiles 
was 0.81.  These correlations were significantly higher than those obtained using a linear 
regression (0.72 and 0.55 for mRNA and protein prediction, respectively).  Plots of actual 
and predicted relative expression of proteins and mRNA, using SOMEIRA and linear 
regression, are shown in Figures 7.3-7.6.  In general, SOMEIRA performs relative 
abundance predictions of proteins and mRNA reasonably well.  When we performed the 
same mRNA and protein abundance prediction using only the invariant gene-pair and 
protein-pair sets (in which case general, de facto predictions are given), we found that 
these correlations were significantly lower than previously obtained results based on t-
test evaluations (p < 0.001).  One great advantage of SOMEIRA is that both mRNA and 
protein measurements corresponding to the same gene are not required, since feature 
pairs within only one data type are used to binarize a dataset.  
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Figure 7.1 Protein vs. mRNA relative expression from profiles of the same (a) GIST and 
(b) LMS biopsy source.  Protein and mRNA correspond to the same gene.  The chosen 
profiles were those that have correlation coefficients closest to the average of the 
phenotype. 
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Table 7.1 Correlations between actual gene (or protein) expression profiles and those 
predicted using a different data type from the same patient biopsy source. 1. Pearson 
correlation coefficient; 2. All values were compared based on t-tests with those obtained 
from using invariant gene-pairs only (p < 0.001). 
 
 
 
 
 
 
 
 
 
 
 
 
SOMEIRA2 Linear regression
GIST/LMS 0.91 0.72
(a) Proteins (40) mRNA (2,094) GIST 0.92 0.64
LMS 0.92 0.69
GIST/LMS 0.81 0.55
(b) mRNA (2,094) Proteins (40) GIST 0.79 0.67
LMS 0.84 0.67
Used for prediction 
(# of features)
To be predicted 
(# of features) Phenotype
Correlation coefficients1
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Figure 7.2 Actual and predicted mRNA expression in (a) GIST and (b) LMS profiles 
using SOMEIRA.  The chosen profiles were those that have correlation coefficients 
closest to the average of the phenotype. 
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Figure 7.3 Actual and predicted protein expression in (a) GIST and (b) LMS profiles 
using SOMEIRA.  The chosen profiles were those that have correlation coefficients 
closest to the average of the phenotype. 
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Figure 7.4 Actual and predicted mRNA expression in (a) GIST and (b) LMS profiles 
using multiple linear regression.  The chosen profiles were those that have correlation 
coefficients closest to the average of the phenotype. 
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Figure 7.5 Actual and predicted protein expression in (a) GIST and (b) LMS profiles 
using multiple linear regression.  The chosen profiles were those that have correlation 
coefficients closest to the average of the phenotype. 
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 Our next analysis was to evaluate how well protein profiles can serve as proxies 
to infer biological information concerning mRNA profiles.  For this we used DIRAC, a 
recently published method from our laboratory that uses expression profiles to identify 
tightly regulated and differentially regulated pathways based on the extent of expression 
conservation in cellular pathways (Eddy, et al., 2010).  We extended the use of 
SOMEIRA to assessing states of intracellular networks by applying DIRAC directly on 
all mRNA profiles inferred from protein profiles.  
 When we compared results from actual mRNA profiles, we found significant 
overlap in (DIRAC-defined) tightly-regulated pathways in GIST and LMS, and also in 
differentially-regulated pathways between the two phenotypes for the top 5% (top 13 of 
248), 10% (top 25 of 248), and 20% (top 50 of 248) pathways.  As shown in Table 7.2, 
the tightly regulated pathways in GIST and LMS, and those that are differentially 
regulated between the two phenotypes showed significant enrichment (p < 0.01) based on 
hypergeometric tests.  Hence, our results indicate that molecular signatures of common 
expression patterns can be used to map protein profiles back onto intracellular networks.  
To the best of our knowledge, this work is the first systems-level demonstration of 
analyzing biomolecular network states of human cancers using protein profiles as proxies 
to global gene expression.   
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Table 7.2 Common DIRAC-based tightly and differentially regulated pathways from 
actual and predicted mRNA expression profiles.  1Dirac-based pathways are from the 
BioCarta database.  2Based on hypergeometric tests. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
among Top 5% among Top 10% among Top 20%
  Tightly regulated in GIST 6 (2.5 x 10-6) 7 (6.3 x 10-3) 20 (2.1 x 10-4)
  Tightly regulated in LMS 4 (2.5 x 10-3) 10 (2.1 x 10-5) 22 (1.1 x 10-5)
  Differentially regulated for GIST vs. LMS 4 (2.5 x 10-3) 7 (6.3 x 10-3) 18 (2.5 x 10-3)
# of common pathways (p-value2)
  DIRAC-based pathways1
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7.4 Chapter summary 
Currently, predicting protein expression from mRNA expression, and vice versa, is not 
possible due to many unknown complex processes involved in transcription and 
translation, and many in between.  In this study, we developed a novel algorithm 
(SOMEIRA) that uses conserved expression patterns hidden in both gene and protein data 
to infer relative abundances of each data type.  The predicted mRNA and proteins do not 
necessarily correspond to the same gene, since these levels do not correlate sufficiently.  
Our results show that SOMEIRA worked well to predict relative feature abundances 
across mRNA and protein profiles in comparison with a linear regression method.  In 
addition, we found that predicted mRNA profiles from protein expression could 
characterize biomolecular networks.  Although we can obtain only relative abundances, 
our results clearly show that these are still capable of giving relevant biological 
information (e.g. state of biomolecular networks) when coupled with the suitable method 
(e.g. DIRAC), representing a significant advancement in utilizing heterogeneous data 
types simultaneously.  
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Chapter 8. Final remarks and future directions 
 
The advent of omics technologies for the comprehensive and rapid measurement of 
virtually all molecular components within human cells, tissues, organs, and serum has led 
to the generation of a tremendous amount of raw information.  However, converting 
large-scale data to essential knowledge on human health and disease has been a 
significant challenge thus far to the scientific and medical community.   To this end, we 
call for the systems approach. 
 
 The general goal of our work described in this dissertation was to develop novel 
systems approaches to advance personalized medicine, mainly through blood diagnostics.  
In particular, we made three novel contributions: (1) development of two supervised 
classification techniques for distinguishing binary and multi-category clinical phenotypes 
(Chapters 3 and 4); (2) identification of comprehensive molecular signatures of major 
human brain cancers through transcriptomic meta-analyses (Chapters 5 and 6); and (3) 
development of a computational method for predicting relative expression profiles across 
heterogeneous data types to monitor disease-perturbed networks in vivo (Chapter 7).  
Summary and conclusions of these investigations are provided in the following, and 
future directions are given subsequently. 
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8.1 Summary and conclusions 
8.1.1 Newly developed classification methods based on relative expression reversals 
of biological features demonstrate robust phenotype distinction in binary and multi-
class scenarios 
TSPL (Top Scoring Pair Lists) is a natural extension of the TSP and k-TSP classification 
methods, and was developed to address small feature-set limitations by incorporating a 
broader range of gene-pair classifiers.  In contrast to k-TSP, TSPL selects classifiers from 
a collection of non-disjoint gene-pairs with minimum TSP scores of 0.6, and classifies 
test samples based on an iterative majority-voting scheme that involves all chosen gene-
pairs.  TSPL and three other methods  (SVM, TSP, and k-TSP) were evaluated on various 
binary-class transcriptomic datasets from a wide range of clinical phenotypes and 
measurement platforms.  Among the four techniques, TSPL had the highest average 
leave-one-out cross-validation accuracy, even in the case for which total feature size was 
greatly reduced. 
 
 ISSAC (Identification of Structured Signatures And Classifiers) uses a data-
driven, hierarchical approach to first organize multiple clinical phenotypes into a global 
hierarchy, and then learn corresponding (binary) classifiers.  The classifiers at each node 
and edge of the hierarchical structure are then accumulated into a panel of biomarkers, 
which can then direct classification down the tree to select a particular phenotype.  The 
cumulative expression patterns in the biomarker panel thereby constitute “hierarchically-
structured” signatures for a set of classes.  Six multi-category classification methods 
(including ISSAC) were evaluated on various multi-class transcriptomic datasets, and 
ISSAC had the second highest average performance in ten-fold cross-validation. (behind 
only to SVM.) 
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 Based on our classification results, we believe TSPL and ISSAC hold great 
promise for binary and multi-class phenotype distinction, respectively, and we look 
forward to their use in future omics-based classification problems.  
8.1.2 Multi-study integration of brain cancer transcriptomes reveals organ-level 
diagnostic signatures  
We identified comprehensive diagnostic signatures of major cancers of the human brain 
from a multi-study, integrated transcriptomic dataset.  These signatures are based on 
comparing ranked expression values within gene-pair sets, which are aggregated into a 
brain cancer marker-panel of 44 unique genes.  Several genes in our marker-panel had 
previously confirmed ties to brain cancers and cancer biology.  The hierarchically 
structured signatures achieved 90% classification accuracy when training and validation 
sets were drawn from the same population distribution (cross validation).   
In addition, our brain cancer marker-panel obtained an average classification accuracy of 
87% when using genes annotated to encode extracellular products.  This suggests that 
strong signal may possibly persist for phenotype distinction even when using secreted 
proteins from diseased-afflicted organs.   
 As shown by our hold-one-lab-in validations for our five datasets of glioblastoma, 
when we performed the stringent test of obtaining a diagnostic signature from a single 
dataset of glioblastoma, we found the variation among individual studies often have a 
larger effect on the transcriptome than did phenotype differences, resulting in 
dramatically decreased average accuracy.  However, we found that learning signatures 
across multiple datasets significantly improved average accuracy with concomitant 
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reduction in performance variance, even when sample sizes of the training sets were kept 
consistent.  This was most likely due to the meta-signature encompassing more of the 
heterogeneity across different sources and conditions, while amplifying signal from the 
repeated global phenotype characteristics.  Therefore, we found that sufficient dataset 
integration across multiple studies can provide molecular diagnostic signatures that have 
strong phenotype-associated signal in comparison with noise from batch effects and other 
sources of variance.   
8.1.3 Conserved expression patterns in mRNA and protein profiles for human 
intestinal cancers allow prediction of relative feature abundances across 
heterogeneous data types for in vivo monitoring of disease-perturbed networks 
The mechanistic relationship between transcription and translation remains poorly 
understood, and several studies have shown that, in general, no significant correlation 
exists directly between gene and protein expression.  However, if we are to eventually 
use blood protein measurements for in vivo monitoring of biomolecular network states 
within disease-perturbed cells, it is critical to establish a framework for reliably 
predicting expression levels across heterogeneous data types.  To this end, we developed 
SOMEIRA (Signatures of Matching Expression to Infer Relative Abundances), a novel 
computational method that allows prediction of relative expression levels of mRNA 
profiles using protein profiles (and vice versa).  This is achieved by first binarizing all 
mRNA and protein profiles based on pair-wise relative expression feature comparisons.  
Then, gene-pairs and protein-pairs that display consistent binary patterns across all 
matching samples are identified to form the basis for predicting relative abundances of 
expression profiles.  Importantly, inference of expression levels is possible even without 
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the complete understanding of the intricate cellular processes that take place in between 
gene and protein expression. 
 The predictive performance of SOMEIRA was evaluated on mRNA and protein 
profiles from Gastrointestinal stromal tumor (GIST) and Leiomyosarcoma (LMS) biopsy 
samples.  Each protein profile was composed of 40 protein measurements, while each 
mRNA profile was limited to the 2,094 features that map to all pathways in the BioCarta 
database.  Training and performance testing of SOMEIRA followed a leave-one-out 
cross-validation approach, in the sense that conserved expression patterns between pairs 
of mRNAs and pairs of proteins (which form the framework for predicting relative 
feature abundances across heterogeneous datasets) were learned on all but one sample.  
The remaining protein profile was used to predict relative levels of the corresponding 
mRNA profile from the same biopsy source.  Our results showed that SOMEIRA can be 
highly predictive of relative expression levels for different data types; for all 49 cases of 
matching mRNA and protein profiles, the average correlation coefficient between actual 
and inferred mRNA profiles was 0.91, while the average correlation coefficient for 
protein profile estimation was 0.81.  These correlations were significantly higher than 
those obtained using a linear regression-based method (0.76 and 0.66 for mRNA and 
protein prediction, respectively).  One great advantage of SOMEIRA is that both mRNA 
and protein measurements corresponding to the same gene are not required, since feature 
pairs within only one data type are used to binarize a dataset. 
 Our next analysis was to evaluate how well protein profiles can serve as proxies 
to infer biological information concerning mRNA profiles.  In particular, we extended the 
use of SOMEIRA to assessing states of intracellular networks by applying DIRAC 
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directly on all mRNA profiles inferred from protein profiles.  When we compared results 
from actual mRNA profiles, we found significant overlap (based on hypergeometric tests) 
in (DIRAC-defined) tightly-regulated pathways in GIST and LMS, and also in 
differentially-regulated pathways between the two phenotypes.  To the best of our 
knowledge, this work is the first systems-level demonstration of analyzing biomolecular 
network states of human cancers using protein profiles as proxies to global gene 
expression. 
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8.2 Future directions 
We hope the work presented in this dissertation will bring many more analytical 
opportunities to the field of personalized medicine, particularly in molecular diagnostics.  
For example, fellow colleagues (in our laboratory) are using ISSAC to identify diagnostic 
marker-panels for human lung and liver diseases, and to analyze and address batch effects 
issues even further.  In addition, they are building software that will continuously mine 
all online high-throughput expression data of various clinical phenotypes, across many 
sources (labs), populations, microarray platforms, etc., to lock-down the most up-to-date, 
comprehensive molecular signatures in real-time.  Next, we provide rough, “big picture” 
ideas for future research areas. 
8.2.1 Multi-omics profiling to dynamically monitor individual health  
The current use of omics-based molecular signatures involves iteratively stratifying a 
patient into one or multiple combinations of clinical phenotypes (e.g. disease subtype, 
prognosis, treatment regimen).  However, this diagnostic strategy relies on population-
based statistics using data from a range of heterogeneity and bias.  In addition, data that 
was used are from specimens of single time-points, which do not tell anything about the 
progression likelihood at the particular time-point for that specific measurement.  We 
need to account for differential information, or in other words, the degree and direction of 
changes in the measurement of particular biological features that could signal clinical 
phenotype “transformations” in an individual patient, e.g. from healthy states to disease 
states.  The best way to utilize personal omics data is to start collecting data even before 
the patient shows symptoms of disease (healthy), and uses those readings as the base-line 
control.  Then, those initial readings must be compared to future readings, taken 
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continuously at precise timeframes, to look for any anomalies.  
 We propose the continuous monitoring of as much omics-level information from 
the blood as possible – this means we will consider transcriptomic, proteomic, 
metabolomic data, and even comprehensive profiling of miRNAs.  It is critical that many 
data types are monitored; this will mitigate confusion from false positives/negatives that 
occur by looking at only one data type, and abnormalities in more data types will be more 
credible than those in only one (and a good way to control for specificity).  
Measurements will be logged continuously at the healthy state of a patient, but once a 
significant change shows up for multiple data types, that will be the cue for additional 
diagnostic procedures and/or therapeutic intervention.  
 When significant anomalies to normal readings are discovered when looking at 
differential information, those measurements will be compared to an established database 
of continuous readings taken at the population-level.  This database will have stored all 
previous readings in the form of a continuum within individual patients, and will show 
what disease manifested in patients (if any) with similar measurements over time.  Thus, 
the patient will have a list of candidate diseases that may result from his/her observed 
molecular profile.  This work is contingent upon having a long log of previous collected 
clinical data.  Therefore, success will not be instantaneous, but setting up infrastructure 
for this type of data collection and analysis will be essential to taking the next step 
forward in personalized and predictive medicine.   
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8.2.2 Mapping molecular signatures from multiple omics data onto interaction 
networks to identify high-confidence disease modules 
The classification methods presented in this dissertation can be performed on any omics 
data type.  But methods to elucidate classifiers’ relevance to disease biology are 
unavailable.  We propose to identify signatures from multiple omics data types, identify 
which functional modules of interaction networks those features are located on, and 
prioritize the most commonly identified modules for analysis and targeted therapy.  Since 
we’re using multiple data types, commonly identified areas in the network that are 
indicative of case vs. control will be of higher confidence than disease modules obtained 
from only one data type (which is commonly seen in the literature).  In addition, we will 
identify and analyze disease-relevant modules within a patient’s own disease specimen 
dynamically (as mentioned in the previous section), which will allow us to pinpoint 
disease modules not only for a particular phenotype, but also for the particular individual.  
This way, we will be able to establish links between the patient, disease phenotype, 
molecular signatures, and disease modules.  Establishing these links will be the first step 
towards identifying the biological meaning of molecular signatures, and their relevance to 
disease. 
8.2.3 Monitoring cell-secretion to infer intracellular expression behavior  
Currently, high-throughput gene or protein expression measurement requires the lysis of 
cells.  Therefore, the same cell cannot be harnessed for continuous monitoring, which is a 
key limitation in all time-course studies due to the cell-to-cell variability.  We propose to 
use SOMEIRA to monitor all secreted biomolecule data types (e.g. proteins, miRNA, 
metabolites) along with all intracellular biomolecules that are dynamically expressed, to 
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infer expression patterns of intra/extra-cellular biomolecule composition.  This can be 
applied towards many clinically relevant avenues, including treatment of 
neurodegenerative diseases, in which the goal is not to kill the diseased cell (as in cancer) 
but to modify its behavior towards normal function.  One direction would be to test 
whether candidate drug combinations can lead to hypothesized or intended changes over 
time in gene and/or protein expression inside the cell, and thereby manipulating network 
behavior, by reading only the secreted profiles. 
 
 
 
 
